var title_f16_31_16880="Seasonal variation VTE";
var content_f16_31_16880=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F72351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F72351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 579px\">",
"   <div class=\"ttl\">",
"    Seasonal variation in venous thromboembolism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 559px; height: 433px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Depicted are the monthly percentage variations in French hospital admissions for deep vein thrombosis and pulmonary embolism. Hospital admissions for venous thromboembolism were most frequent in the winter and least frequent in the summer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Boulay, F, Berthier, F, Schoukroun, G, et al. Seasonal variations in hospital admission for deep venous thrombosis and pulmonary embolism: analysis of discharge data. BMJ 2001; 323:601. Copyright &copy; 2001, BMJ.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_31_16880=[""].join("\n");
var outline_f16_31_16880=null;
var title_f16_31_16881="Sausage toe reactive arthritis";
var content_f16_31_16881=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F61696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F61696&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sausage toe in reactive arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 259px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEDAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5kowaBSgfn7VNiBKMUtFFgE9eDRil7UfjRYBBQR9ad6UmPbn2osAh46ijtS+/QUY74zRYBAPrR+FO/D8qPXk0gG+lFO5ooAbRT/xox7DrTAZ06UYqTA6Yz2oA47Uh2I+1H4U/HHSlwPT8qAsR4o/Gn4z2oAGBQFhn4UfkKftB/Kgj60BYZRTsc/8A16VkKuVZWVlOCCOQfQigLDKKcFAo2igLDe1JT9vHejZ7imKwyin7Tik2nsaQCUUu0+2PrS+W3Tj86YWGUVJ5TelHkyZ+5n8RS0HyvsMpKl8iX/nmf0pPJk/55v8AlRdByvsMpBUhikH/ACzf8qTy3zjy3z/umjQVmMpadsfrsf8A75NNIIHIIHuKAsFJSn9PWkyO5x+NMAooyPUUUhocMgc0uKBRgUxB9KKKMUAGKKWj1oATk0DFLRRcBMetHXrS0UAJj2NLjrRjmgDrSGJS/hSj8aKAE/WgdaXFLigBOlLg0YFKKLjsJRj2pwHFJimOwmOtHY07v0pB9aAEowaUDHT9KO1ADfyoHalophYTHHSg0uOeKMe1ILCYo/Sl/wAaMc0CE/rQKMcfpS0AApRSdfxpRTGh6+lSKf8AOKiFPH5VDRqiUHPalB/L61GD6jnvTwfes2i0x386XJ9aaffp70DPp9aVh3HAn1NKGOep/Omg9/5Ue2aQ7j9x9TRub1P4Uz/PNHeiw+Zj93NFMB+tFJ6DuzPA44z+ApaB0pR+n5V0nAJ+FGPypcfXNAFA7CeuaPy/GlHtS0BYSjHSlox09BQOwmKKdjn3opBYQCilHP0pcUh2EIo/KlA9aUChsLDcUuB6U7FJj1FFx2EApcetKOlORS5AQFj2CjNK40ruwzA70pHNbWm+GNV1DHk2zKp/iaussPhdfShWuptgPOelcdbMMPQ0nNHo0sqxdVXULLz0POAOvpRivXo/hNAQN923TqD3psnwptgDm7YNn1rl/t3B3+L8Dp/sHFd19/8AwDyPHrSYr066+GATPk3uevUgVUj+GshI8y9wvcDmtVm+Eavz/gxf2DjL6JfeeeYpUBdtqgsx6BRk163p/wANtOUh7pppgvJG7ArttH8Pafp6RLZWcEI9dg3ZHufx5/8A11yYjiChT/hpyf3f19x1UeHKjd600l5a/wCX6ngdl4b1q+x9k0q6cHoSm0frW7afDPxNcn/j1giGP+Wkw/pX0JHaBYlI3jnkdjV21TYoaROFOPunj/PFeTU4lxD/AIcUvvf6ndHI8JBXd5er/wAkvzPnmf4UeI4Y9xaxJHO3zCD/ACrHvfAXiS0TedNaeP8AvW7B8V9URwW9yjbIvOuIwWYsQA3/ANf/AArEtrdoLeW4nhdzNIwgRWwE/Dv35rOPEeLh8aT+Vv1B5PgpppRafk/87nyddQS2kpiu4ZbeQHBWVCh/Wo+oJ6ivrG6kgu4xb6ho1ndQHAZbgCQ//qri/FXgrwleK6w6d/ZNwBkSW7MoX8DkH9OPSvSw3EsJtRq02vNNNfozz63D00/3Ur+v+av+R4F3pR2rT8Q6NcaHqTWlwd6Eb4ZQMCRPX6+orMH619LCcakVODumeBUpTpTdOas0KOlOBptOHFNgh4pQRn1pgpy5qWtCkOzx1xSr+tNJwM80Z9ue1Kwx4P169qCeOQOnQ00de1APYE0rDHA5PrijPHB7U3PP+NGcdKLAOzz3H40U3OKKTiO5VHSlxzSjpShfbNa3OWwmOKADnilxSgelJsY0DmgD8qfg9/1FHQ570XHYbj060Y6ZqRULYABNSx2k8mNsbHPtScrblwpTn8KbK+B3HFGDWjHpF4/IiOKtQeHL+ZgqxtnOBxzWUq8I7yR0xy/ES2gzFI60YHNdxpnw+vrggzZRMZJ9q6/SfhzYxFTOBJkZyDn/ADx/+quCvm+Fo7yu/I7KOSYifx2ieNxxSOcIjN9BVuDSb6c/u7Zz+FfQNl4V0+3UFLZCuO57VpxabbRZVYkBHcDmvLqcRxXwQPQp5FSXxzb9D58h8J6rKP8AUYB9iav2/gTVJWAKlQf9ntXvhtFyflwMjOO+P8/5xULWicKB1OD3+v6VyPiKs/hSR2QyfBr7LfzPJtO+HPIa7lB74Peuy0jwdp9oBsh3MO5HX/6/cfWutgs/nLbfnHtyKu21o7MDswfXH4f415+IzXEVvilod1KjQofwopFC3sVto8hVQdFA/wA81MvyKWZfmPH+ff8Az2rTFrjKnGBx3wR3plxEBtyOnOSP88V5nPzPU257lVY3VdwAGeAD/Kq9wFK/vzhTgc9P/wBfT/PFXZiiKuCSvA5PP+TWZqN62zEYVfZRjj1pxTk9Co3bKdw4jikZEyVBwCMjNUllAgUHduxkg98+9Q3E+dw4YMeh5z71GjdGDZBON3c+1d8adlqdSRrWgbggAA5Iz0zxx+VatoqksxC5JAXJ+6f89/5VmWJkIxu5+8cjrWs9xGYjIGbc0Sgqo6lTzn29q5Kl72MZt3sa8EVxkiTy5FwMBXySfUD0p0jRxRbVlGTz1z+v51lW+pW0B3RurOSCYWBEjHuAR/KlkvnmUlQFfcSXOGYcjGB0z069MdKy5WmYcjb1LlhdSLrCOdirsHzMccD39jT728sBFAFuBMUUjbEC+09dufu5PPFYyo9wUeYlx1LOen0H+H41f+zpGuXbHIXbtyzE9BjpnP1xnNDdhyox5k3+BKupp862ujxlnYFZb+4KhPbbGDnPuRWLeafPfTM90IV5OFjTaFHoCck9u9dIlhFujHz4J25TnA46dx9fXsKSeO2WMLEVQHOVU7l9uT2J9AD9etHO0+aKSFCcIP3Vv6s4DV/Cuj6pbRR6sqSQRNtjYTFCGI6AjGT7H0ya5i5+Eukzqf7O1HUYnOcFjHcIffgLkfQk16rBHE73INqwYQNFEqrwHLqDu44+UHI75x3xV6WQW+qTnTdRlsYFTekSGSO3x04UsQvQ4HHHGOK7KeZ4nDq1Oo1+K+4xxNChWl79NN97fqtT5t1/4ba7pcUk9qiapaoNzNag+Yo9WiPzfiMiuKUgjKnI9q+vtRutZNo816tpcmHb5kgiCy+WT1BC9sd/T3rgPi34CstUsxqehQoNdWMTSrCflvkK7vu4GJAOmASeh6jPvZdxG5yVPFW105l+v+f4dV4ONymMVz0N+17/AHPc8Cz60o600EEBgcg9D60vFfWngIdQDSdqB14oGKDjtSimj6UfWlYY6j8vrSH6c0UALnvzRSfhRRa/QDeh8HanJDBKkW6OaNJFI6EMoYfoetTL4M1HHzIw5r3/AE1Ik0PTEVAUWztwrD0ESAdabcRqDj5Tk9AP8818a+Iq97cqPqqeVYVxTcfxPAx4NviOhxxz6VNH4JvWYBgVb0Oa9na3kkJZI+P73501bOXJDID2+bv/AJ/zmqee1n2NllWFX2DyOLwLPxvOB7/pWrZeBIxgyMCOnH+ea9GaznPHl5YEZyOvP6U9bGZULFQO/HH+f8+lZTzmvJfFY3hgcPT+GCOOtfCNnEfubiea1Lbw7AuNsS/jg45roltZSMlT/j6f5/nU8NhK2TyPRVNcNTHVJbyOhJRWmhix6LChGEXIODx2/l+HX9Kv2tkkeFRQAOMj+Hpiry2Uw24Azngjt+f86nSwuTlgRgdj1+tc060pbsbfmRpa7QSTnJOc9D/n29amWNEGWK8nPTrViHTpGX99Iw6Hnk/h/j71Z/s6JEywb356+1c97uxm5FJHJk4PtwcU8DfyF4HPStiKKHy1wo3HAGasxxRq2QqqBz9P8/rSbJ57dDIS0kO3OVAPP/6/8PTpVhbIbwMY456Y+laDTIvXB46D/P8Ak0LMqtkj6gcUJkuUuwyO2SIYXGcdaE2h8kE47/hT3kAYfNnvj/JqB3AzgfX8vek7Eq7GzOFyQBwOOe9Z1wjSqCn3TjjuT7VekWNl2uBnH+f8/SopMsgVAoA6g459qlKx0RdjLNv8j+YFCkdMYzxx/ntWXcxYU5DHHT3rpJgSmDkk8sWHP+f8KzLmFCjswJOM+gzjjmtYTsbwlrqcte22wGUK3PUevfpSWyqWDNIQc8dOP89a6XQ47W4lmnuAvlw4Ea5Cj3IH1/SsPxLpFtezvJa3F3bhCDLJDgAnnp/jXZCsnL2c9PM2jUTfKyC41KCzjdvtAQgYXnB3Z4AA5q1ZC+u7VnCNbFAX2cmYr67B0GDnJ5xniq1jp1joyTLYwKt6zKv2i4BeUAjkc9Mg5yMHgVoG6Q20wtW2qmELqTyD12nGM8nOfTp3om4/8u182D12Q5ZBa4CRlWkUEvICTJz784B7j/CrVhcrIsSNllBwCTnC9+D/ADPFc/cpJazy21xDcQ3QbbIsikS+oznqMcjnvViweMBtzvGM/N8uefp1x/k1MqS5b7g0mtDq7eRGmRgR22qwORjPfv8AXvVuPaIHBVzk7Nyk8e2MH1Az7YFc9A8kDk4Z0OdyxkFlwMbsA9PpyPyq755gKGaHbKgDMAcg5JwevuQOAeDnpXHKGujMpR7GzcNkCRN6YH3UPy49unPPp39qoyopEYCqWGfl25AGMn3H0/EcVnnWYoAY1mYPgowxgYzwBxkjnkc1QuNcjgZxFJFGMYIYkgHnkZGM4HQnHpnBqo0aknsVClJaHRWN9b2ttI8md3yRqUf7p35ZiD/FhcDp6+lc5dzQW4OIzLthnBKh84ZyeR9e/A/Kkl1Oz1GxaGK4hNwy+XHdA7WjYHMZ+QbWUNjJIAweTxzyd5HrjXbwz6LfxS78vH9nLleOWBC4POcc4/nXVh8LzSfM7fh/X9eRdOklJ30O/HiK3/4Ro28EV216ti9t5ancrEuCsrM3RV5557YzxWjp90k+n2EsZEbCNcnGNrBzyfTP9PWuCs9N8RBPPj0242D5RGZUU9CMkluF69P6VppFrkMABs0Z87siaHbvznKgMRtUYPOMnBx1rOvhqb0jJb90c9XDwV1F9b7njfxT0uHS/G9+lrGYoLn/AEpIyOELE71HsGDdhXJjrXqXxP8ADniPWtUi1GDRbueOODy3MTRyP17KhyR3Jx1NeXsjJI6SKyuhw6MpVlPoQeRX3uV141cLBcyckknZ3+8+JzKg6WIk7WTf56v8bjf1zR/nijt/OivRPPAUtJR/OgYoopM0v1JosAd6KT6CimFz6zt7OFbK1T51Igj4P3l+QcH0I/pTXgRWI8snB9uR6+3/ANY9M1YCrFaw5G6ERL+9Q4C8DJYDjGcfMOPYdakaB9+Arcdge2a/J23fc/QIbIoSuIlBTOTwFwOPxzTMzzKoBCBfQdPrV/7CdxZ2+THccZ75pWSFs7N2Cei8cdqLpFproVo7cCMLGxBIHzA/h/nrUscDKpIY7c549PSpYo4xnKsCR+VSMUyoUqSfmOew9PepvqJtld49yqBGVPPXnj/P+elOVTGi5IPc47f5yashVYgLnaefmOe1RSR9HDsV6DAyQfb/AD/hTvrYhiqWLZUfie3+P1p4cKW3YBI78YNQRyIkbOGBRRuYn+EetMhk81FcMWByQ3r9PanqFrlx5AxKtjpzmmn5zkEkdcZ6VUSUNdSxRhW2gAkfdGeev4/rTzHKcSGXZHn7oXBJ9PwpK6Y7WLwkXgRDJOeTTXui+AzEE+g6fn1qptMhBByRjAA/n7/571KQ2VG1fTaOef8APb/GncnlSJvNC7cDqOe/vx/P8KRnJYZJAHfHb/J/CodkmQqoSex68+vP41LFbzEBy/B9OeKAdkSoqgD5mwed2cfz/wA/TNSMV3BUY4xu4PX3oSyfAO0YI+bd2PGKfHbNu+UEcclsdP8A69J3Icl3GgKCWK5z29aiZF5G5PoTn2NSSwzHCsyk8dV/z+FMNup4lZiepBJ49KT7jT8yOaVFRgduSfQ8/wCFY17IzIVhG4jO3A4x9K33itUTeUBUjnn9KyLuaFckouANvyjGM/5+lON7mtJ9jDFqiHfLjJOfnOFUep96ztSvE3NsDsqHb/dGCB/nGMc1NrOoB90UQDCM4AB6g/8A68f5xXPT3M8j7WUAkYJ5Pfr9Ogr06FKUvekdsY9WXn1B7q3kaRV82GRQZWckkFSOQeOo68nrUaXsIG0qQ7rhUOACADnI9u+f0rmZrmSLfvZolA2y7iR16Bh3x269at72CCWKDy4wqs0sowXBOAQMfdzge+feu94VRRV0tDoFvLGW2tle2kT7Onlxz72w8ZYuMjHP3tucnCjIAPSNp0jJLMYkLMFA5Cg9eeOR0x8pOM9KwLi+toopZZrhXPJx5gUhzjkIeCTk8DsKuaZo2sapHFJHbR2ltuylxdAorL22oPnbg8E4XA6ipdCMFzSdl5/p/XyM1KMepsC58pXYTRFVwDJuAABGQTnngDr0zV/S9P1XUDGLa08qzCg+bJvjeTjLFVwXxzgHaAOcHuDSdH0/TAkoZr+7DKsU04/dxsTy0cY+VcBep3EcdDXcK+YgjSM+z5yspO75snnnk4AGB0B715mIxChpTV/N/wCX+f3CqVWtkc3H4Vt7cLNez/b2TDtGFEUbrjG4gZYqDgn59uTnFTQaHp0ar5em2zMAceYhkfn1Y5Y846nIrekuYwxTyFuZDiIyBclsjp6hc56c5zUrxxDEcaPH5rbB85OzHVgMZbA6GuKVerLeX6fgZKtJfF/X9egSaZBbtEsiiZGj3rIoCjaeCFx0AIznHPsagFiViAjOyNTwqjCgdAQP61d3GTT7bYioNknlsgLFlyByeg4ySPemQ+aY/mCnn7xBULnp3/DmsHdSsYKcrasqbTHEzmQuYyI4yAFYAk87sZPIxtPr2pYnuXtbdY/LcyEsjElfJ5Izj+IHafunGe/am62Hhto7iBykgG9htB2jp6c/l2rY09XfSrH7Tc3E86lkWSUAM6AcdOPTpW1ON1cKk7QUu7KHm3kDuYrjzUzwk483B74ACrg+mD0/GsTW9C0XxGj/ANs6bZ3twBt8wxCGYKeflkXByOT39+OK6e6tEkiRS5Xc/YHg+vHeqgtRsQh237SCxQqSP8jpSk50Xzxdn5aP/MytTqRtJfgfK3j7w1J4T8T3OltI00Kqs1vMwAMkLjKkj1HIPbIrna9++P8AoH2zw1a67GgFzprrDOc8mCQ4HXrtfHP+3XgPQ1+j5Njvr2EjUlrJaP1X+ej+Z8hjqCoVnFbbgKPwo/zzRz+NeqcgZ96P0oFHWkAv5Cik54NFFm9v0/UD7RG3B2J5bRnY6D5tpx1/3T1B71VDC3dIguEc7YsHIRv7hPbPb8vSrV7EsJ+0Rq+YoyrrGuC8ffj1XqP+BDvUNxbpJE6SkMjAZQc5UjPX36g9sDvX5M7H3cHcqmJ3uGEp9gAfm/ECh03gBTwpK5z+ualtTIsjrNI0k0YByFwZEP3X9OxB9wexoSIxEM3llyzNtPbPX+lS9DXmK7oysXZnkXPzHGBxUpglbaoOA3Unk0+RS0qqATsIO08Bm7AfT/Cn3STfKqyNCZc44yVUDJYgenH6UXYOZVBkjkCSea6nIVlxhj6H/wCv6VPMZfL8x2aCGMZBBHHPPNFy8XkGN4yYnUbY1BMjdhj0571RtEnvHkg1FNs9rIBLGGG0EDK4PckEEnt096rpcnfVlK93XU8EaBkt5MspfA3hOSzZ7Hjg/WpbS5N3E7IDDbk4AYYJA6n2A/WjUyLu4urlpkNvpwTfhSd5A3OvpjG0HHU8djWXM88ttp0sLB5LmIXF5GOQluzZ3MB36ADqQrY6VtGN0un9XNVJNJM37QJBbGQpnzm3KoPY9D/n6VNFIGIbfuA4LcA/gKasPkPi6cNLJ/q9rdfYD2GOfcU6RVhdBIw8xhkRouW/Lt+NYXTM7pj55VQYReSM5B6cZz+OKkilcLtaEsp7YANQJDKYGkAjTI+8TnJHUemen9OlJ9ikuma2ZnSBADM2cM2eQhPbI5I7A4q7Kwm47MltpPPuicsYVOBk8Se/0/nWlHLtcOCRg5yemartb7FSNFREAOMdAPT/AD/9aljjdAF8zzD0VcAgH+lJavQiVpF3cWX5zgbSfvdc/wA6PMMYPHy9ORjnHUVUijd3QszEEnGT1A4Jz9T+lWJA6opPzZ6qQSB+H9Kbb3MnFJ2IZ2kz1DED7pOcjFUZFuZpmG5BAI8jGQ7Pn19MdsdatvC0jMyLjc3fJwPanmKQBSOg6k9e/wCdQzVNRMeW2O1j86sVwTn8Bj8KyrqzmYk7XaQjaE7Ef5H866ryXWQkISWwDk8fyqGSAgH5FyxwSB6/561Sm4s2hWscXJpoEj7du7cCvOOB1zjoOtQ/2PG2x5VICnKoF+TGOx69ecfnXUSJNISgMapnBO3AznHH0qvN5YTcsn3SR7jsOe/06Vv7ea0udHtWzldT8PeZ9nlkuI7a4wVDY4c9lxjngn6Csq68Gz2gjkutYhjt3jPmRW8bNJhuCgydp7ENnPfBxXU3k8cN1FIWYMCCrEjcvzYxk5C8Y/nWQbuK7jguDIqkj97F5RjUTKSXVexyNpDAj72MDGD2Ua9dLR6eiK1luTaZo+naOBLZW8UU3zFLmbE00gAGNsh4DHIO1QvU4xjNbMygRu87IpDbnEh/eGQcMvIyTgtxxnaSScc8mtyZ7VsCQkQDcPLyM44Xk46nj/d+lX7TU7hnYB55J3tfmlMhJ2Nwu5s/MflOQ2fpkAVNWlUk+aTuw5FFe6XPtqrMmwky9QVO3bgZ6Yxkgf8A663Ir9BEsjtLvkRoTGGwpYcqrMTkZ3E56DHeuPiCiHdx5Y3orxPgu46gk9AMjnqR0yel0antiJAhUkoUWMFQXwV3lQchyCPmGM45FZ1KClshzipbHSzYDyifgowWRQArA4xgYPI4PerVhcB57fdIS6TL855LHd0J7Zzg+ntXI2l3cLEiXKR/aSNpbbjJY9cduDUzajbwucu0OB5bKq7iVHUnsRnjrmsXh5bITptqx3UWok2Z0/U4HiaKRntp4yMJljlX9QeoYZNKs8ARtk6L83yAKVdz7ccD/Irg28Rh53lZBEd2SgbhOmOe/wDn0qu3iTlmRlwCSwYgE/SpeCqSd7GSwj9L6noFwYLuYDiMshHzNwpAORn0NXLFVhSGANkbSynJOcnIAHT/ADz615QPFJSVmd2weM5OT3GeeK6DR/GEvliS4itLi3IwUkkDjAxk8HIPvWjwVWnrawVcHU5bLY646ylrJEw3MY5BLs4JPPf8q7LTdas9QR5NQBMEqqEynTHfA7f4V5lP4j0AEXDabbSSPy4Yk45x19Dgc85FcP418UXxu4Lqz1K8t0dQfJilYRRg5GxQMA9O+e/NVh6NepNQitPPZ/I5KuXrEKzTi11/yOx+Ml7bnQrvRUIkkvYXlmOP9XEATHn0ZnAIHopNfKincik9wDXf6zq8sOkXdy7TS3N+ShnnmDNkDaRxySN3U4GBwK4EcAAdPY19hkOCeDoyh3f49f8AL5Hz+dxjTlCmndpO/wA7W/ISgUfSjvXvHhi/yo+tFJRYA9KKD1opNXGfcMqGMiRXEbKRz1Pt09P6VlKywSMhjIhwXi3HgJn5vptJz/ut7Zq7IjReeyqWhUbvMA3GPjuP4lxzkcjvnrULyABRI21mxIsy4I6fKwPQ9s44INfknqfbw/r+v6/ELsM6qY1USITtdQeQRyrf7LD9QD2qCw2TWFtdRlwsiCXKnceenXrTrVmid4tmzYeiAksD2U+3r6Y5zWTZ3cUSWriR/shUSywxru+Yk7jGBzkY3lPdjxg5Ero1UdLI2I9zzZkQ73JPrz6A/pVO5mW2JuZCFSZlhhVgQG+bkgDLNk+g7Cr920pFuMGCJ8qNoDk7hwQegzjGRnr1qrLbJHHBHagxl2XEmeUXuxPXPQY9aUXrqEWuoyOaSQtPHbyvEh2rK42ebJnBOOuB0HQdTWdeadLE1vKXaZ3IhdV4BJJKSgdypyOe3XpzvKis6QxLt8kAKoOAOOOnGcdz6+9Z2psJFkZhILZ1eFVUMS6jmV2GfunAUDucZpxlroOMrPQzryaM6PrLI2yys45meYAHziFwCg6HB65/j47VD4RRLbTrK1kgQ3N5axyMGywbYgRowOpVBjJPc9ayfE0kGjafZwazMFsraQTyWXlszyFVMi4GRlnyqtn5dwLY+U1a0xrm7sGvblmiKsJTCAJJJUZBwVGQFAdmAb5cjODkY63TtS02b/r17v5Fb3SZf0wiPTpFtpQ0tsdgvp5M+dFgsixr1Py7l4GAVJ5rWs7m3hUGGOeR5RuBZfnkGM7vm6D/AGj0PT0pTDLa3sEqb0uNht5WLZYoRuAZ/XIGFHqfrTtKtodKtFIXewiKzM2S0kiuVHXnJ4wPTpxWEpKWr/r+v+GIlJNf1/X6FS8mlXUYoozm4vV3Kmci1AOPNAPVs4A9T6DIra0zItl+Vk2qD1JL553n1JP65FVPsckVpLK0sbahMRIzhflDj7oA/uqBgD8epp1nKfsVs0MgVwPlj3ggdip9m45PQ4NJtPYidpR0JTIknnoHCmNwCDnv0/yKY/mOyxxSEIwZA2PvY+8/0UYAPc1Cl0H1S6fOyzWCPz58/NGQWyOM/MNwVh2P1p7yG1thNJHie42xwW0YIY5J8uIHH1LkdMNg4UGhJphexasSn2i427mSACJmPOw/3frjH51YeQkfLtJJG0H0z1b+lZcb+S1tZQukjRMzSSRxjYXAy2OezEeoBIB6Vosixfu2UNM2WI6lzx8x/LGfb8Kp3IktbkjM2X6jBIxjOR7cU1pAkQPzZ6AD/DH+c1XklZUPm5JyPmUZJbgAAdzkgfjUgOUYsT5jDOMgbB6Bv85P1FZuTDltuU57/wCzsrbX+YA57Af59OnpVCXUGiXaG3gFWBJxx1xg98fyq9LErvlQoxyx+6Pc+9VJLRHJIy4YnCqOoA6HGfX/AD1p3T3OmCj2Mq9vpoyEAfGC4ATl+euPz4rDu75p0k5DqHAbgKTkk7gOcjgZx0yPrW/caUTgIDt3bsHJAOODj+ufx61nXVns8zKMSqHqefUZ9snt24ropSprY6Ycq2Obu7iVoW3TGPaAVbyyX56rxkjBx16Zz2rMuZZpILK5tXdDEFjAj+byXzu2uANy7sMwOCG59DXQXloPOc8A7t2cHocH9PWsyDRmun+zedhFJ3KZPKWNchmywG4AYzk5AIHAzXqUqkErs0fc57UNSe6uJZBAqRuwbyTjC5XBfgDBOS3ygDkcVcjvYiJwLiSUSbeCFB4A4bBPQ5xjr7ZIq1q/gXVVQTWslo1uXZIW+0rE5B6MVI+7+X+6vNZR8G+Icqht7N2JPzG6UhADwenIPbGeueK9CMsLOKtNL5/5mftkaE+sQgH5lhLBdwJ646Z9Tkdc8Z78VCmvfZ/OW2aKMTx7JWX5nJznBJyBn1GDj8zJbfDjUJD/AKVq1nGi5LLbQtIfwLFR+PSt3Sfh74dWeOLUbzVb52GB5TpHGr/7QHO31IaspVcBBW53LySf62X4i9s7fD/X4nKv4ijWFlfLMRgFnwqjHv6fWqa6rNOXFlDPMmdy7ImfA6duK9dj8J6Ro9xHDDpNgszEfOF89uT3ZySPwxW4ztHhLaZWKnYCoIXj0rilmtCD/dUm/V2/BJ/mWsQ7XR4NIuttkLpuoFSOP9Hf/Cq8kWrb1RtNvw8n3VNq+T9OK+iILd5Y8PK2/buDKc5PpnPB4pPnWMOtw4IXkZI59APWiOfOP/Lpff8A8Al4mV9GfP0Wj+I7pgsejamcZ+9AUA/E4q5b+DfFBO5dPFurHYXkuEUdOe/T1r2xpeco7rlgSVbcMduT371JBHFJIm2JAzYbaMnA/wB49TTlxBWt7tOKXo/8xe1mtW2eRQfD7xBMrF7/AE6Jg23aZpGJPr8qnIz3q1H8Mr2ZCJ9dtw6A5WOB32/TcRXsphiK4b5WA+UcA/hWZql7MYlsrdEe5LARSYUHkcg/XPXt/Pm/tvFSdotL5L/JmftpVHb9WeTXHwfN1NGkniNkA4H+gggH/v4PWuX8S/CbxHo8TXFlEur2qAljaoVmQDuYjyR7rkV9CPo063TiS8kjkVdr+ScJnGSQCMkZyMmp1s5IIWxdzpKeN+7n8c/yrWGf46hJOUlJdmkvySf9bHl4nAYavef2n1u/+GPjIMCAQeDyDRn617X8YfA2mW+gXGu6RaC1vreYG8SN/kmRjgvs6KwYg8YGCeK8SPBr7bL8fTx9H2tNW6NeZ8ri8PLDT5ZfIdn6UZpmfegn8a7Tl5h+aKjB5FFDDmPt2G5RIomB8vZgscnIb0z2zz7VBO8YjZShdGB3woAevdV6e+O/Uehpaa6rBLAgLiKVirkE/KecE1Nd3CW8InmMUUKkAtI6xqAT3ycf596/Hm7Ox+gezSYSsUt47mFwzxLuGCdxUfeTJ5Ixn6flilokCxW8tzHmRCzTE/8ATPccADjb8gUN0PX0qKXUEmu3tFtZZoLhfPYuvkxkg7XQFwDydpA2kHJ5xUvnyw3V2GuIYY5fMfzIYmk3tiMOvJAVhndwCPvelapSSsaJNK3c0790tdPlcKGhRlzu/wCWS5BEy+xBBK5HIYjoQZIUaGSdZLcmVH+9I+FHGR8xz7ngE8E+lVJbeSKdZp7i6+xw7UkSRoUVSOkjbYwQq5xyf4ie1Z9k73EkyQxzpASsNm87MzvEFGW+ZiFIHVQB8oTPqJW11/X9fkZpXVrmjfXyWsEsIuY0upBuXYo3c8bwvUYwcAcnjjrjGvru9u7m2g05jbm6CLGzoyyCAA84IwgPOBhmbdn93jNaEoS2ecCJZdRliDgsn3udg9lwCcM3YE880s8sel23n3cyhi/mSuQVDYRujddvGBj8ulXB2s1r/XYrlVv6/q39enJXmhRz+I5YDNdXMdhbKb6Zp2k80yOFUFiSzEFncjp8gPpW3EjWNheaXbTiOYNEI0LB8Fc5cjHIKx7sd/mFL4aLmC5upYl8y6ujOyBSPup8o25yANzZz93HrUdnEH1WRbgkmGErIQ+4qQ6sAGHpxk9OccV0TqSl7rei/P8A4e/ysjSz1Uuh0N0rKIoQnnb5lkct+7aTnOWPOSTg9F9+lU0mifXPMlUG2t45J4WOSgm4SRwykg7RtXjoWbnk1aubpTLCsW7zpsKFI+6GPLYzzjHv17ZqKdYra8scQ+YI0lSM/dGShOM9f4D17ZPFYRaSOdLuWiWknBjAcI/lcx9WOMjOevpn9az4na3m1KzO1Wd1eGNeSjOMd8clgODx1J4BNTwTJYRQ4zNK/LLEAcuycD1GDnIOT26kGqL2lze68RNckRBVa5eJdu0btrRgjrtD/Mc4IO3AxzUEiku+wzTokfVYra4YyJDtZYn+5JMd/wC+cHk5IJGe+TgYXElrP/aNxPOAxs7ZHFvMT8zqB+8cj72M4VcclRkkbsGLV9yXl1Fp58mOFYlJUBQsKFzhVAxubsCMAfNySBWlqBaJYLZY/slgXCSQ8/MigOA3phVI/EknJAp+b6/1/XzKetmuv9MXSkuZ5HdYo4oIwLeNmX94V6uwAwEycDHOAo6c1qKiQxEM6mMDcxJxtGOST9B3qWEMtvF5igShcv8ALwGPr7DOB7deaqaosUkS24dQJCiscZ5Y8A9ewY59QKHaxz83NK3QSIl2E5Y72GUiYcqpzjj1IP4AketWJSVjG4BRkdemT3z/AJ7VVSNo5VLspHI47HPoOvb1pbmWTAwOCpxk9enQVm9i3G7RIyKQoYIIyepxjn/I/OoZ4m3bWypA2kE9Tnof/retQTz5cNEd2/HTqT3JGP0+tVpbwuFbajAYI3ZP1OMc/nRa5pGEizJGo27m3AkksM/L6kHt/TFU57VGwgTccYZd2e2T+NVp74LiBJCsrRkhcbc8HBx+vfNZtzqkLBhK5+dVZeeAM85PUdO/PvVKnJvQ3jCRbvYolZ25OXK7FxnBGCPy7dD1qlGEjkdodnmSKF3OgbJyCM5PTjjoM4+tU7q/jdyRsbDbkYAOMgdevA+8cEdePes9rhIpAZAHjwCyliuRzyTg5GB6cjPI61006MmjZQdtTVuXWO4YzxRtPMhJaZfnDHqdobBA5II4z1qaKWNHUiOOWSQB1EgyXz/Fxgc9uxweO1YX2ydpGKgFnKYiUkgYOVwM9gRgc9OvWrMkx2qu0NsbABAwSDuIJPX8TxWkqT0THy9DWu3D2U3lvDl5QmGIztOSTj0zgHt/KoLZksi3lTLI7oqYVCpjIPO0noD68VnRXB3oJIxOcljFuK5GOhYchf8ADioI73MheQADdhgAT09+/wD+qiNF2sNR6HVJLBHCQWUmMBTt6e7HuSc8itK3JjVTuOx8EAHqD0P/ANeuTtr7fbKu4KR2A98n/wDVWi19CR5cKkjJO49OnJ9q5p0XexE6b2OoR0RS0mQzrhQg5yecj06fjTWd/MZsAleeeQDj261jQaputpGTY6AgAscAt2/D/wCtUi3kLhCjMXI3SlhjDjsMdfrWThboc3s2tzVgtCwbeAqrkttHTngfSpzaeWzA7doIzjt9P5f4Vm6VeTvKTDI26TKvzkMMZwa2lkHlDJBGd3zDHPfGKiT1s9zOo5RdhTHH5e35enTGaxNMjEni21jn2OpVuTzggcY9eprWmulI2qChxggHjr6+lc7c3Bsdasbw5zFOpPbjv/OnStzjpRk4yXVpna21mIluQzsXt0Z8Hvg+v0qnqMaLDexBQDGqTKBycHqBUjaiItQuAvCyqx2k8lSM1n6lMhicjAbyhFtznv3rorODjZI46UZuV35HM+IbdNT0q9sputxBJBwMAllO3684/nXycudoB+9jBr60uvMjuVdDmNWUkZ7jnPFfK+sqqaxqCx8ILmXbn03GvpuFZNKpDpo/zPNz+muWE13/AD/4Yp55pB0paT6V9fufMhmik7+1FO4z63urvyTHBNf21uc/LEmC7DqeHJ44PzcdKbHerbMJ1k3ybcm4ZAxC452u54HcgHH41DbpChYxQqqufm6b2z1DHq344/pUl1tnmWLG0kAyEDCNg/KpPGc45/KvyXljt/kfp1lsxtvPcPJ9omidZJgHxJJ5ZCdApUKQeuSM9Twanfz7e5jWdoWn3yXEZUHO0qQy4J5LKcAYGT06VGhkmvAUYqgUBSqgA464xxg9On5cVC9wPtMMMcksrRl9pUgFFCkHDdm3fKF5Khs4BNFuZ6LoDjfY0bWOG7LJdO8mlxbj5cx3+co5yzDJKrkgjuR14NT2s58oSzzFnVRJC0eTJ5kjZDBumT8qH/dIPDVWgsFu7NrbUWi2x4HkxSGOOP8AiGB/GM9M8DAAA6VHLP8A2ZeRiVn3PvMMUON0mcb1UdBwVbn5QBk4ANR8Tst/6/p/5GUknfX+v63NBZSsrfbY7c3jRieYN9wNuCh1wcmPjaqjnPGMgmsnxBcxqFe9LCXc0rwyAcBFPlwqBkLk7CcDnI54yLMUc1xqU93JLHPeqsS2yRbvJjAViU9TnPLN1BVuFwoxL24t11SJ41eWGKQtJvKmSWZei4GM7TIwKjpyOcc6U4Jz0/rT+v61CnC7Og0mF7eSOe4TeWg+dioACsQ/P/AlBIzkfKKNFfzJpJJGlYySyo6gA53KGz14wEx2zUOpXLwWGyErLctHJJMY2JGQrED8wBjsABkdKk0/baxeXDGjNbTKF2gYb9wB069xxnkZ9ajWSbYNNpvqyxYwI+p6gwkJ2mOONSxwUyS24Y4O4EEc9vXg1GKe4LFvN2gukcQYEPkEMzHpkk4A/M81E7R6e1nJa7ftDslsXzt8xuMt74OWBwe2fSr+oQ4tVtYCwVUYFwPuoijcOn3juUD2yc5IpXs7r+v6/wAzNu0kxVkme8uXRAEt/wB3bEngEZzJj1GMD0ABJ5FZupXAhvjbwwBo0QWbR5aPLFd+0cZyfvMew69QDpxszXNxY2oWORpdzbG2+SmFwv8AvMcn1AOecis67ttnh15oVeVoy15JIOskhLSe5XAJbtj5fXBqKX9f1/W4oWTV/wCvMm06B7SWO6kdZL29VjLKy5LONhBx0yADx7+2KstCBHY22WAS6dmLnJYqCcnjuCMnGTk0mmRuZ7a5n3CWYPKYtoOVwAAW4wB8gY+rKAQcVYsF3aoogbETRucBeJBkZb3BcnGDngHnmk77kye/l/wTQFxmY4kf5uCy4AOfr0/L8ulQExyXCxg7gWZlznAH3AefYD9TipUWRnMbKhYnerqDgKAMnkY4OMcdxVGwYGyikO8JMQqkDnaCR0PU5L8mmzGMVui87hpX+cOCNxYkg5ycD39az7iGWMkpjJPO5sZJ9c446f55q23cznIQHLOdi8dWOegzjPPWhUh8tRFMsinlGVd6/TIB+lS073Ki+UypIklhYhVZW4dgv3T65A+n4Cqb7yuCzDac4Y5wCMY4PI4H5fStq+hygMg+7nmQYJHtkYA6c1lTIqOFdD5U7AI3Jw4UDZ04Y4yuMAncOuMtam8amlzAuVmBRULlCrZWQA4UnnIxwc5+bOaxLkSgFojkCLamOGQ54A7n6H24ya6q8gSRo5izPIOVyxBXuP8A9fNc9foUTKK7ooyys2MeueOh5GfXp2rtoTvodkZaGJeTNsVv3TNyvMm/HcE8cEHPX86ij1LTzo2sxX9z5eqOInsX2OwIBBcHA2qDnr1HI5zRqUR2En947DcgZcHj1OOARj8+a5bUJS0rksjY4AA+VQTntn/DivZw9CNVW/rf+rkzeh0Ed2IpGiBAUgxM2SyOo5OB6ZwastdYiJDs0cZ2Ftw4zzjPcHBrhjeFWJJORwP4s8jPPbH8qsLqbtEUaVki5PAGPM9cew7da654B6NEKujs7K6AeNtzPHjc/wA+MdOGPp7HrwOKhu7uOSZ/JYRK56KcjGeuf8/lXGy6gpIWEeXGcLtL5ycdSfXue2aRtWKTq9sOAFwsgB5HXIHvn86I5dK90CxMU73O3jvmX5VwGJx1H86WPWHDbGTep6t3GPQ/nXH3+twXF08tna/YopOTbhyyoe+3PQHrjtUUeoHPUnjgZ/Kp/s52vJWN44iEkehWl7mRGtnXywPmDnls9R+f8/aibU95J3bOdpJIB+n4Vw0V4NvLfiMcVNJqblmbcoHQH/Cud4D3iHVjc9Hs7823yTL06mPjnI53d63ZNZiDqscmY2Bx/s+o/wA+teOLq5UBN3yjBPPU1bj1zaSd7DIxnoa5KuVOTuS5Rlqz1BtXG8gNgsMDB/pUN1qEd1A/UluMkD9B+f5V58usgOMkcZ4IHNaNvqquVVnI/Hj8qxeXOGti0o7o9Kt7+N7OI7BFIiIvJIzgc5Pc9+/FLZ3DXs+FkQrnjLAkj1x2P51ydr4htI4DHIFdSuBkZX34/rWbrHiGxS2zbQRRMvQRDa35+v8An2rkWDqTbikzD2Nr6HbeLLm30TQry8f7wHloC3V2BGB/ntXybcSebcTS5zvdm49zXV+LPEd/exLbXV7NPsBCRyEHywe+PXt61yH06dq+yyPLZYGlJzd3L8j5LO66clRTvbf+v63A9TSDnrS9+lJxXvI8ETNFLRQNM+oba4D2a/auRgjeGC7hnoy5wpPHPfuFNTRokKky5wx2sdm5j7keoHrx6dq5+z1BvJVXSTIUDcvI6dwePXv+FWRPGiOQ7SxIwVImwdh7bc9fcc47Y7/mU6DTaP1A2i5lLp5z/ZARuCnbIw/uk8EjPUZB9+ac8dvcXNsyxEx27BAoQqEDcdBjHbj6+9Y0N24Zgh27yA7Acj0PPY/59yNw7LsZ0mWbPmxkk4B6dwR2wRj371DotdbD5TeluUhlVtjJkKhAYjcAM469cdPQEk+ojM63XnzXYCwqONzHCoM7mAHJyC3OB06d6zPtD/aibjyY3AKowG7zRu+faCDwDgFSeoPLDmqd/qDJJHAXP2beDIEViVjGPlyB0JKg47MaUcO27IXLfY2DqIsdPfUJIk88RF/KZ9mTnCg8YGSVPTv6VzdtcvNdWyqSwWD+1Lq5I2/vN7YYDt+8KNj0TuuKy9Vvhdb497fZBuYBUyeFwjv6nDBVXoOCeeKktZLhdSuYpEX97NFGys25TujwqHHB2qFY8dRXfTwvJBt7v/hvwv8AlcpJHd3gjudAmWWBgLwIqooClUPzEFTjBIByR/QVL4aufP05ZWRCZyJCHYoV4Cj05BUEZzggYBxXOrKqz6WqW6bROZCEl3DoSBznI3DcR27YAIqbw3ciKwhjWYojyywIFI4IOQN2e2OPQdjXDKk1Tdu/+f8AkRy6NHWTJHcX0KxnEaxMC6kLhnUncCcYJ5znqR6mr4cTS3DhwzCGNRvPGWBJG7JHfn0xWEl+zy3ZkdRF56hZd43KhjRT6c8jAGQTnmlttSjS3lkuWaNLpjKeAG8lflQbR94ELuJ6fNg4ya5vZu39epzuD2N6PddS3BSOTeUYImGYoCwUMB6k7m49B0qvrBNzo88aSCGKdZIxlRkQLxwexchcHnjvWXperSXH29nVkuZXzEAGbGV3Yz/CypgkE8HA71ortGnxRO5UzxC3UABRsVcHgduCfXJHA4ocXB67k8jjJX6GqRGZrdjxJcRuszcBghG8KeevUenJx6VPC4QzEmKKPaOckYUdfpzjp6DFVXmnluLYwszSGJ5d3l7sHCj7uQf4j3/HFUri8jF2E8+a6vYU8wW1swjEGP4pGB2oOvzOxPHANKKutDDl5tP63JtWvfskbTSyGPfblgk3ysEXkkKOTkkgepPoADCbh47axgtLeQhE5lbCDGUBO5v4Mtgsoc56YxzmXVrN5cU92kZeeUSmOJsFFByVU9d7cZx93dntk6Y2TX89xPKjKjLHucHMkgJYoOoIGU45O4H0JNKNkbciil1/qxatnKTE+bDHK2D5iA3En+0AzdF9lVcdcU6aZpeB5kgKkGWQgqR0xjo31IP41YlRJFXCiKMgEIuOT059R04FN3AKHhALKct2UduB/IH0+lTLQyunrYqLZRxBQsMGS3CIg5PPG7H5YwBz6mkubNLiYyMjrJgANv4XpztJ257ZAz1yTzVuQRlWbKjDdc/Lj1z6elEsxEYDqATlsMfu88AGmO7bTM2W3XaQfnfJ3DPUnvwDzzn3/Wse9tJo/wB4S8YUhk2MQQ3Q4PQ5GTkiukmjMscgBySSCw6jJ7eh+uaZIqAYmAZhwVYdO5OenOBx61mp8uptGoeXaxpaokqxWUX2iMb41jAjJOeeu5Twc4P4Y4xyGvaTcxLLIJ4rmJScNG67gCcg7RwwPPKFunIHSvadQsd0aNBIrNGd6hh8qex/2R7AH0OOK5nWLTHnC6smkWdUIkhQCRWDZGwE8ggkEjnBOM5yPYwWYSg1/X9f59zo/iI8RkZ2JYbiCcZC/pTDnAUZCgYAOflFaniXT2trt54EkVH5+ZShJ78EDPPXHSsA3Y3ZdAc9SDj/APVX29GSqQUonlV5KjK0yyd34D8cVGwZieeT3qFr5RxkjHrTXvl5AwRnjitlBnLLFUN3InO71JpQWB64qg1638K/pUT3kzd1H4ZquRnPLMqMNm2a/msSOegxxSmUjBeQDHTceKwnklfrI5/GmBCecHPvR7FGTzZt+5Bv5/8ADnQbxtH7wdeuQKkWdioClcjnK4z+Nc75BOfl/SnLbkkZGPpSdBPdmkcyqvan+P8AwDpFlYAFpB0qcapHFG6yXUS9h824g1zCWef4c/QZqylmFGSmBnGSMc+lZzw0H8TOynjsRLaFvnf9EbE3iGPn95NMw4Gxf6msu/1+7mysANrF32klj9W/wrU0nQL3UWUWVpNMCcZCEL/30eK9D8NeC7K1cPrEH2mQAERLKFXPfPFcGIxWDwerV326/dsbVKWMxMLOpyryX/Bv+J4gCDnB3dzzSH86+l9U8LaFd7VXw3pzxDq+1kLA9SCu0/Tng81xHib4Vada6BqV/pF3qTXFrEZ1hmCurKDyuVAOcZ59qxw/EWGqtRmnFvTvv6HgYjJa1PWDv+D/AF/M8f70nI70o5wVHBFJX0B4ohopaKY0euJroTakbgnGSD1Q5wcqPwOenoaki1JQ6u0gC55boR/u+n4cVyf22OVXMhUOQMktjP19eT06fjU0V2rFTuEhAAXqzH+n49frXzMsEl0P0WOIuzq7fUQbqVYkPlMckZI5PoQcj88VeGohnENrGqBVwG2qVTjtgAZPtwOv14uCdd5Vv9Z2Cn5vpgEf/XqxLfFISqxiNuyg4JPrj+f61zzwd3axqqyOovdRUWrLMpNsi5wHw7Mo4KgDC+3Oee1Nv7ozBBuHmSKsW+MglFUEtjPy45YAe5OfTkJL2OWFleVRIoBPlsG47Dv3x0A7c1K16fMBdQFKjY0rZ3++0nA7dgfSmsDy2H7eLNaR4xJJuRXgUxosML8Ha+7avI2gkk85wQT2zViwnm+1XgvfLmllmRpA8asrBkGDtIOeh5Azx27c5NOH8h2eIbHwgwwyTnLDPOCeP1was2t0dkk0BLtu+6gyxGACD+Q9sgGtJYd8v9eX+X9WJVZNnWx6nF5xkbLou6Ub23ckgAZ4HCr0/SjRpMIsM28PvaQZyC3zHPQE/wAQ54HOeBWBHfiOGWWEXHkhdrltquewXp68E445A5BNWLC5MIAt9hkIO49nJOW5wMg/Kec9q454e0WkjRTXQ6JpLiRbryz5SGYRRpxukYxqC5xkAbQ2CuTkE960YJkm002fl3EZfHmkIFaQrxkk5JXAxg5G3gcACuPsrtpL2XIEeFXaqdtpJx7nJB544HBxmtq31SOG3mleMOIz/qmIJdscDHBZienOfTvXLWw8lZJdiubQ07i/l3sp2mS2UhSXJzKRkgDHTy8ocgY8055Wtq11qOEE3Aae5dV2JG4Z1RgpHcBBk8s2Acnk8Z4W5Z5raMiZwwDFjny/MZjl2PoNxwOmBzn00/D2oKNKt/LjWNJYoyxVcY+QLuLbQNxO4d+uMjrWNXCrkul/X9dAaTOs8271O8khu5zBAsQZ4LaQjZubo0hwWbCA5G0Lxwc8ayT2tuItPt4I1hV9zQRrne33gvXGTnex7fL/AHueTsbvMlwiRJgtsWR0LdAMnBPJJJPJ5PrVpNQ+y25SGZ4ZmUnzJQSyKCdzP64J/FmAFcUqbvZf1/X3/rnKF9Do7i9cLc3DRpPOo+y26hCQJCSdijrguDuY4yI/RcCxZMttH5O6SR4kIZ2HLMTliecgk88461zVkyIEuHTyB5Zjt1kUBo06Mxyf9YcZbqcADPXM6aji1LLMWeblQVJbGcJ0XAH8hzUuF9EL2XRHW+eCjFQGc8jleMd8+2QeuaSbYUZQCq9ckbTkeuODn/8AV74n2wJuYhY4+gLAHPPBB7/yNWluSJMyHLIMsHQ5J4A4GO5Hr+lYtNGXsrbGgzYX5vvEYUdSAO2R3/DFAYRsd6q7kZCgkAk9fr2561VhnDBGf73LbdwA4PBwcd8/jTpnYuAZCp3ZIk4De/PTjPfg9qQuXWwplLkgrGzA924HsPw/H61E1yF2jKugI2BB/F647devPbmpsIIyQ7AlyGZZd2P8R/jVaeNVWTYdw6soxnt2znpz7dqjQuNmO3gOHAPyfLkrg+/4j/Oe0NxGkwK24dUdMAEcsvYE4wB14P68CozsiUTGQhHHc9Bj0+hpZJSDvYNtIwTn9PX+WaFdPQvl6owNb8PC/hMU8bvEBuKM3Hbnb6kY5xnA5xXGzfCGC4+ddQmsiR91o/MA546ZP1Az6cV6cElZzvDhkyV3E5GeSfr2zQspT5cY/uljzjvjuR0+td1HMsTQVqU7f153Jq0o1o8s0meOXnwevU/49tZtp2HYwsCfpjj8yKxrr4Y63AcBRMpB24+Utj0B/wA/zr6Ce7EccgbLDOODnt6Z7HNV2bejEOQzcZB64/zxjjtXbS4hxsfiafyX6WOP+y8K9XT/ABf+Z4CfhrrqYL28Sp2ZpkI4685960NP+FGs3Pm75LS3WMkHe/PtgAc57Y9OcV7TcSxQxO8oZz3AzsDegHTkA9arvfi7iCusaSR5zICQ3pg/7P6n26Vs+IMbKOll8i45ZQWsaa/H/M84tfhRbR7ftmp71YD5oVyAe3J6g9QBz6gd7sHgXQYgwSG5mIAG55MHjrx2+ntXaXM8s1vGJpThF2JwAADzx6ZP8qpyKAM7R6fNng+/4VzvM8XU+Ko/lp+VjrpYSnHaK+4x7PwJ4daLzHtneJ3ZAxlIkDA9FA4Ocgfh0qxD4R8PQxASaYkW1dweW4dmcnsSMAdPzrTjuC8cXynauRlflYDr1/ujOf6+r0eXcIyFLM6eWQM/MRjjsQAMnucVjLFYl71H97LdFR1OY1rQbWScQ6Tp0UTj78pLKqHjAb1Y9do9s472NG8KWNhIZ5lN9eKcmafhFPfYvQfqa6Z7GGytHigDECQyGSQlixJ5Zj2J71X5fcx+70GTjFN4uq4cik7fn/XYy0nqIjyELGGPl8HYOB+X5/rV22twVHYYwMj+Z71BsLD9yCVz8xGMfQmtG1REiwzrnGSFz8v5VxzehcnZaEdvI0W7oqr+YHr7f5+tWY2QglS2dhIbPA4/+vj8aitY2WfdbspkchdhHUH19O3FX790tTccxgRxbRgcZNcs3rZdTmrauyPmP4h6Gul6otzbxLHa3ZJ2KOI3HJA9jwwrk/b+Ve0/E+yW58P3GFJeACYf7JHUfkTXix6V+mZTiXiMOnLdaHymdYZUcRzR2lr8+v8An8xPfvRQaK9VXPHNd5XJznBpolK8DGD14FQGTAPBPrzTC3tisVHyPbliXe6ZdFxkYb5j2yMj9asQTxIGZ4xu/hAiB59PQD8PwrL3ZxjOfWlDkHPWplTTVi4Y2S3NcXLSRqG8sopyoI+5/wDW75A+pqTzl2tsUyE/KWXdn6knnn0/KsUSMSCMnHanrK4OR6fWodFHRHHrqdBBdMYi0h2BPvBZNgA/L9B6003JAZgWjLMWDMCSPcDqTxz07Hrmsc3Du+9iTIed3c0+O62DBGccA/xD6HtWTw/WxvHGxfU3knucJnAU4IHUkdiAT9Omf0GJ/MKFXBBZecOMbfbvj06fjWAt2QvyZAJ5KjDfi3rz/wDrq3FfYGFdyo5VHwAuex7fkBn2rGeHfRHTTxS7nTw3OHWYhTIBtBKNgD0BHI9cYz6Yp0N5JuMxEqnJbaMAohxlRnpxgnA5wORxXPPerhEljCoSCQFyrLzwM9s9QOvrU9vfKjFIGjRGwSkg+X6gD+R45rjeFdtjrWIT6m9JcyrbSSIZBhGKvhGwAM8DJbPH8WOoOPW7YXohs7aMERskQRT5vA/hILHGPw9+CK5wXzNAYxhgeHUAgAA9Dx36ZHTnqasRXjLCq7lwq5IY7sj6Z4GfoPxrnnh242aNo1k2dda3wSJdsUKJ91pCofH1468ZwRzS2N9EZkkf940j7ledFJPZQAAQSB0XGRk4xzXLRXv70RhQu8YcSNnCZGSCvQdAMetaN5IsinB2pJwQpAQg9vvZ5+nGc5BrjlhUnZ9TZVEzpLG5aRoUM7rEwYAbTzliV3MeTx27fpWvNdMIWZG2bV++z45xzjGTz+vua5iC9jlVY2BQYwAsmBjjgen5dKnt5CuC4bdgBTIQdg7bRjj27/rXFUo3d7FqWp0Gn3TieXzsOWfeWOOgyB0POff19eKuJe+XbmMx7FDgsu4kg9dwA4znrwCO9YDzSMhbzcsW5ZuDnHPHIPP/AOqpkuWUhsv0AB3bs5/HB6Y/DBHeueVK+rB2ep1SXQdH8xyrJjPfgAHGCen0xVmO8YKuSwIbJwBjP+T9cAfhxlveyxRfumwpKtxkAE+4+Yc49fQVat9TIzuBLqSvzLjn6EAf5z3xWUqEtbEumdcbnylAjCKY8nfHlcnvkD0qCSZFBBJBc4UDkj16f4GudfUXlWH51Yj7rElef8e34/jRDemX5WK7tmNpI4J/2e3b3rL2D3BQ0OocBklMmCOQuzJH4YJ7c49TUD7lTK42A7SeCD65P/6qo29wUAcMCi4BLgArkdT04/M01n81lkBdMEKHU8Dn1BwenT2rPk1JimjTQfNwkmcgcjJ+vBOO35+tJNIZI1ZAx5JCA43HOPw+tUXvHt1Bl3I2QwdRhW69fT0qO7nMhB2Ri3xg7Bhj7H2+hqVB3uNRuyV2ZN+SHb7o2LhY2PGM9+v41FNOEkdA++XnIQncemOcdPbpVdbhJA/2b5ZY+CrPzx2zjNZ17qEoaU3Dom/5t6Bmcv6nsMdPwreNFt2NYxuy9dPNIsTqqhAOckHHqPeo3ncK4dmD/fwRwc57/wCfbtVL7TCfL3K07KOEdzGmfUhT2+pzUqTutuYcKIyQMZ/l3GcCtORroa2L0ZYoC0QBHCkk9PTrTLiP7q5BweNwHT0596qh2xt2sRnON3H1Hv71YYFl+9kBc7gO3bP+f/rzy2dxbMhBmV/lx5fIBb+IelaWjI6N5hGxI1Ku2OGY8cHqMDNUpXV4ljySergYBY+x7duKsaNIHfOG4BBAxjGRg5+ufyoeq1Ir6wZevmUBAx9VzzgDn9fas2NkZTtHT7xbqOaNZneIkOWAjYg46E+59PQVTs7qNY3UKrsV2qTkFD/e4PXqMNkc9DxRGDauzmhH3bl9Hy6hu2MZOQfoOlWWuApJY5GMYYYHPtWE2oBJuWX37k9fypDqSFGYEDbwSTnB/wA/5FN0JPoa8pYnvZ/NxEep6KOf0/z1rZtHxb3M024r5fBcdD61xS6gJJ02kjBO7Ppnp9K27i8lnxbwNkTEfMzADA71VbDvRWsZV0tEYniXbNp91C2PmiIJ9Mgj+deBKMKBnpXumuy43ncGx15GBjqBXhj/AH3xx8x/nX1+QpqnJen6nznESVqb9f0G80UGiveZ8yWc8UDrxTecUD8/rSOy47uMgUU3J/yKX6mgLi5PUk596Un6U3PTmj/OaAuOA7cfnn+VLuHYnPbimA8c0Zx3o9R3Jd56gY/rQH6fzqP/ADzQKVilNk6ylenGalW4YqAwyoPA7Cqufpj6UZ65z9aXKmaRrzj1L6XGG+U7RjtzVqO6PUscEZyG9+/v9eayAf0p6SMpyrFSP7pwRUSgmdNPGyW5tpcmRt0z5Ynuen4/nn8OuKvWtwi4++VPJAz6evBP4fnXOR3DKMZOD1qwl1kgksD7GsJ4e+h30sb5nVwXQVyySkoSOh+b37g/561rQXxKAtIz5yfUY/Hj35riY50YcqCc9Qef8M1aguhGxK/L3+7XBWwXMejTxSO1hvXbH70ts+6B/LkZ/I/pVtb7zgwkAdC20nLE/Q4x1/E8cYrjYrgFXAQfN1XOe/rViCQsRkhtuMZPJ9sng/jXDPBpanXGsmdfBeZmkDOgmOcEMQVJ4AIbqfpz9MCpzekNlmhKc5VjtbOPQ4Axzx3PYcZ5mC43FQMkgYC99vOBjv37d+3WpWvDsPzbVA3bQxZMenfFcssLqaOojZe8wQyopVfm+bD9se5HPrTo71923zMsCNzL79cc5A/nXMyXjI48zag6gbcY9wQcd+/4iqjXrxsCGY4+6WYMfw9a0jguYPbJbnptjqBVA21soOPm+77k9AOcjp15q8uqQOrAfu5NuSGG1uvBGOvt/nPlY1uRVCnLKAcZ/wAasDxMyxLC8wMeMhT03EdR6HrmuSeUzbukZurB63O8uNb2kpCruGYIEiIkBbOBx19emc+lUotTijDyJbJ94FpIcAqem0r2xniuGfV2kOZpN5+7uJIOB069Dj0pkWuSQyLmWRpEJ2SvlnKkfdY9xjPB962jlbSskWq0Fpc9BN+ZpjDLMjMgwBcAIyKOfvdsH1x1HvVX7Y7FTCzGHAYFQNw/4Fj+ea47Tr3zHKhipjX5eQc854I5HY4rXt5OfMV1+ZQWbJ2t65P59c1E8GqTszSFRPY2WljfI8kMCfnjkyCD34NTsCm1ttwEPcgEgY4GR61niYeQvmK8TsPlLnCt1yQ3b9RUiHDKbjCK5+Ug7lPPNc7gaqRpWc2ZG3nChvlb1PpxwePX/CrUkjKw+ZwzHBITAz3A/wDr1nWu2MloXEbj/lmWyG57A1c+1bkGVV48EbEHKj0/z71zzjrohuRMSEUeZmQAZyFyo/8Ar1JYTo8zxwP5RwxLgkEjj/vkcVChlltm8gK8C8vFnbn0OO+D3z1rLEsdrJ5yKNw42yqTkHqG7c+pqYw5k11FJc8Wh+u3QUyREHfuwV/z7egqmt6v2fYW4wAMHCj8Ky/Ek/ly+ZEHSFxuQu2T9CR3HT8qxnvW8sDnB4B7E+g969OjhOamjn5rLU3Ly/BdgG6dMggVRl1AiF/n+h61g3F0/JP4nrWbNesRgP16816dLAXRnPEqKOgOpmOM4kYFu+a2dN1ZJhDCyhs8YJ6nrXDQ215erusrO7uQgwxjiLAH64rR8PR3cGsRXF3C6rCpby8YLHGADmnXwtPkeuqOKVecpaI6PxHebbZ3Zlwq7/pweK8hBzye/Ndt4s1UmzEfy+a/ylccKD2riieufyr0crounSbfU8HPK6qVIwXT9RPzoo780V6TPC+Q4HApdxpv6UdqfUfM11HbjilDkGmZooY+eXceHNG725ptJ7Ug55Egb6/40u+oqX/PSgpVWS55ODS59uKhzRmgpVe6J89v0oqEMacHx2oKVWJLmgmmBwRjtSgg570FqSexJnjjmlDHt+lMDEeopB+FFi1IsJKyngip4rjBGRgj0NUcn1pQ3v39KlxujeGIlA2ILsAj5jir0d+cgZ4xgZ6Y9q5tXp4lOPUVjPDxkdtPMGtzsEvIT/Gyt6j86U3mcgEnHG7PJ+lcoLhhxk08XTddx6etc7wS6HZHMIs6SS4TjoCeu3ofWq74ODnr0zn/ACax1vnXAz6Uv2wde/Q570LDOInjIvqW3YgsflHbCj+YqJZnVwQQCvYn/Pr0qIXmzoAMdsUjXjED5hxzyM4rXkl2MXXT2ZIHwCpzg/w9KUTOgUoCrjj0yPwqL7WD94ICe6ioXlU8jjjvVKLe6J9ulszSspVV5Gdiy7MDtmuh0+/2qpZm4wBjvXHLMmCPunPY8VYS82HCEAHg+n0rmr4X2u510MYo9T0CLUWLFoWCrIMMm3Cseeq9vwq3Y3+G8sjb0+Q8jgdPfv8AhXnsOospDK/uRmr0Or4VQzDA798ema8yrlrSskenTxkJbnoiyRPCGbyzlgTwAfz/AM9KkhRWmyhf0ZRwdxPb16/4VxlvrMbRv9oZ2wuUK4Cl+wPoOvTmrEWrwgBreVw3I+fgYI6D2+tcEsFUV0dKrRa3OsaV0cJbuxcf8siuWGOwqO4ubZmI1JSshOfl+/8A99fh071zr62s9x5uMoq4aOFQGbjGck9uDkU6G8lvo3E7oZIyC6s3OO2T+FZ/VZR1lp+ZSqrudHssb+1aBruQqcFXlhVhx0z2I6Vgz+FLQy/8hNo1JwY0jC/XqcD2rPv7mWxbym2CYZY7eq+n6VSfWcEkNnPBrqoYWtHWlLR+gN03q2bbeG9IgmVWM1yF6+Y+M/gK2LODSrVwUtLRSnfy881xcmvHbkyZbHrWZca7IW+9wPfrWrwOJraTkzKdajBbnrUvjKexsfIs2ARQQFRRgjrkmvMvEWtyS3Uk8rh7iQ7iQfu+1Yd1rEroRvIHesW5uWlJGTt7+9dmByeFGXM1ueHjcxpUk+TdjbqczS552jgVD2/yKPxpP1/CveSS0R8rUm6knKW7FopD1oo2ID8aXHFIKOtHUQpoHWk+lKPbmgA9M4ooFHvxSAPxoP8A9ej60e1ABnFA9KCfc5zRQAUfhRx9KPX1oGLRR9OlFAhQSDwadvP4fSme1L3pjUmuo8SCl3A96jFFBaqyJcj1FLnNQ0f56UDVXyJs0oY4/wAKhyemTRuPXNFilWJw/wCdG41Bub1oLEjqaLD9sT5Of8KN3Tmq9HT1pcovbMn3/wC0M0hkHrUOaKdifayJfMBxil80etQ9+aM+/wCNFh+2kT+YT3p4lwaqdqM++KRpHFSRfS5dejGp1v5OhJ9fpWWHI6jP0NODj6VLhF7o64Y+S6mxHqJXJ2r5rEHz+rpj+7zj61oW/iFreNEWCB1Rt4WSNWGSMN15GfrXMbx/eGaN47Gsp4anPSSNlmU11Nm81ee4REkYMi52+oHpkdfxrPa4Y9/aqpkHXP5U0uc8DHrmtIUowVooxqZhOXUsGVjzUbTehJqEsT1OaSrt3OSeKnLqKzFutJRR/nmmc7bbuw79KQYo6n/69H4UxB+FFH+fpRSduogzwT70tFFD3AD1/wA+tIDxRRSXwghf4gO1DcZxRRQhCDpQfT60UUyhaB0+lFFOOog7kfWkbgHFFFR1H2F7mlHeiiqYg70veiil3DoIO1B4FFFUtwF/hB9jQaKKUhCHvSjpRRVD6AORzRRRSjuAdPwH9KPX2NFFJ7oQUjcUUUxi9yPcU3PBooqVsCFHagcjmiihgIBzjtmloopsa3DvTQf6f1oopAGeRSmiiqYCDofrR2oooAX0pPSiikhIAeRQPSiiqloAfx/jRRRWU+hEz//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sausage toe (with diffuse swelling) of the second digit and mild keratoderma blenorrhagica on the dorsum of the foot in a man with reactive arthritis (formerly Reiter's syndrome).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Wiesenhutter, MD and David Yu, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_31_16881=[""].join("\n");
var outline_f16_31_16881=null;
var title_f16_31_16882="Molluscum neck";
var content_f16_31_16882=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molluscum contagiosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the linear configuration of lesions resulting from autoinoculation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_31_16882=[""].join("\n");
var outline_f16_31_16882=null;
var title_f16_31_16883="Patient information: Rheumatoid arthritis (The Basics)";
var content_f16_31_16883=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15445\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/5/31828\">",
"         Rheumatoid arthritis in the hands",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/21/26962\">",
"         Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/11/7347\">",
"         Patient information: Hand pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/6/11363\">",
"         Patient information: Narcotic pain medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/3/43058\">",
"         Patient information: Osteoarthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/14/39138\">",
"         Patient information: Rheumatoid arthritis and pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/57/37778\">",
"         Patient information: Steroid medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?38/29/39378\">",
"         Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/40/27266\">",
"         Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/52/12098\">",
"         Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/61/21463\">",
"         Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/44/24264\">",
"         Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Rheumatoid arthritis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/rheumatoid-arthritis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H473801963\">",
"      <span class=\"h1\">",
"       What is rheumatoid arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Rheumatoid arthritis is a disease that causes pain, swelling, and stiffness in the joints. It is 1 of many different types of arthritis. Doctors and nurses do not know what causes it. But they do know that it happens when the body&rsquo;s infection-fighting system, called the immune system, &ldquo;attacks&rdquo; the joints. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H473801970\">",
"      <span class=\"h1\">",
"       How can I tell whether I have rheumatoid arthritis or another type of arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You cannot tell. Only a doctor or nurse can tell you that. But there are some clues to look for. For instance, rheumatoid arthritis usually starts by affecting the small joints in the fingers (",
"      <a class=\"graphic graphic_picture graphicRef70434 \" href=\"UTD.htm?31/5/31828\">",
"       picture 1",
"      </a>",
"      ), the balls of the feet, and the wrists. It usually affects both the left and the right side at the same time. (Other types of arthritis tend to first affect larger joints, like the knees or hips. And they may affect one side much more than the other.)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H473801977\">",
"      <span class=\"h1\">",
"       What happens as rheumatoid arthritis gets worse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Even though it may start in the fingers and toes, rheumatoid arthritis can affect any of the joints. Sometimes it damages the joints forever. Plus, rheumatoid arthritis can cause problems in other parts of the body, such as the heart, lungs, or eyes. Doctors and nurses have no way of knowing which people will get which symptoms or how bad the symptoms will get.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H473801984\">",
"      <span class=\"h1\">",
"       Get treated early for rheumatoid arthritis",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your doctor or nurse tells you that you have rheumatoid arthritis, start treatment right away. Do not wait until your symptoms get worse. Getting treated early can help prevent a lot of the damage the disease can do to your body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H473801991\">",
"      <span class=\"h1\">",
"       What are the treatments for rheumatoid arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are dozens of medicines for rheumatoid arthritis. The right one for you will depend on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        How bad your symptoms are",
"       </li>",
"       <li>",
"        How many of your joints are affected",
"       </li>",
"       <li>",
"        How your disease has changed over time",
"       </li>",
"       <li>",
"        What side effects you feel with the medicines you try",
"       </li>",
"       <li>",
"        What your X-rays look like",
"       </li>",
"       <li>",
"        The results of certain blood tests",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In general the treatment options include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines called &ldquo;nonsteroidal anti-inflammatory drugs,&rdquo; also known as NSAIDs (see",
"        <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"         \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)\"",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Medicines called steroids (see",
"        <a class=\"medical medical_basics\" href=\"UTD.htm?36/57/37778?source=see_link\">",
"         \"Patient information: Steroid medicines (The Basics)\"",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Medicines called &ldquo;disease modifying antirheumatic drugs&rdquo; also known as &ldquo;DMARDs&rdquo; (see",
"        <a class=\"medical medical_basics\" href=\"UTD.htm?26/21/26962?source=see_link\">",
"         \"Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)\"",
"        </a>",
"        )",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People who have severe pain that does not get better with the medicines listed above sometimes get narcotic pain medicines, but that is not usually necessary. (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/6/11363?source=see_link\">",
"       \"Patient information: Narcotic pain medicines (The Basics)\"",
"      </a>",
"      .)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H473801998\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It is very important that you stay active. You may want to avoid being active because you are in pain. But that can make things worse. It will make your muscles weak and your joints stiffer than they already are. A physical therapist can help you figure out which exercises will do the most good. An occupational therapist can help you figure out how to keep doing the everyday tasks you need to do&mdash;even with arthritis.",
"     </p>",
"     <p>",
"      Another thing you can do to on your own is to eat a healthy diet. People with rheumatoid arthritis are at risk for heart disease, so avoid fatty foods. Instead, eats lots of fruits and vegetables.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H473802005\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk to your doctor or nurse about it before you start trying. Some of the medicines used to treat rheumatoid arthritis are not safe for a baby, so you may need to switch medicines before you get pregnant. Plus, there are things you should do to help prevent problems during the pregnancy. The symptoms of rheumatoid arthritis often get a lot better during pregnancy. But they can get worse again after the baby is born.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H473802012\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/57/37778?source=see_link\">",
"       Patient information: Steroid medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/21/26962?source=see_link\">",
"       Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/14/39138?source=see_link\">",
"       Patient information: Rheumatoid arthritis and pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/6/11363?source=see_link\">",
"       Patient information: Narcotic pain medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/11/7347?source=see_link\">",
"       Patient information: Hand pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=see_link\">",
"       Patient information: Osteoarthritis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"       Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"       Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"       Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12098?source=see_link\">",
"       Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=see_link\">",
"       Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/31/16883?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15445 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-118.97.94.19-D16481E7D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_31_16883=[""].join("\n");
var outline_f16_31_16883=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H473801963\">",
"      What is rheumatoid arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H473801970\">",
"      How can I tell whether I have rheumatoid arthritis or another type of arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H473801977\">",
"      What happens as rheumatoid arthritis gets worse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H473801984\">",
"      Get treated early for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H473801991\">",
"      What are the treatments for rheumatoid arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H473801998\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H473802005\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H473802012\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15445\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/5/31828\">",
"      Rheumatoid arthritis in the hands",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/29/39378?source=related_link\">",
"      Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/21/26962?source=related_link\">",
"      Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/11/7347?source=related_link\">",
"      Patient information: Hand pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/6/11363?source=related_link\">",
"      Patient information: Narcotic pain medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=related_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12098?source=related_link\">",
"      Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/14/39138?source=related_link\">",
"      Patient information: Rheumatoid arthritis and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/57/37778?source=related_link\">",
"      Patient information: Steroid medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_31_16884="Echo 4-chamber view MR";
var content_f16_31_16884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/75955/4chcodmr_conv.mp4?title=Echo+4-chamber+view+MR\" style=\"width:360px;height:272px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echocardiography apical four chamber view of mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 462px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Apical four chamber view with color flow Doppler shows severe mitral regurgitation during systole associated with marked enlargement of the left ventricle and left atrium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_31_16884=[""].join("\n");
var outline_f16_31_16884=null;
var title_f16_31_16885="Eculizumab: Patient drug information";
var content_f16_31_16885=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Eculizumab: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     see \"Eculizumab: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4426547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Soliris&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10205364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Soliris&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700493",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad meningococcal infections have happened in patients who have taken this drug. Get a meningococcal vaccine at least 2 weeks before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3532545",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get this drug only from the Soliris REMS Program.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692177",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a blood disease called paroxysmal nocturnal hemoglobinuria (PNH).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3532546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a blood and kidney disease called atypical hemolytic uremic syndrome (aHUS).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to eculizumab or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you did not get a meningococcal vaccine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701374",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a meningococcal infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad infections have been reported with use of this drug. If you have any infection, are taking antibiotics now or in the recent past, or have many infections, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697571",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Make sure you are up to date with all your vaccines.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3532548",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have patient safety card with you at all times and for 3 months after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3532549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698974",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Neck stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698630",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cloudy or pink-red urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698635",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11727 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-BB90AC98B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_31_16885=[""].join("\n");
var outline_f16_31_16885=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4426547\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10205364\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023985\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023987\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023986\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023991\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023992\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023994\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023989\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023990\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023995\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023996\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=related_link\">",
"      Eculizumab: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_31_16886="Left anterior fascicular block";
var content_f16_31_16886=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Left anterior fascicular block",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/31/16886/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/31/16886/contributors\">",
"     William H Sauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/31/16886/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/31/16886/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/31/16886/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/31/16886/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/31/16886/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the discussion that follows, it is assumed that the reader understands the general concepts of cardiac vectors, asynchronous activation of the ventricles (delayed as in fascicular or bundle branch block, or early as in preexcitation), and the effects that asynchrony has on the duration, morphology and amplitude of the QRS complex. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9283?source=see_link\">",
"     \"ECG tutorial: Physiology of the conduction system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13271?source=see_link\">",
"     \"General principles of asynchronous activation and preexcitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FASCICLES OF THE LEFT BUNDLE BRANCH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic hypothesis was that the left bundle branch divides into two fascicles of rapidly conducting Purkinje fibers (ie, phase 0 dependent on the rapid inward sodium current) (",
"    <a class=\"graphic graphic_figure graphicRef63340 \" href=\"UTD.htm?42/52/43841\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/1\">",
"     1",
"    </a>",
"    ]. A more recent understanding of their function stresses that they primarily affect the direction of depolarization [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The left anterior fascicle crosses the left ventricular outflow tract and terminates in the Purkinje system of the anterolateral wall of the left ventricle.",
"     </li>",
"     <li>",
"      The left posterior fascicle appears as an extension of the main bundle and fans out extensively posteriorly toward the papillary muscle and inferoposteriorly to the free wall of the left ventricle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a third fascicle, called the left septal, medial, or median fascicle, is found in nearly 65 percent of people [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. This fascicle runs to the interventricular septum, and can arise from the common left bundle or from the anterior, posterior or both fascicles.",
"   </p>",
"   <p>",
"    Support for the trifascicular nature of the left bundle comes from the observations in animals and humans that depolarization of the left ventricle begins in three areas corresponding to the terminal portions of the anterior, posterior and septal fascicles [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In the normal heart, the three fascicles of the left bundle are simultaneously depolarized.",
"   </p>",
"   <p>",
"    Further evidence of simultaneous activation of the fascicles can be found with routine electroanatomical mapping of a structurally normal heart. Using a catheter to record sharp Purkinje potentials seen after the activation of the His bundle but before the QRS complex, a three dimensional reconstruction of the heart with location of the fascicles can be created. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=see_link\">",
"     \"Electrophysiologic cardiac mapping: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a large amount of individual variability in the size and distribution of the left fascicles. The left bundle may initially branch into two or three initial branches, but these branches further fan out and intersect with each other. This is the basis for fascicular ventricular tachycardia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=see_link\">",
"     \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\"",
"    </a>",
"    .) In dissections of twenty consecutive cadaveric hearts, there was no discrete pattern of left ventricular fascicle distribution noted [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Blood supply",
"    </span>",
"    &nbsp;&mdash;&nbsp;The left anterior and median fascicles are supplied either by septal branches of the left anterior descending artery or by the AV nodal artery (",
"    <a class=\"graphic graphic_figure graphicRef70956 \" href=\"UTD.htm?21/44/22213\">",
"     figure 2",
"    </a>",
"    ). The proximal part of the left posterior fascicle is supplied by the artery to the AV node and, at times, by septal branches of the left anterior descending artery. The distal portion has a dual blood supply from both anterior and posterior septal perforating arteries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ELECTROCARDIOGRAM IN LEFT ANTERIOR FASCICULAR BLOCK (LEFT ANTERIOR HEMIBLOCK)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior and posterior fascicular blocks mainly affect the direction but not the duration of the QRS complex, because the conduction disturbance primarily involves the early phases of activation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16420?source=see_link\">",
"     \"Left posterior fascicular block\"",
"    </a>",
"    .) The electrocardiographic criteria for left anterior fascicular block (LAFB, or left anterior hemiblock) are depicted in the ECG (",
"    <a class=\"graphic graphic_waveform graphicRef78636 \" href=\"UTD.htm?10/10/10402\">",
"     waveform 1",
"    </a>",
"    ). The changes that are seen reflect alterations in the different phases of activation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74736692\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A task force from the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society has defined the electrocardiographic features of isolated LAFB. These criteria incorporate the activation forces described above and include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Frontal plane axis between -45&deg; and -90&deg;",
"     </li>",
"     <li>",
"      qR pattern in lead aVL",
"     </li>",
"     <li>",
"      R-peak time in lead aVL of 45 msec or more",
"     </li>",
"     <li>",
"      QRS duration less than 120 msec.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These above criteria do not apply to patients with congenital heart disease in whom left-axis deviation is present in infancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Early activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The left anterior fascicle normally initiates activation in the upper part of the septum, the anterolateral left ventricular free wall, and the left anterior papillary muscle. The initial anterior paraseptal activation is absent in LAFB, while the remaining activation fronts caused by the posterior and median fascicles are normal. The net effect is that the 10 msec spatial vector is activated normally in time, but has an abnormal direction. Rather than proceeding superiorly and to the left, the vector points inferiorly and to the right (55 percent) or less commonly to the left (45 percent).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the initial direction is to the right and inferiorly, there will be a small positive deflection, an R wave, in the inferior leads II, III, aVF, and a small Q wave in leads I, aVL, V5, and V6.",
"     </li>",
"     <li>",
"      If the initial direction is to the left and sufficiently inferior, the initial forces may result in a small R wave or even a Q wave in leads V1 and V2. If the precordial recording is made one interspace lower, the r waves will again be seen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mid-temporal activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efferent limb of left ventricular activation in LAFB proceeds superiorly and to the left at 40 msec and then typically proceeds superiorly and to the left, inscribing a counterclockwise loop in the frontal plane due to delayed depolarization of the areas normally activated by the left anterior fascicle. As a result, the mean electrical axis is extremely leftward, defined as an axis that is greater than -45&ordm; or -60&ordm; depending upon the author. There is, however, a spectrum of LAFB which probably begins in the range of what is defined as having no axis deviation, through left axis deviation (-30 to -44&ordm;) to marked left axis deviation (-45 to -90&ordm;) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/8\">",
"     8",
"    </a>",
"    ]. A progressive leftward (actually superior) shift in axis over time allows the diagnosis of incomplete LAFB, even with a normal QRS axis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect of the late left and superior forces includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      S waves in the inferior leads, resulting in an rS pattern in II, III, and aVF.",
"     </li>",
"     <li>",
"      R waves in the leftward leads, resulting in a qR or R (depending upon the initial right or left orientation) pattern in leads I, aVL, V5, and V6.",
"     </li>",
"     <li>",
"      Because of the left axis deviation, the QRS complex in aVR and aVL ends in an R wave. There may also be a persistent terminal S wave in leads V5 and V6 due to the delayed activation of the high lateral wall that is normally activated by the left anterior fascicle. The S waves disappear if the precordial electrograms are recorded two interspaces higher.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Terminal activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terminal vectors are more superior and also to the left and posterior. The very last terminal components may be directed slightly to the right or left.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     QRS duration and T waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The QRS duration in LAFB is often less than 100 msec, although the",
"    <span class=\"nowrap\">",
"     WHO/ISFC",
"    </span>",
"    Task Force allows up to 120 msec or 20 msec above the previous baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/9\">",
"     9",
"    </a>",
"    ]. The T waves are often normal, but the T wave vector may be directed anteriorly and downward.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnostic problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG in LAFB can mimic the findings seen in a number of other conditions. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An anteroseptal or even lateral myocardial infarction (MI) may be suspected because of the QS pattern in V1 and V2 and the qR pattern in aVL. The Q waves in the precordial leads are due to the inferior orientation of the initial vector. They may disappear in the precordial leads if the electrocardiographic leads are positioned one interspace lower.",
"     </li>",
"     <li>",
"      The small r waves in the inferior leads with the superior axis deviation may be confused with an inferior wall MI, particularly since approximately one-third of patients with an inferior infarct can reestablish small r waves in the inferior leads. There are a number of findings that help distinguish an inferior MI from LAFB. As an example, persistent ST-T abnormalities suggest a prior inferior MI. In addition, inferior MI is usually associated with Q waves which can result in an axis that is extremely leftward; this phenomenon was, in the past, termed \"periinfarction block\" and must be distinguished from a left axis due to conduction disease. Vectorcardiography may be helpful in this setting, since the vector loop in the frontal plane is counterclockwise with LAFB versus clockwise an inferior infarct. In some cases, the two conditions appear together.",
"     </li>",
"     <li>",
"      The orientation of the mid-temporal vector in LAFB may mimic left ventricular hypertrophy in leads I and aVL, and conversely, may conceal signs of left ventricular hypertrophy in the left precordial leads.",
"     </li>",
"     <li>",
"      Chronic pulmonary disease may at times produce left axis deviation. Findings suggestive of pulmonary disease include a negative P wave in aVL, and tall R waves in aVR and V1, reflecting right ventricular enlargement. In addition, S waves may be present in leads I, II, and III.",
"     </li>",
"     <li>",
"      Preexcitation can occasionally produce left axis deviation. The presence of preexcitation is indicated by the short PR interval, the delta wave, and the widened QRS complex. This pattern often has Q waves in leads II, III and aVF and not infrequently is misdiagnosed as an inferior wall myocardial infarction.",
"     </li>",
"     <li>",
"      The left anterior fascicle usually has a refractory period that is shorter than that of the right bundle branch. Functional right bundle branch block is often associated with a functional LAFB. Less commonly, the refractory period of the left anterior fascicle is longer than either the right or left bundle, so that isolated functional LAFB can occur [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/10\">",
"       10",
"      </a>",
"      ]. This is usually seen with an irregular rhythm such as atrial fibrillation, frequent atrial premature beats, and other irregular rhythms.",
"     </li>",
"     <li>",
"      A number of conditions may present diagnostic problems including a horizontal heart, left ventricular hypertrophy, hypertrophic obstructive cardiomyopathy, inferior or inferolateral wall myocardial infarction, chronic obstructive pulmonary disease (particularly emphysema) straight back syndrome, Wolff-Parkinson-White syndrome, and some types of congenital heart disease including corrected transposition, tricuspid atresia, single ventricle, endocardial cushion malformations and Ebstein's disease. If the S wave in standard lead II is deeper than in lead III, the diagnosis of LAFB is unlikely. Not infrequently, other diagnostic approaches are required to clarify these issues such as echocardiography, radionuclide myocardial perfusion imaging, and, with suspected preexcitation, electrophysiologic studies.",
"     </li>",
"     <li>",
"      LAFB may cause the S waves to disappear in leads I, aVL, and V5 and V6, and rarely in V5 and V6, thereby obscuring the diagnosis of RBBB [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/11\">",
"       11",
"      </a>",
"      ]. At times, the ECG pattern more resembles LBBB than RBBB, which is one of the causes of RBBB simulating LBBB.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;LAFB in the absence of apparent organic heart disease and not associated with block in the other fascicles is usually benign. It may, for example, be a benign consequence of aging [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/12\">",
"     12",
"    </a>",
"    ]. Furthermore, no excess mortality was found with isolated LAFB in the Tecumseh population study [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/13\">",
"     13",
"    </a>",
"    ], a large insurance study [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/14\">",
"     14",
"    </a>",
"    ], or the Honolulu Heart Study [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/8\">",
"     8",
"    </a>",
"    ]. The Framingham study found progression to bifascicular block in 7 percent and to complete heart block in 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The left anterior fascicle is often a discrete ramus. It crosses the left ventricular outflow tract and can be damaged by high flow, high pressure, and turbulence as occurs with aortic valvular disease, hypertension, and cardiomyopathies. LAFB can also occur in coronary heart disease, Chagas disease, infiltrative and inflammatory diseases, congenital heart diseases (including tricuspid atresia, endocardial cushion defects, single ventricle, spontaneous and surgical closure of a VSD and other disorders), and as part of a primary sclerodegenerative disorders, such as Len&egrave;gre&rsquo;s and Lev's diseases. Aortic valve surgery not uncommonly causes LAFB [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/16\">",
"     16",
"    </a>",
"    ]. LAFB occurs in over 70 percent of patients with obstructive sleep apnea [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Coronary artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;With respect to coronary disease, LAFB has been associated with significant disease in the LAD coronary artery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/18\">",
"     18",
"    </a>",
"    ] and rarely has been induced by ischemia during exercise testing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/19\">",
"     19",
"    </a>",
"    ]. LAFB that develops during an acute inferior wall myocardial infarction may be an indicator of LAD lesions, multivessel coronary artery disease, and impaired left ventricular systolic function and occurs more frequently in a left dominant or balanced coronary artery system [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LAFB was found to be more common in patients with false positive nuclear stress tests [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/22\">",
"     22",
"    </a>",
"    ]. Two hundred and seventy individuals with abnormal stress technetium sestamibi SPECT studies were referred for coronary angiography. Among those without significant coronary artery stenosis (41 patients), LAFB was more common than in those with significant coronary artery disease. The reasons are unclear, but microvascular disease, underestimated CAD, and perhaps the conduction disease itself may be involved.",
"   </p>",
"   <p>",
"    The prognostic significance of LAFB was assessed in another study of 250 patients who had positive echocardiographic stress tests [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/23\">",
"     23",
"    </a>",
"    ]. At a mean follow up of 41 months, in multivariate analysis, bifascicular block with RBBB and LAFB was associated with increased mortality, but isolated LAFB was not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Conduction disease progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a retrospective study of patients in whom single lead atrial pacing was used for sick sinus syndrome, it was found that a history of LAFB was not more frequent in the group that eventually required ventricular pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no symptoms induced by an isolated block in one of the left bundle fascicles. Therapy should be considered only in patients with persistent bifascicular or trifascicular block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12261?source=see_link\">",
"     \"Course and treatment of chronic bifascicular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6391185\">",
"    <span class=\"h2\">",
"     Neuromuscular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of neuromuscular diseases are associated with fascicular block. These include myotonic muscular dystrophy, Kearns-Sayre syndrome, Erb&rsquo;s dystrophy (limb-girdle), and a peroneal muscular atrophy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1351?source=see_link\">",
"     \"Inherited syndromes associated with cardiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These patients represent a special class and are treated more aggressively with pacemakers due to the potential for unpredictably rapid progression of conduction disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16886/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link&amp;anchor=H23#H23\">",
"     \"Indications for permanent cardiac pacing\", section on 'Neuromuscular diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74736711\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolated left anterior fascicular block (LAFB) has the following features on an electrocardiogram (see",
"      <a class=\"local\" href=\"#H74736692\">",
"       'Definition'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Frontal plane axis between -45&deg; and -90&deg;",
"     </li>",
"     <li>",
"      qR pattern in lead aVL",
"     </li>",
"     <li>",
"      R-peak time in lead aVL of 45 msec or more",
"     </li>",
"     <li>",
"      QRS duration less than 120 msec.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LAFB in the absence of apparent organic heart disease and not associated with block in the other fascicles is usually benign. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Associated conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With respect to coronary disease, LAFB has been associated with significant disease in the left anterior descending coronary artery. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Coronary artery disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no symptoms induced by an isolated block in one of the left bundle fascicles. Therapy should be considered only in patients with persistent bifascicular or trifascicular block. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rosenbaum M, Elizari MV, Lazzari JO. The Hemiblocks. Tampa Tracings, Tampa, 1970.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/2\">",
"      Elizari MV, Acunzo RS, Ferreiro M. Hemiblocks revisited. Circulation 2007; 115:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/3\">",
"      Demoulin JC, Kulbertus HE. Histopathological examination of concept of left hemiblock. Br Heart J 1972; 34:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/4\">",
"      Uhley HN. Some controversy regarding the peripheral distribution of the conduction system. Am J Cardiol 1972; 30:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/5\">",
"      Myerburg RJ, Nilsson K, Gelband H. Physiology of canine intraventricular conduction and endocardial excitation. Circ Res 1972; 30:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/6\">",
"      Durrer D, van Dam RT, Freud GE, et al. Total excitation of the isolated human heart. Circulation 1970; 41:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/7\">",
"      Surawicz B, Childers R, Deal BJ, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009; 53:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/8\">",
"      Yano K, Peskoe SM, Rhoads GG, et al. Left axis deviation and left anterior hemiblock among 8,000 Japanese-American men. Am J Cardiol 1975; 35:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/9\">",
"      Willems JL, Robles de Medina EO, Bernard R, et al. Criteria for intraventricular conduction disturbances and pre-excitation. World Health Organizational/International Society and Federation for Cardiology Task Force Ad Hoc. J Am Coll Cardiol 1985; 5:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/10\">",
"      Cohen SI, Lau SH, Stein E, et al. Variations of aberrant ventricular conduction in man: evidence of isolated and combined block within the specialized conduction system. An electrocardiographic and vectorcardiographic study. Circulation 1968; 38:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/11\">",
"      Rosenbaum MB, Yesur&oacute;n J, L&aacute;zzari JO, Elizari MV. Left anterior hemiblock obscuring the diagnosis of right bundle branch block. Circulation 1973; 48:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/12\">",
"      Blackburn H, Vasquez CL, Keys A. The aging electrocardiogram. A common aging process or latent coronary artery disease? Am J Cardiol 1967; 20:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/13\">",
"      Ostrander LD Jr. Left axis deviation: prevalence, associated conditions, and prognosis. An epidemiologic study. Ann Intern Med 1971; 75:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/14\">",
"      Seavey PW, Sexton TS. Left axis deviation. An electrocardiographic mortality study. Trans Assoc Life Insur Med Dir Am 1971; 54:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/15\">",
"      Schneider JF, Thomas HE Jr, Kreger BE, et al. Newly acquired left bundle-branch block: the Framingham study. Ann Intern Med 1979; 90:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/16\">",
"      Habicht JM, Scherr P, Zerkowski HR, Hoffmann A. Late conduction defects following aortic valve replacement. J Heart Valve Dis 2000; 9:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/17\">",
"      Khalil MM, Rifaie OA. Electrocardiographic changes in obstructive sleep apnoea syndrome. Respir Med 1998; 92:25.",
"     </a>",
"    </li>",
"    <li>",
"     DePadua FI, Pereirnha A, Lopes MG. Conduction defects. In: Comprehensive Electrocardiography: Theory and Practice in Health and Disease, MacFarlane P, Veitch Lawrie TD (Eds), Pergamon Press, New York 1989. p.459.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/19\">",
"      Chandrashekhar Y, Kalita HC, Anand IS. Left anterior fascicular block: an ischaemic response during treadmill testing. Br Heart J 1991; 65:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/20\">",
"      Assali A, Sclarovsky S, Herz I, et al. Importance of left anterior hemiblock development in inferior wall acute myocardial infarction. Am J Cardiol 1997; 79:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/21\">",
"      Ozdemir K, Uluca Y, Dani�� G, et al. Importance of left anterior hemiblock development in inferior wall acute myocardial infarction. Angiology 2001; 52:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/22\">",
"      Ammann P, Naegeli B, Rickli H, et al. Characteristics of patients with abnormal stress technetium Tc 99m sestamibi SPECT studies without significant coronary artery diameter stenoses. Clin Cardiol 2003; 26:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/23\">",
"      Cortigiani L, Bigi R, Gigli G, et al. Prognostic implications of intraventricular conduction defects in patients undergoing stress echocardiography for suspected coronary artery disease. Am J Med 2003; 115:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/24\">",
"      Tripp IG, Armstrong GP, Stewart JT, et al. Atrial pacing should be used more frequently in sinus node disease. Pacing Clin Electrophysiol 2005; 28:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16886/abstract/25\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2106 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-198.199.123.20-28C064E6EE-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_31_16886=[""].join("\n");
var outline_f16_31_16886=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H74736711\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FASCICLES OF THE LEFT BUNDLE BRANCH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Blood supply",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ELECTROCARDIOGRAM IN LEFT ANTERIOR FASCICULAR BLOCK (LEFT ANTERIOR HEMIBLOCK)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H74736692\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Early activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mid-temporal activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Terminal activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      QRS duration and T waves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnostic problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Conduction disease progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6391185\">",
"      Neuromuscular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H74736711\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/2106\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2106|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/52/43841\" title=\"figure 1\">",
"      Normal conduction system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/44/22213\" title=\"figure 2\">",
"      Coronary artery anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2106|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?10/10/10402\" title=\"waveform 1\">",
"      Left anterior fascicular block",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12261?source=related_link\">",
"      Course and treatment of chronic bifascicular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9283?source=related_link\">",
"      ECG tutorial: Physiology of the conduction system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=related_link\">",
"      Electrophysiologic cardiac mapping: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13271?source=related_link\">",
"      General principles of asynchronous activation and preexcitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1351?source=related_link\">",
"      Inherited syndromes associated with cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16420?source=related_link\">",
"      Left posterior fascicular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=related_link\">",
"      Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_31_16887="Pregabalin: Drug information";
var content_f16_31_16887=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pregabalin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/55/22389?source=see_link\">",
"    see \"Pregabalin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F949926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lyrica&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F949927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      GD-Pregabalin;",
"     </li>",
"     <li>",
"      Lyrica&reg;;",
"     </li>",
"     <li>",
"      PMS-Pregabalin;",
"     </li>",
"     <li>",
"      RAN&trade;-Pregabalin;",
"     </li>",
"     <li>",
"      Riva-Pregabalin;",
"     </li>",
"     <li>",
"      Teva-Pregabalin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F949931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Miscellaneous;",
"     </li>",
"     <li>",
"      Anticonvulsant, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F949965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Fibromyalgia:",
"     </b>",
"     Oral: Initial: 150 mg daily in divided doses (75 mg twice daily); may be increased to 300 mg daily (150 mg twice daily) within 1 week based on tolerability and effect; may be further increased to 450 mg daily (225 mg twice daily). Maximum dose: 450 mg daily (dosages up to 600 mg daily were evaluated with no significant additional benefit and an increase in adverse effects)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Neuropathic pain, diabetes-associated:",
"     </b>",
"     Oral: Initial: 150 mg daily in divided doses (50 mg 3 times daily); may be increased within 1 week based on tolerability and effect; maximum dose: 300 mg daily (dosages up to 600 mg daily were evaluated with no significant additional benefit and an increase in adverse effects)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Neuropathic pain, spinal cord injury associated:",
"     </b>",
"     Oral: Initial: 150 mg daily in divided doses (75 mg twice daily); may be increased to 300 mg daily (150 mg twice daily) within 1 week based on tolerability and effect; further titration to 600 mg daily (300 mg twice daily) after 2-3 weeks may be considered in patients who do not experience sufficient relief of pain provided they are able to tolerate pregabalin. Maximum dose: 600 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Partial-onset seizures (adjunctive therapy):",
"     </b>",
"     Oral: Initial: 150 mg daily in divided doses (75 mg twice daily or 50 mg 3 times daily); may be increased based on tolerability and effect (optimal titration schedule has not been defined). Maximum dose: 600 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Postherpetic neuralgia:",
"     </b>",
"     Oral: Initial: 150 mg daily in divided doses (75 mg twice daily or 50 mg 3 times daily); may be increased to 300 mg daily within 1 week based on tolerability and effect; further titration (to 600 mg daily) after 2-4 weeks may be considered in patients who do not experience sufficient relief of pain provided they are able to tolerate pregabalin. Maximum dose: 600 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Discontinuing therapy: Pregabalin should not be abruptly discontinued; taper dosage over at least 1 week",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F1623542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F949966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function may be estimated using the Cockcroft-Gault formula. Then determine recommended dosage regimen based on the indication-specific total daily dose for normal renal function (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute). For example, if the indication-specific daily dose is 450 mg daily for normal renal function, the daily dose should be reduced to 225 mg daily (in 2-3 divided doses) for a creatinine clearance of 30-60 mL/minute (see table).",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Pregabalin Renal Impairment Dosing",
"     </caption>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"75\">",
"     </col>",
"     <col align=\"center\" width=\"75\">",
"     </col>",
"     <col align=\"center\" width=\"75\">",
"     </col>",
"     <col align=\"center\" width=\"75\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mL/minute)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"4\">",
"        <p style=\"text-indent:0em;\">",
"         Total Pregabalin Daily Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/day)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dosing Frequency",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         <i>",
"          Posthemodialysis supplementary dosage (as a single additional dose):",
"         </i>",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:4em;\">",
"         25 mg/day schedule: Single supplementary dose of 25 mg",
"         <b>",
"          or",
"         </b>",
"         50 mg",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:4em;\">",
"         25-50 mg/day schedule: Single supplementary dose of 50 mg",
"         <b>",
"          or",
"         </b>",
"         75 mg",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:4em;\">",
"         50-75 mg/day schedule: Single supplementary dose of 75 mg",
"         <b>",
"          or",
"         </b>",
"         100 mg",
"        </p>",
"        <p style=\"text-indent:0em;margin-left:4em;\">",
"         75 mg/day schedule: Single supplementary dose of 100 mg",
"         <b>",
"          or",
"         </b>",
"         150 mg",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;60 (normal renal function)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         300",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         450",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         600",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3 divided doses",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30-60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         225",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         300",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3 divided doses",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15-30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25-50",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100-150",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1-2 divided doses",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25-50",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50-75",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Single daily dose",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F949971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lyrica&reg;: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lyrica&reg;: 20 mg/mL (473 mL) [strawberry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F949929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F949924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-V",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152825.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152825.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F949967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F949932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of neuropathic pain associated with diabetic peripheral neuropathy or with spinal cord injury; management of postherpetic neuralgia; adjunctive therapy for partial-onset seizure disorder; management of fibromyalgia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6881223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lyrica&reg; may be confused with Lopressor&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pregabalin (Lyrica&reg;) oral solution (20 mg/mL): Prescriptions should be written in terms of mg. The pharmacist will calculate the appropriate dose in mL for dispensing.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F949942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Frequency of adverse effects may be influenced by dose or concurrent therapy. In add-on trials in epilepsy, frequency of CNS and adverse effects were higher than those reported in pain management trials. Range noted below is inclusive of all trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (&le;16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (8% to 45%), somnolence (4% to 36%), ataxia (1% to 20%), headache (5% to 14%), fatigue (5% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Weight gain (&le;16%), xerostomia (1% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Tremor (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision (1% to 12%), diplopia (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infection (3% to 14%), accidental injury (2% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Edema (&le;8%), chest pain (1% to 4%), hypertension (2%), hypotension (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Neuropathy (2% to 9%), thinking abnormal (&le;9%), confusion (&le;7%), euphoria (&le;7%), speech disorder (&le;7%), attention disturbance (4% to 6%), amnesia (&le;6%), incoordination (&le;6%), pain (2% to 5%), insomnia (4%), memory impaired (1% to 4%), vertigo (1% to 4%), hypoesthesia (2% to 3%), feeling abnormal (1% to 3%), anxiety (2%), lethargy (1% to 2%), drunk feeling (1% to 2%), disorientation (&le;2%), depersonalization (&ge;1%), fever (&ge;1%), hypertonia (&ge;1%), sedation (&ge;1%), stupor (&ge;1%), nervousness (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Decubitus ulcer (3%), facial edema (&le;3%), bruising (&ge;1%), pruritus (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Fluid retention (2% to 3%), hypoglycemia (1% to 3%), libido decreased (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (&le;10%), appetite increased (2% to 7%), nausea (5%), flatulence (&le;3%), vomiting (1% to 3%), abdominal distension (2%), abdominal pain (&ge;1%), gastroenteritis (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Incontinence (&le;3%), anorgasmia (&ge;1%), impotence (&ge;1%), urinary frequency (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Thrombocytopenia (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Balance disorder (2% to 9%), abnormal gait (&le;8%), weakness (2% to 7%), arthralgia (3% to 6%), twitching (&le;5%), muscle spasm (2% to 4%), back pain (&le;4%), myoclonus (&le;4%), CPK increased (3%), neck pain (3%), pain in extremity (3%), joint swelling (2%), paresthesia (2%), leg cramps (&ge;1%), myalgia (&ge;1%), myasthenia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Visual abnormalities (&le;5%), eye disorder (&le;2%), conjunctivitis (&ge;1%), nystagmus (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Otic: Otitis media (&ge;1%), tinnitus (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory:  Nasopharyngitis (8%), sinusitis (4% to 7%), pharyngolaryngeal pain (1% to 3%), bronchitis (&le;3%), dyspnea (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Flu-like syndrome (1% to 2%), allergic reaction (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal ejaculation, abscess, acute renal failure, addiction , agitation, albuminuria, alopecia, amenorrhea, anaphylactoid reaction, anemia, angioedema, anisocoria, apathy, aphasia, aphthous stomatitis, apnea, arthrosis, ascites, atelectasis, bladder cancer, blepharitis, blindness, bronchiolitis, cellulitis, cerebellar syndrome, cervicitis, chills, cholecystitis, cholelithiasis, chondrodystrophy, circumoral paresthesia, cogwheel rigidity, colitis, coma, corneal ulcer, crystalluria (urate), delirium, delusions, diarrhea, dry eyes, dysarthria, dysautonomia, dyskinesia, dysmenorrhea, dysphagia, dyspareunia, dystonia, dysuria, eczema, encephalopathy, eosinophilia, epididymitis, esophageal ulcer, esophagitis, exfoliative dermatitis, exophthalmos, extraocular palsy, extrapyramidal syndrome, eye hemorrhage, female lactation, gastritis, GI hemorrhage, glomerulitis, glucose tolerance decreased, granuloma, Guillain-Barr&eacute; syndrome, gynecomastia, hallucinations, heart failure, hematuria, hirsutism, hostility, hyperacusis, hyperalgesia, hyperesthesia, hyper-/hypokinesia; hypersensitivity (including skin redness, blistering, hives, rash, dyspnea, and wheezing); hypotonia, intracranial hypertension, iritis, keratitis, keratoconjunctivitis, libido increased, laryngismus, leukopenia, leukorrhea, leukocytosis, lichenoid dermatitis, lung edema, lung fibrosis, lymphadenopathy, malaise, manic reaction, melanosis, melena, miosis, mouth ulcer, mydriasis, myelofibrosis, neck rigidity, nephritis, neuralgia, night blindness, ocular hemorrhage, oliguria, ophthalmoplegia, optic atrophy, pancreatitis, papilledema, paranoid reaction, parosmia, pelvic pain, periodontal abscess, peripheral neuritis, personality disorder, photophobia, photosensitivity, polycythemia, postural hypotension, prothrombin decreased, psychotic depression, ptosis, pulmonary edema, pulmonary fibrosis, purpura, pyelonephritis, rash (vesiculobullous, petechial, purpuric, pustular); rectal hemorrhage, renal calculus, retinal edema, retinal vascular disorder, retroperitoneal fibrosis, rhabdomyolysis, schizophrenic reaction, shock, skin atrophy, skin necrosis, skin nodule, skin ulcer, ST depression, Stevens-Johnson syndrome, subcutaneous nodule, suicide, suicide attempt, syncope, taste loss, taste perversion, thrombocythemia, thrombophlebitis, tongue edema, torticollis, trismus, urinary retention, urticaria, uveitis, ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F949937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pregabalin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F949938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: Angioedema has been reported; may be life-threatening; use with caution in patients with a history of angioedema episodes. Concurrent use with other drugs known to cause angioedema (eg, ACE inhibitors) may increase risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Dizziness and somnolence are commonly reported; effects generally occur shortly after initiation and occur more frequently at higher doses. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Hypersensitivity reactions, including skin redness, blistering, hives, rash, dyspnea, and wheezing have been reported; discontinue treatment of hypersensitivity occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral edema: Use may cause peripheral edema; use with caution in patients with heart failure (NYHA Class III or IV) due to limited data in this patient population. In addition, effect on weight gain/edema may be additive with the thiazolidinedione class of antidiabetic agents; use caution when coadministering these agents, particularly in patients with prior cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Platelet count: May decrease platelet count. Severe thrombocytopenia is extremely rare.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; PR interval: May cause mild prolongation of PR interval. Clinical significance unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rhabdomyolysis: Has been associated with increases in CPK and rare cases of rhabdomyolysis; patients should be instructed to notify their prescriber if unexplained muscle pain, tenderness, or weakness, particularly if fever and/or malaise are associated with these symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual disturbances: Blurred vision, decreased acuity and visual field changes have been associated with therapy; patients should be instructed to notify their physician if these effects are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight gain: Use may cause weight gain; weight gain generally associated with dose and duration (average weight gain was 5.2 kg for patients receiving pregabalin for &ge;2 years); weight gain was not limited to patients with edema and did not appear to be associated with baseline BMI, gender, age, or loss of glycemic control in diabetic patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiovascular disease, including heart failure; weight gain and/or peripheral edema may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumorigenic potential: Increased incidence of hemangiosarcoma noted in animal studies; significance of these findings in humans is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal. Tapering over at least 1 week is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F949947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Pregabalin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F949949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F949933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F949934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increased incidence of fetal abnormalities, particularly skeletal malformations, were observed in animal studies. Male-mediated teratogenicity has been observed in animal reproduction studies; implications in humans are not defined. Impaired male and female fertility has been noted in animal studies.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to pregabalin during pregnancy are encouraged to enroll themselves into the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F949936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F949962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Lyrica Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (90): $361.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (90): $361.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (90): $361.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (90): $361.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (90): $361.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (90): $361.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     225 mg (90): $361.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (90): $361.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lyrica Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (473 mL): $506.05",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F949969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Measures of efficacy (pain intensity/seizure frequency); degree of sedation; symptoms of myopathy or ocular disturbance; weight gain/edema; skin integrity (in patients with diabetes); suicidality (eg, suicidal thoughts, depression, behavioral changes)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Gabica (PK);",
"     </li>",
"     <li>",
"      Lalaca (KP);",
"     </li>",
"     <li>",
"      Lyrica (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IN, IT, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RU, SE, SG, SK, SV, TH, TR, UY, VE);",
"     </li>",
"     <li>",
"      Neurum (EC)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F949963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to alpha",
"     <sub>",
"      2",
"     </sub>",
"     -delta subunit of voltage-gated calcium channels within the CNS, inhibiting excitatory neurotransmitter release. Although structurally related to GABA, it does not bind to GABA or benzodiazepine receptors. Exerts antinociceptive and anticonvulsant activity. Decreases symptoms of painful peripheral neuropathies and, as adjunctive therapy in partial seizures, decreases the frequency of seizures. Pregabalin may also affect descending noradrenergic and serotonergic pain transmission pathways from the brainstem to the spinal cord.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F949952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Pain management: Effects may be noted as early as the first week of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 0%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Negligible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: &gt;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 6.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 1.5 hours (3 hours with food)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (90% as unchanged drug; minor metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bril V, England J, Franklin GM, et al, \"Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2011, 76(20):1758-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/31/16887/abstract-text/21482920/pubmed\" id=\"21482920\" target=\"_blank\">",
"        21482920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hill CM, Balkenohl M, Thomas DW, et al, \"Pregabalin in Patients With Postoperative Dental Pain,\"",
"      <i>",
"       Eur J Pain",
"      </i>",
"      , 2001, 5(2):119-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/31/16887/abstract-text/11465977/pubmed\" id=\"11465977\" target=\"_blank\">",
"        11465977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9473 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-221.179.173.170-4115C7D097-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_31_16887=[""].join("\n");
var outline_f16_31_16887=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949926\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949927\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949931\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949965\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1623542\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949966\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949971\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949929\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949924\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874966\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949967\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949932\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6881223\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949942\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949937\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949938\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299940\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949947\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949949\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949933\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949934\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949936\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949962\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422158\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949969\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869449\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949963\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F949952\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9473\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9473|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/55/22389?source=related_link\">",
"      Pregabalin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_31_16888="Treatment of the carcinoid syndrome";
var content_f16_31_16888=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of the carcinoid syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/31/16888/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/31/16888/contributors\">",
"     Stephen E Goldfinger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/31/16888/contributors\">",
"     Jonathan R Strosberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/31/16888/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/31/16888/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/31/16888/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/31/16888/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/31/16888/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/31/16888/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H624741546\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoid tumors are neuroendocrine tumors that originate in the digestive tract, lungs, or rare primary sites such as kidneys or ovaries. Although use of the term &ldquo;carcinoid&rdquo; usually implies well-differentiated histology, the term is sometimes applied to the rare high-grade or poorly differentiated neuroendocrine tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=see_link&amp;anchor=H440387068#H440387068\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on 'Pathology, tumor classification, and nomenclature'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carcinoid syndrome is the term applied to a constellation of symptoms that are mediated by various humoral factors that are elaborated by some carcinoid tumors (",
"    <a class=\"graphic graphic_table graphicRef79329 \" href=\"UTD.htm?34/59/35771\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/1\">",
"     1",
"    </a>",
"    ]. Two of the most common manifestations are flushing and diarrhea (",
"    <a class=\"graphic graphic_table graphicRef63079 \" href=\"UTD.htm?37/54/38763\">",
"     table 2",
"    </a>",
"    ). Symptoms are associated with elevations in serum serotonin or its metabolite urinary 5-hydroxyindoleacetic acid (5-HIAA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carcinoid crisis is a life-threatening form of carcinoid syndrome that results from the release of an overwhelming amount of biologically active compounds from the tumor that may be triggered by tumor manipulation (biopsy or surgery) or by anesthesia.",
"   </p>",
"   <p>",
"    More than 90 percent of patients with the carcinoid syndrome have metastatic disease, typically involving the liver. Exceptions are bronchial and ovarian carcinoids, which can release hormones directly into the systemic circulation, thereby producing symptoms without metastases. When it does occur, carcinoid syndrome associated with bronchial carcinoids is often atypical; episodes of flushing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diaphoresis, which may be accompanied by other symptoms such as tremor, periorbital edema, lacrimation, salivation, and edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical features of the carcinoid syndrome\", section on 'Bronchial carcinoid variant syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic provides an overview of treatment for patients with symptoms of the carcinoid syndrome. Diagnosis of the carcinoid syndrome, radiologic staging, tumor localization, histologic assessment of carcinoid tumors, and presentation, treatment, prognosis, and posttreatment surveillance of patients with localized and metastatic carcinoid are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=see_link\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=see_link&amp;anchor=H440387068#H440387068\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on 'Pathology, tumor classification, and nomenclature'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691390#H691390\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Surgical options'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624742796\">",
"    <span class=\"h1\">",
"     SOMATOSTATIN-ANALOG THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin is a 14-amino acid peptide that inhibits the secretion of a broad range of hormones. It acts by binding to somatostatin receptors, which are expressed on the majority of carcinoid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/2\">",
"     2",
"    </a>",
"    ]. Nearly 80 percent of carcinoid tumors express somatostatin receptors, as determined using somatostatin receptor scintigraphy (SRS) with a radiolabeled form of the somatostatin analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    &nbsp;(indium-111 [111-In] pentetreotide, OctreoScan&reg;). However, whether SRS is necessary before a trial of somatostatin analog therapy for patients who are symptomatic from carcinoid syndrome is controversial at best. There is no evidence that radiotracer uptake on SRS predicts symptomatic response to somatostatin analog therapy among patients with carcinoid syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link&amp;anchor=H5#H5\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Somatostatin receptor scintigraphy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because the somatostatin analogs",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    bind to somatostatin receptors on the tumor cells, they are highly effective at inhibiting the release of bioactive amines. Flushing and diarrhea are significantly improved in over 80 percent of patients with the carcinoid syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A depot form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (Sandostatin LAR&reg;), which is administered intramuscularly on a monthly basis, has largely eliminated the need for patients to inject themselves daily with short-acting subcutaneous octreotide [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/4\">",
"     4",
"    </a>",
"    ]. Depot octreotide is typically initiated at a dose of 20 to 30 mg IM every four weeks. Unless patients are severely symptomatic, we generally initiate therapy with octreotide LAR rather than short-acting octreotide.",
"   </p>",
"   <p>",
"    Gradual dose escalation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    LAR or supplementation with short-acting octreotide may be necessary for patients with refractory symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H624742803\">",
"     'Management of refractory symptoms'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    A long-acting formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    (Somatuline Depot&reg;) is also available for monthly injections at doses ranging from 60 to 120 mg every four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/5\">",
"     5",
"    </a>",
"    ]. Lanreotide appears to have similar clinical efficacy and tolerability as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    for treatment of the carcinoid syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/6-11\">",
"     6-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    are usually well tolerated. Rarely, patients may develop nausea, abdominal discomfort, bloating",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    steatorrhea, often during the first several weeks of therapy after which the symptoms subside. Pancreatic malabsorption may be a contributing factor, which can be alleviated with pancreatic enzyme supplementation.",
"   </p>",
"   <p>",
"    Another effect of somatostatin analogs is inhibition of gallbladder contractility, which can lead to gallstones or sludge. For that reason, a prophylactic cholecystectomy is sometimes recommended for patients who are undergoing abdominal surgery for other reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H945119\">",
"    <span class=\"h2\">",
"     Antiproliferative effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The somatostatin analogs",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    were initially developed for control of the carcinoid syndrome, and they are most effective for this purpose. Past studies have indicated that few patients with advanced carcinoid tumors have objective tumor shrinkage with somatostatin analogs. However, more recent reports suggest that, in addition to an improvement in symptoms, treatment with octreotide may be associated with an inhibitory effect on tumor growth in patients with small bowel carcinoid tumors. This subject is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948935#H190948935\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Use in asymptomatic patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H945488\">",
"    <span class=\"h1\">",
"     HEPATIC RESECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic resection is often considered for the treatment of potentially resectable liver metastases in the absence of diffuse bilobar involvement, compromised liver function, or widespread extrahepatic metastases. Among patients undergoing complete resection, long-term disease-free survival is reported in up to 20 percent of patients, and hepatic resection can also provide symptomatic relief in patients who are symptomatic from tumor bulk or the carcinoid syndrome. Preoperative and interoperative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    therapy is essential to protect against carcinoid crises that can arise from anaesthesia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tumor manipulation. (See",
"    <a class=\"local\" href=\"#H624742810\">",
"     'Prevention and management of carcinoid crisis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    More controversial is the value of cytoreductive hepatic surgery in patients with more advanced disease. Advocates of this approach cite numerous retrospective series reporting palliation of symptoms and prolonged survival durations among patients undergoing surgical tumor debulking. However, the lack of randomized, controlled studies precludes any definitive conclusions regarding the benefits of cytoreductive surgery. When it is performed in this setting, hepatic resections are generally restricted to patients in whom 90 percent or more of the disease bulk can be successfully resected or ablated. These issues are all addressed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691406#H691406\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Resection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624742803\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF REFRACTORY SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with persistence or recurrence of flushing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea may benefit from higher doses or more frequent administration of long-acting somatostatin analogs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. For example, patients who experience exacerbation of symptoms towards the end of a four week treatment cycle may achieve palliation with increased frequency of administration (ie, every three weeks). Likewise, higher doses of depot-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (up to 60 mg monthly) may be administered for patients with refractory symptoms. Doses exceeding 60 mg are unlikely to be of additional palliative benefit given saturation of somatostatin receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/15\">",
"     15",
"    </a>",
"    ]. Another option for patients with breakthrough symptoms is use of supplemental doses of short-acting octreotide (ranging from 100 to 500 micrograms every eight hours) on an &ldquo;as needed&rdquo; basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H945210\">",
"    <span class=\"h2\">",
"     Interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another option for control of refractory symptoms of carcinoid syndrome in patients treated with somatostatin receptor analogs is interferon alfa (IFNa) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/16\">",
"     16",
"    </a>",
"    ]. Interferons can exert antitumor effects via stimulation of T cells, induction of cell cycle arrest, and inhibition of angiogenesis.",
"   </p>",
"   <p>",
"    In retrospective series, low-dose IFNa alone (ie, 3 to 5 million units up to three to five times weekly) reduces symptoms of hormonal hypersecretion (flushing, diarrhea) in 40 to 50 percent of patients who are refractory to somatostatin analogs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/17\">",
"     17",
"    </a>",
"    ]. Objective tumor regression is less common, though has been reported in up to 15 percent of patients with advanced neuroendocrine tumors in some studies. Unfortunately, the benefits of IFNa for carcinoid tumors are counterbalanced by sometimes debilitating toxicities, which can include fatigue, depression, and flu-like symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948949#H190948949\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Interferon'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H945242\">",
"    <span class=\"h2\">",
"     Liver-targeted therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is the predominant site of metastases in patients with metastatic carcinoid. Liver-directed treatments, such as surgical resection, transarterial embolization, and local tumor ablation, play an important role in the management of patients with advanced carcinoid tumors.",
"   </p>",
"   <p>",
"    Hepatic arterial embolization with or without selective hepatic artery infusion of chemotherapy is frequently applied as a palliative technique in patients with symptomatic hepatic metastases who are not candidates for surgical resection. In uncontrolled trials, up to 75 percent of patients with carcinoid hepatic metastases have marked symptomatic improvement in flushing and diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691449#H691449\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Hepatic artery embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early studies noted a significant incidence of severe postembolization complications, including renal failure, hepatic necrosis, and sepsis. More recently, improvements in technique have reduced the incidence of such complications, making embolization an important and generally safe treatment option for patients with metastatic neuroendocrine tumors, including carcinoids. Nevertheless, careful patient selection is mandatory because of treatment and disease-related adverse effects, which can range from transient symptoms (pain, nausea, fever, fatigue) and biochemical abnormalities (elevated liver enzymes) to florid carcinoid crisis, which may be fatal. Prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    is indicated prior to embolization. (See",
"    <a class=\"local\" href=\"#H624742810\">",
"     'Prevention and management of carcinoid crisis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <br/>",
"    Experience with radioembolization using 90 Y-labeled resin or glass microspheres is limited but growing. Radioembolization using 90 Y-labeled resin or glass microspheres has been reported to reduce symptoms in about one-half of patients with functioning neuroendocrine tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, in the absence of randomized trials, it is difficult to know when to choose this technique over other embolization techniques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691449#H691449\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Hepatic artery embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H944956\">",
"    <span class=\"h2\">",
"     Antidiarrheal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidiarrheal agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/56/9094?source=see_link\">",
"      diphenoxylate",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"      atropine",
"     </a>",
"    </span>",
"    (lomotil) can be used for control of refractory diarrhea. For more severe diarrhea, the opiates",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/32/20997?source=see_link\">",
"     paregoric",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/3/35893?source=see_link\">",
"     tincture of opium",
"    </a>",
"    may be prescribed. Several studies demonstrate that serotonin receptor antagonists, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    , can alleviate diarrhea in patients with the carcinoid syndrome; however, the magnitude of benefit is small [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other causes of diarrhea should be considered. Patients who have undergone resection of the distal small bowel frequently develop bile malabsorption and bile-salt induced diarrhea that can be treated with bile acid sequestrants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/26/12710?source=see_link\">",
"     colestipol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/25\">",
"     25",
"    </a>",
"    ]. A trial of a bile acid sequestrant is reasonable in any patient who has refractory diarrhea after right hemicolectomy.",
"   </p>",
"   <p>",
"    Symptomatic fat malabsorption and steatorrhea from somatostatin analog therapy may respond to pancreatic enzyme supplementation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H945796\">",
"    <span class=\"h2\">",
"     Systemic therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H945804\">",
"    <span class=\"h3\">",
"     Cytotoxic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most well-differentiated carcinoid tumors appear to be refractory to conventional cytotoxic agents with response rates of &lt;10 percent in modern studies. Conventional cytotoxic chemotherapy is generally not helpful for control of symptoms in patients with carcinoid syndrome from well-differentiated carcinoid tumors. Its use should be restricted primarily to patients with poorly-differentiated (high-grade) carcinoid tumors, where objective response rates are higher. Poorly differentiated tumors are rarely, if ever, associated with the carcinoid syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949019#H190949019\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Poorly differentiated tumors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948991#H190948991\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Carcinoid tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H945841\">",
"    <span class=\"h3\">",
"     Molecularly targeted agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limited efficacy of conventional cytotoxic chemotherapy has prompted the development of novel therapeutic approaches for patients with advanced carcinoid tumors. These include therapies targeting the vascular endothelial growth factor receptor (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    , an inhibitor of the mammalian target of rapamycin (mTOR). The benefit of these agents has been shown most convincingly for pancreatic neuroendocrine tumors (pNETs), and their benefits in patients with advanced carcinoid tumors remain uncertain. In particular, whether or not any of these treatments helps to control symptoms of refractory carcinoid syndrome is not yet known. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949082#H190949082\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Carcinoid tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H945282\">",
"    <span class=\"h2\">",
"     Peptide receptor radioligand therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiolabeled somatostatin analogs (eg, 90-Y-DOTA tyr3-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    ,",
"    <sup>",
"     90",
"    </sup>",
"    Y-edotreotide) can be used to deliver targeted radiation to somatostatin-receptor expressing tumors. Objective radiographic response rates vary widely, but symptomatic responses have been observed in the majority of patients with carcinoid syndrome who were refractory to octreotide [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiolabeled somatostatin analogs are not widely available in the United States. Selection criteria for treatment must include evidence of strong radiotracer uptake on OctreoScan (at least as high as normal liver tissue). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949126#H190949126\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Radiolabeled somatostatin analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624742810\">",
"    <span class=\"h1\">",
"     PREVENTION AND MANAGEMENT OF CARCINOID CRISIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoid crisis is a life-threatening form of carcinoid syndrome that may be triggered by tumor manipulation (eg biopsy, surgery) or by anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/27\">",
"     27",
"    </a>",
"    ]. It is less commonly reported after chemotherapy, hepatic arterial embolization, or radionuclide therapy, mostly in patients with extensive tumor bulk [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/28-35\">",
"     28-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carcinoid crisis results from the release of an overwhelming amount of biologically active compounds from the tumor (",
"    <a class=\"graphic graphic_table graphicRef79329 \" href=\"UTD.htm?34/59/35771\">",
"     table 1",
"    </a>",
"    ). The predominant symptom is wide blood pressure fluctuations with a predominance of hypotension.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    should be readily available during any surgical procedure. Preemptive administration of octreotide prior to resection (300 to 500 micrograms intravenously or subcutaneously) reduces the incidence of carcinoid crisis and is mandatory for patients with a history of carcinoid syndrome who require surgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H25195080#H25195080\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Prevention and management of carcinoid crisis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948942#H190948942\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Prevention and management of carcinoid crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When it occurs, treatment for carcinoid crisis differs from that for other causes of acute intraoperative hypotension. Symptoms are generally refractory to fluid resuscitation alone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/28,38,39\">",
"     28,38,39",
"    </a>",
"    ]. Calcium and catecholamines may provoke release of mediators from the tumor and worsen, rather than ameliorate, the syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The blood pressure should be supported by infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (500 to 1000 micrograms intravenously; a continuous intravenous drip of octreotide at a rate of 100 to 200",
"    <span class=\"nowrap\">",
"     micrograms/hour",
"    </span>",
"    may also be used) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/13,28\">",
"     13,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624742817\">",
"    <span class=\"h1\">",
"     CARCINOID HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoid heart disease occurs in fewer than one-half of patients with the carcinoid syndrome. High circulating concentrations of serotonin are thought to be the major underlying factor. Among patients with carcinoid syndrome, individuals with carcinoid heart disease exhibit higher levels of serum serotonin and urinary 5-HIAA excretion than do those without heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=see_link&amp;anchor=H2#H2\">",
"     \"Carcinoid heart disease\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carcinoid heart lesions are characterized by plaque-like, fibrous endocardial thickening that classically involves the right side of the heart, and often causes retraction and fixation of the leaflets of the tricuspid and pulmonary valves (",
"    <a class=\"graphic graphic_picture graphicRef77192 \" href=\"UTD.htm?14/26/14755\">",
"     picture 1",
"    </a>",
"    ). Tricuspid regurgitation is a nearly universal finding; tricuspid stenosis, pulmonary regurgitation, and pulmonary stenosis may also occur. The resulting right-sided heart failure produces significant morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=see_link&amp;anchor=H4#H4\">",
"     \"Carcinoid heart disease\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Left-sided heart disease, which occurs in less than 10 percent of patients, is almost always associated with an atrial right-to-left shunt (as with a patent foramen ovale) or a primary bronchial carcinoid. This permits serotonin-rich blood to enter the left heart chambers without passing through the pulmonary capillaries.",
"   </p>",
"   <p>",
"    Although evidence suggests a pathogenic role for serotonin or one of its metabolites in the development of carcinoid heart disease, it remains uncertain whether somatostatin analog therapy can inhibit or reverse progression of existing carcinoid heart disease. It appears that the incidence of carcinoid heart disease has decreased over the past several decades, possibly due to increased use of somatostatin analogs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=see_link&amp;anchor=H13#H13\">",
"     \"Carcinoid heart disease\", section on 'Antitumor therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend that echocardiographic evaluation be limited to patients with a cardiac murmur or signs or symptoms of right heart valvular disease or right heart failure, or prior to surgery for patients with carcinoid syndrome. These recommendations are consistent with consensus-based guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    . Other guidelines advocate a baseline echocardiogram in all patients with the carcinoid syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with carcinoid heart disease, valve replacement surgery (typically bivalvular replacement of tricuspid and pulmonary valves) can prevent progression to frank heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=see_link&amp;anchor=H14#H14\">",
"     \"Carcinoid heart disease\", section on 'Cardiac surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624743869\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carcinoid syndrome is the term applied to a constellation of symptoms mediated by various humoral factors that are elaborated by some carcinoid tumors (",
"      <a class=\"graphic graphic_table graphicRef79329 \" href=\"UTD.htm?34/59/35771\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16888/abstract/1\">",
"       1",
"      </a>",
"      ]. Two of the most common manifestations are flushing and diarrhea (",
"      <a class=\"graphic graphic_table graphicRef63079 \" href=\"UTD.htm?37/54/38763\">",
"       table 2",
"      </a>",
"      ). More than 90 percent of patients with the carcinoid syndrome have metastatic disease, typically to the liver. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"       \"Clinical features of the carcinoid syndrome\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H624741546\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Carcinoid crisis is a life-threatening form of carcinoid syndrome that results from the release of an overwhelming amount of biologically active compounds from the tumor; it may be triggered by tumor manipulation (eg biopsy, surgery) or by anesthesia. It is less commonly reported after chemotherapy, hepatic arterial embolization, or radionuclide therapy, mostly in patients with markedly elevated serum serotonin or urine 5-HIAA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H944743\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Somatostatin analogs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      are highly effective in controlling the symptoms associated with carcinoid tumors. For patients who are symptomatic from carcinoid syndrome, we recommend initiating treatment with a somatostatin analog (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H624742796\">",
"       'Somatostatin-analog therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We usually begin therapy with octreotide LAR 20 to 30 mg every four weeks. Depot",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"       lanreotide",
"      </a>",
"      is another alternative to octreotide LAR. &nbsp;",
"     </li>",
"     <li>",
"      For patients with liver metastases, hepatic resection can provide long-term symptomatic relief of the carcinoid syndrome. While resection is widely accepted for symptomatic patients with completely resectable disease, the value of cytoreductive or debulking surgery in symptomatic patients with more advanced unresectable liver metastases is more controversial, and decisions must be individualized. (See",
"      <a class=\"local\" href=\"#H945488\">",
"       'Hepatic resection'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Patients with persistence or recurrence of flushing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diarrhea may benefit from higher doses or more frequent administration of long-acting somatostatin analogs. (See",
"      <a class=\"local\" href=\"#H624742803\">",
"       'Management of refractory symptoms'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Interferon alfa may be palliative for patients with carcinoid syndrome that is refractory to somatostatin analog therapy. However, the benefits are counterbalanced by sometimes debilitating toxicities.",
"      <br/>",
"      <br/>",
"      Patients with refractory diarrhea may benefit from use of an antidiarrheal agent, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"       loperamide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H944956\">",
"       'Antidiarrheal therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Other options for symptom control in patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      -refractory carcinoid syndrome and unresectable liver-predominant disease include transarterial embolization or chemoembolization, radioembolization using 90-Y embedded microspheres, and where available, systemic radionuclide therapy using radiolabeled somatostatin analogs. (See",
"      <a class=\"local\" href=\"#H945242\">",
"       'Liver-targeted therapies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H945282\">",
"       'Peptide receptor radioligand therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The benefit of systemic therapy for symptom control in patients with the carcinoid syndrome is unclear. Most patients with well-differentiated tumors are refractory to conventional cytotoxic chemotherapy, and whether any of the molecularly targeted agents improves the symptoms of carcinoid syndrome is not yet known. (See",
"      <a class=\"local\" href=\"#H945804\">",
"       'Cytotoxic chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H945841\">",
"       'Molecularly targeted agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients undergoing surgery for metastatic carcinoid who have a history of carcinoid syndrome, we recommend prophylactic subcutaneous or intravenous administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      prior to the procedure to reduce the incidence of carcinoid crisis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We also recommend the use of prophylactic octreotide for patients with carcinoid syndrome and extensive tumor bulk prior to hepatic artery embolization (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H624742810\">",
"       'Prevention and management of carcinoid crisis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Carcinoid heart disease can occur in patients with severe, longstanding elevations of circulating serotonin, and is typically characterized by fibrosis of the right sided (tricuspid and pulmonary) heart valves. While some guidelines advocate echocardiograms in all patients with carcinoid syndrome, we recommend that echocardiographic evaluation be reserved for patients with clinical",
"      <span class=\"nowrap\">",
"       signs/symptoms",
"      </span>",
"      of carcinoid heart disease or if major surgery is being planned. (See",
"      <a class=\"local\" href=\"#H624742817\">",
"       'Carcinoid heart disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/1\">",
"      Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/2\">",
"      Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50:5969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/3\">",
"      Kvols LK, Moertel CG, O'Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/4\">",
"      Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/5\">",
"      Ruszniewski P, Ducreux M, Chayvialle JA, et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996; 39:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/6\">",
"      Faiss S, R&auml;th U, Mansmann U, et al. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 1999; 60:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/7\">",
"      Wymenga AN, Eriksson B, Salmela PI, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999; 17:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/8\">",
"      O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000; 88:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/9\">",
"      Ducreux M, Ruszniewski P, Chayvialle JA, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000; 95:3276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/10\">",
"      Faiss S, Pape UF, B&ouml;hmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21:2689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/11\">",
"      Khan MS, El-Khouly F, Davies P, et al. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther 2011; 34:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/12\">",
"      Strosberg JR, Cheema A, Kvols LK. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control 2011; 18:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/13\">",
"      Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/14\">",
"      Strosberg JR, Fisher GA, Benson AB, et al. Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process. Pancreas 2013; 42:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/15\">",
"      Woltering EA, Mamikunian PM, Zietz S, et al. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. Pancreas 2005; 31:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/16\">",
"      Oberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983; 309:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/17\">",
"      Frank M, Klose KJ, Wied M, et al. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999; 94:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/18\">",
"      Ruszniewski P, Malka D. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion 2000; 62 Suppl 1:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/19\">",
"      Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 2006; 13:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/20\">",
"      Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 2003; 9:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/21\">",
"      Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998; 83:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/22\">",
"      King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/23\">",
"      Cao CQ, Yan TD, Bester L, et al. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 2010; 97:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/24\">",
"      Wymenga AN, de Vries EG, Leijsma MK, et al. Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome. Eur J Cancer 1998; 34:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/25\">",
"      Westergaard H. Bile Acid malabsorption. Curr Treat Options Gastroenterol 2007; 10:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/26\">",
"      Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010; 28:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/27\">",
"      Woodside KJ, Townsend CM Jr, Mark Evers B. Current management of gastrointestinal carcinoid tumors. J Gastrointest Surg 2004; 8:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/28\">",
"      Warner RR, Mani S, Profeta J, Grunstein E. Octreotide treatment of carcinoid hypertensive crisis. Mt Sinai J Med 1994; 61:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/29\">",
"      Dav&igrave; MV, Bodei L, Francia G, et al. Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). J Endocrinol Invest 2006; 29:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/30\">",
"      Majeed F, Porter TR, Tarantolo S, et al. Carcinoid crisis and reversible right ventricular dysfunction after embolization in untreated carcinoid syndrome. Eur J Echocardiogr 2007; 8:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/31\">",
"      Gillams A, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 2005; 30:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/32\">",
"      Kharrat HA, Taubin H. Carcinoid crisis induced by external manipulation of liver metastasis. J Clin Gastroenterol 2003; 36:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/33\">",
"      Vaughan DJ, Brunner MD. Anesthesia for patients with carcinoid syndrome. Int Anesthesiol Clin 1997; 35:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/34\">",
"      Gates J, Hartnell GG, Stuart KE, Clouse ME. Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Radiographics 1999; 19:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/35\">",
"      Lewis MA, Jaramillo S, Roberts L, et al. Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. Oncologist 2012; 17:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/36\">",
"      Kinney MA, Warner ME, Nagorney DM, et al. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth 2001; 87:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/37\">",
"      Veall GR, Peacock JE, Bax ND, Reilly CS. Review of the anaesthetic management of 21 patients undergoing laparotomy for carcinoid syndrome. Br J Anaesth 1994; 72:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/38\">",
"      D&eacute;ry R. Theoretical and clinical considerations in anaesthesia for secreting carcinoid tumors. Can Anaesth Soc J 1971; 18:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/39\">",
"      Memon MA, Nelson H. Gastrointestinal carcinoid tumors: current management strategies. Dis Colon Rectum 1997; 40:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16888/abstract/40\">",
"      Arnold R, Chen YJ, Costa F, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 2009; 90:227.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16638 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_31_16888=[""].join("\n");
var outline_f16_31_16888=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H624743869\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H624741546\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H624742796\">",
"      SOMATOSTATIN-ANALOG THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H945119\">",
"      Antiproliferative effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H945488\">",
"      HEPATIC RESECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H624742803\">",
"      MANAGEMENT OF REFRACTORY SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H945210\">",
"      Interferon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H945242\">",
"      Liver-targeted therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H944956\">",
"      Antidiarrheal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H945796\">",
"      Systemic therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H945804\">",
"      - Cytotoxic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H945841\">",
"      - Molecularly targeted agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H945282\">",
"      Peptide receptor radioligand therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H624742810\">",
"      PREVENTION AND MANAGEMENT OF CARCINOID CRISIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H624742817\">",
"      CARCINOID HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H624743869\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H944743\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16638\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16638|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/26/14755\" title=\"picture 1\">",
"      Carcinoid heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16638|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/59/35771\" title=\"table 1\">",
"      Products of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/54/38763\" title=\"table 2\">",
"      Carcinoid symptoms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=related_link\">",
"      Carcinoid heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=related_link\">",
"      Diagnosis of the carcinoid syndrome and tumor localization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=related_link\">",
"      Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=related_link\">",
"      Treatment and surveillance of non-metastatic carcinoid tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_31_16889="Pulmonary hypertension associated with interstitial lung disease";
var content_f16_31_16889=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary hypertension associated with interstitial lung disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/31/16889/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/31/16889/contributors\">",
"     Jay H Ryu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/31/16889/contributors\">",
"     Michael D McGoon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/31/16889/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/31/16889/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/31/16889/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/31/16889/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/31/16889/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/31/16889/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hypertension (PH) is increasingly recognized as a complication of interstitial lung disease (ILD) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/1\">",
"     1",
"    </a>",
"    ]. It can exist when ILD is mild, but is more common when hypoxemia and severe pulmonary dysfunction exist. The definition, classification, prevalence, pathogenesis, and clinical manifestations of ILD-associated PH are reviewed here. In addition, diagnosis, treatment, and prognosis are discussed. A specific type of ILD-associated PH, PH associated with systemic sclerosis (formerly called scleroderma), is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6935?source=see_link\">",
"     \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;ILD-associated PH is considered present when PH exists in a patient who has ILD, and no alternative cause of the PH can be identified.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PH is defined as a mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest, as measured by right heart catheterization [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Previous definitions that are no longer used include a mean pulmonary artery pressure greater than 30 mmHg with exercise (measured by right heart catheterization) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/3\">",
"     3",
"    </a>",
"    ] and a systolic pulmonary artery pressure greater than 40 mmHg (measured by Doppler echocardiography) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link&amp;anchor=H17914506#H17914506\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ILD is inferred when the history, physical examination, imaging, and pathology suggest diffuse parenchymal lung disease. Common manifestations include dyspnea with exertion, cough, auscultatory crackles on chest examination, diffuse bilateral reticular or nodular opacities on chest imaging studies, and interstitial inflammation or fibrosis on lung biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=see_link\">",
"       \"Approach to the adult with interstitial lung disease: Clinical evaluation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=see_link\">",
"       \"Approach to the adult with interstitial lung disease: Diagnostic testing\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) classifies patients with PH into five groups based upon etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients in the first group are considered to have pulmonary arterial hypertension (PAH), whereas patients in the remaining four groups are considered to have PH (",
"    <a class=\"graphic graphic_table graphicRef66348 \" href=\"UTD.htm?42/38/43628\">",
"     table 1",
"    </a>",
"    ). When all five groups are discussed collectively, the term PH is generally used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of pulmonary hypertension in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group 1 ��� Patients with certain rheumatic diseases, typically scleroderma but possibly others (eg, systemic lupus erythematosus, mixed connective tissue disease), can develop Group 1 PAH in addition to ILD. PAH is suspected when the elevation of pulmonary artery pressures is out of proportion to the extent of ILD [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/5\">",
"       5",
"      </a>",
"      ]. These disorders are also causes of PAH in the absence of ILD.",
"     </li>",
"     <li>",
"      Group 3 ��� Typically, when patients with ILD develop PH, they have Group 3 PH, which is defined as PH owing to lung disease or hypoxemia (",
"      <a class=\"graphic graphic_table graphicRef66348 \" href=\"UTD.htm?42/38/43628\">",
"       table 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/5\">",
"       5",
"      </a>",
"      ]. The mechanism is destruction of the pulmonary vascular bed due to lung parenchymal disease or chronic pulmonary hypoxic vasoconstriction. Other types of group 3 PH include PH associated with chronic obstructive pulmonary disease (COPD), pulmonary diseases with a mixed restrictive and obstructive pattern, sleep-disordered breathing, alveolar hypoventilation, or other causes of hypoxemia.",
"     </li>",
"     <li>",
"      Group 5 ��� Patients with ILD due to certain systemic diseases may develop Group 5 PH due to unclear or multifactorial mechanisms [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. In these patients the degree of pulmonary parenchymal disease and the reduction in arterial oxygen tension (PaO",
"      <sub>",
"       2",
"      </sub>",
"      ) are insufficient to explain the elevation in pulmonary artery pressures. Various potential mechanisms of PH have been implicated, such as granulomatous infiltration of the pulmonary veins (sarcoidosis), pulmonary vasculopathy (pulmonary Langerhans cell histiocytosis, neurofibromatosis type 1), and pulmonary capillary destruction by cystic lung lesions (lymphangioleiomyomatosis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of ILD-associated PH is uncertain. One prospective cohort study reported that 32 percent of patients with ILD had PH, as measured by right heart catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/7\">",
"     7",
"    </a>",
"    ]. However, this study may have underestimated the true prevalence of ILD-associated PH because it defined PH as an mPAP &ge;35 mmHg, instead of the more commonly accepted lower values. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definition'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are limited data regarding the prevalence of PH in specific types of ILD. However, it appears that PH is most commonly associated with pulmonary Langerhans cell histiocytosis, connective tissue diseases, sarcoidosis, idiopathic pulmonary fibrosis, and pneumoconioses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary Langerhans cell histiocytosis (PLCH) &mdash; PH is common among patients with PLCH. A retrospective cohort study of 123 patients with PLCH identified 17 patients who had their sPAP estimated by Doppler echocardiography [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/10\">",
"       10",
"      </a>",
"      ]. Among these patients, 15 (89 percent) had an estimated sPAP &gt;35 mmHg and nine (53 percent) had an estimated sPAP &gt;50 mmHg. PH was most common among patients with extensive pulmonary parenchymal destruction, although advanced PLCH was not required [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/10\">",
"       10",
"      </a>",
"      ]. PH associated with PLCH tends to be more common and more severe than PH associated with other lung diseases (eg, emphysema, IPF) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=see_link\">",
"       \"Pulmonary Langerhans cell histiocytosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Connective tissue diseases (CTDs) - The prevalence of ILD and PH alone or in combination varies widely among the different CTDs [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/12-20\">",
"       12-20",
"      </a>",
"      ]. Most data come from studies that enrolled patients with systemic sclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. One retrospective study evaluated 619 patients with systemic sclerosis who had pulmonary function testing and Doppler echocardiography within six months of each other [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/20\">",
"       20",
"      </a>",
"      ]. ILD alone, PH alone, or both were identified in 23, 19, and 18 percent of patients, respectively. Among patients with PH, the estimated sPAP tends to be higher in patients who have ILD, compared to those who do not [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sarcoidosis &mdash; PH can exist in any patient with sarcoidosis, but is most common among patients with advanced disease [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/22-26\">",
"       22-26",
"      </a>",
"      ]. In a prospective cohort study from Japan, 212 consecutive patients with sarcoidosis underwent Doppler echocardiography [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/23\">",
"       23",
"      </a>",
"      ]. Twelve patients (6 percent) had an estimated sPAP &ge;40 mmHg. In contrast, a prospective cohort study that included 363 patients with more severe sarcoidosis (who were awaiting lung transplantation) detected PH in 74 percent of the patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/22\">",
"       22",
"      </a>",
"      ]. PH correlated with the need for supplemental oxygen, but not spirometric results or treatment with glucocorticoids.",
"     </li>",
"     <li>",
"      Idiopathic pulmonary fibrosis (IPF) &mdash; Studies in which patients with IPF underwent right heart catheterization reported a prevalence of PH of 8 to 34 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]. A decreased diffusing capacity may be a reasonable predictor of elevated pulmonary arterial pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/30\">",
"       30",
"      </a>",
"      ], although spirometric abnormalities correlate poorly [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/11,31\">",
"       11,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pneumoconioses &mdash; PH can complicate pneumoconioses, including asbestosis, coal worker's pneumoconiosis, silicosis, and unspecified pneumoconiosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/32-34\">",
"       32-34",
"      </a>",
"      ]. In general, the severity of the parenchymal disease correlates with severity of the PH [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PH may be caused by one or more of the following ILD-related abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypoxic pulmonary vasoconstriction and remodeling",
"     </li>",
"     <li>",
"      Vascular destruction due to progressive parenchymal fibrosis",
"     </li>",
"     <li>",
"      Vascular inflammation",
"     </li>",
"     <li>",
"      Perivascular fibrosis",
"     </li>",
"     <li>",
"      Thrombotic angiopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The precise cause of these abnormalities is uncertain, but probably includes pulmonary endothelial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/35,38-45\">",
"     35,38-45",
"    </a>",
"    ]. As an example, endothelin-1 is a mediator that is synthesized and secreted from endothelial cells. It acts as a pulmonary vasoconstrictor, a stimulus of smooth muscle cell proliferation, and an inducer of extracellular matrix formation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/35,38,40-43\">",
"     35,38,40-43",
"    </a>",
"    ]. In patients with ILD &mdash; and especially those with coexisting ILD plus PH &mdash; its plasma level is elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/35,38,40,44,45\">",
"     35,38,40,44,45",
"    </a>",
"    ]. Nitric oxide, prostacyclin, and thromboxane may also play important roles [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the different ILDs, the abnormalities described above probably exist in varying combinations and to varying degrees. Additional abnormalities may also exist:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PH associated with PLCH tends to be more severe than predicted by the degree of hypoxemia or spirometric abnormality [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/10,46\">",
"       10,46",
"      </a>",
"      ]. This suggests that hypoxemic vasoconstriction, hypoxemic remodeling, and vascular destruction are only some of the contributors to PH. A proliferative pulmonary vasculopathy involving the muscular arteries and veins has been reported in patients with PLCH, which supports this hypothesis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with PH associated with IPF may have an abnormal vascular phenotype, characterized by aberrant gene expression [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with PH associated with CTD have intimal thickening and medial hypertrophy of small and medium-sized pulmonary arteries, as well as pulmonary thrombi and vasculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/9,13,18,49,50\">",
"       9,13,18,49,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anti-endothelial antibodies and other autoimmune processes have been implicated in the development of PH associated with CTD, suggesting that inflammation contributes to the pulmonary vasculopathy that exists in some patients with CTD [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early PH is difficult to detect in patients with ILD because its symptoms are the same as those of the underlying ILD: progressive dyspnea on exertion and exercise impairment with an insidious onset. In addition, findings may be absent or minimal during physical examination and imaging.",
"   </p>",
"   <p>",
"    The symptoms and signs of advanced ILD-associated PH are similar to those due to other types of PH. Patients may report abdominal bloating, anorexia, plethora, and fatigue, which become more severe as right ventricular dysfunction and tricuspid valve regurgitation advance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/12,51\">",
"     12,51",
"    </a>",
"    ]. Signs of PH include peripheral edema, abdominal distension, elevated jugular venous pressure with accentuated V waves, an accentuated pulmonary component of the second heart sound, an early systolic ejection click (due to sudden interruption of pulmonary valve opening), tricuspid and pulmonary regurgitation murmurs, a right ventricular gallop, and a right ventricular lift [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/12,51\">",
"     12,51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of pulmonary hypertension in adults\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ILD-associated PH consists of three steps: initial detection, further evaluation, and confirmation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Initial detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the routine evaluation of ILD, patients provide history and usually undergo physical examination, imaging, pulmonary function testing, and lung biopsy. Each may provide evidence that PH coexists, but a high index of suspicion is required because the findings of PH are often subtle or obscured by the underlying ILD. The following should prompt consideration of ILD-associated PH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/52\">",
"     52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exertional dyspnea or fatigue whose severity seems out of proportion to the degree of parenchymal lung disease",
"     </li>",
"     <li>",
"      Chest pain, syncope, or any of the physical signs of PH described above",
"     </li>",
"     <li>",
"      Electrocardiography (ECG) that demonstrates right-axis deviation and right ventricular hypertrophy",
"     </li>",
"     <li>",
"      Chest radiography or computed tomography (CT) that demonstrates enlarged pulmonary arteries, attenuation of peripheral pulmonary vasculature, or right ventricular enlargement.",
"     </li>",
"     <li>",
"      Pulmonary function tests revealing a diffusing capacity that is decreased out of proportion to the severity of the restrictive defect.",
"     </li>",
"     <li>",
"      Lung biopsy that demonstrates pulmonary vascular remodeling, destruction, inflammation, or thrombosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, certain complications due to lung biopsy may provide a clue that PH exists because PH increases the morbidity and mortality of surgical lung biopsy, as well as the likelihood of bleeding during bronchoscopic lung biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/12,53\">",
"     12,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Further evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further evaluation is indicated any time ILD-associated PH is suspected. The purpose of additional assessment is to identify evidence that PH exists and estimate its severity. In addition, alternative or additional causes of PH should be excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Doppler echocardiography is performed in all patients with suspected ILD-associated PH. It estimates the sPAP and identifies related abnormalities such as right atrial enlargement, right ventricular enlargement, right or left ventricular dysfunction, intracardiac shunt, valvular disease, and pericardial effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/12,54\">",
"     12,54",
"    </a>",
"    ]. However, in some patients visualization is poor, the sPAP cannot be estimated, or the estimated sPAP is inaccurate. The estimated sPAP obtained by Doppler echocardiography identifies PH with a sensitivity of 79 to 100 percent and a specificity of 60 to 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/12\">",
"     12",
"    </a>",
"    ]. These test characteristics were derived from studies of patients with various types of PH, not exclusively from patients with ILD-associated PH.",
"   </p>",
"   <p>",
"    In contrast, the following diagnostic tests are performed on a more selective basis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overnight oximetry can be used to screen patients for obstructive sleep apnea (OSA)-related nocturnal oxyhemoglobin desaturation, although it is not an acceptable diagnostic test for documenting the presence of OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/2\">",
"       2",
"      </a>",
"      ]. Polysomnography is the gold standard diagnostic test for OSA and should be considered when the clinical suspicion for OSA is high, or the results of overnight oximetry are discordant with clinical expectation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=see_link\">",
"       \"Portable monitoring in obstructive sleep apnea in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=see_link\">",
"       \"Polysomnography in obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ventilation-perfusion",
"      <span class=\"nowrap\">",
"       (V/Q)",
"      </span>",
"      scanning is used to evaluate patients for thromboembolic disease. When the",
"      <span class=\"nowrap\">",
"       V/Q",
"      </span>",
"      scan suggests that chronic thromboembolic disease exists, pulmonary angiography is necessary to confirm the positive",
"      <span class=\"nowrap\">",
"       V/Q",
"      </span>",
"      scan and to define the extent of disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7320?source=see_link\">",
"       \"Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exercise testing is most commonly performed using the six-minute walk test (6MWT) or cardiopulmonary exercise testing. It screens for alternative causes of the patient's symptoms, determines the patient's New York Heart Association (NYHA) or WHO functional class (which guides therapy), and establishes a baseline from which the response to therapy can be measured.",
"     </li>",
"     <li>",
"      Laboratory studies may also be helpful. Arterial blood gas analysis quantitates the degree of impairment of oxygenation. A brain natriuretic peptide (BNP) level indicates the degree of cardiac impairment [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/31\">",
"       31",
"      </a>",
"      ]. HIV serology screens for HIV-associated PH and liver function tests screen for portopulmonary hypertension. Antinuclear antibody (ANA), rheumatoid factor (RF), and antineutrophil cytoplasmic antibody (ANCA) titers screen for PH due to the connective tissue diseases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Confirmation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right heart catheterization is necessary to confirm the diagnosis of PH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/5\">",
"     5",
"    </a>",
"    ]. Additional benefits of right heart catheterization include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accurate determination of the severity of the hemodynamic derangements [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/12,51,55\">",
"       12,51,55",
"      </a>",
"      ]. This provides prognostic information and a baseline from which response to therapy can be measured.",
"     </li>",
"     <li>",
"      Detection of left-to-right shunts when noninvasive studies are inconclusive",
"     </li>",
"     <li>",
"      A vasoreactivity test can be performed to help guide the initiation of advanced therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of PH can be divided conceptually into primary therapy and advanced therapy. Primary therapy targets the etiology and sequelae of the PH, while advanced therapy targets pulmonary vasoconstriction, cellular proliferation, and vascular remodeling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link\">",
"     \"Treatment of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Primary therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary therapy of ILD-associated PH consists of treating the underlying ILD, if possible, and correcting the hypoxemia with supplemental oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/52\">",
"     52",
"    </a>",
"    ]. Diuretics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , and anticoagulants may also be helpful in selected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Primary therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of the underlying ILD varies according to the identity of the ILD, but usually consists of glucocorticoids or alternative immunosuppressive agents. Treatment of various ILDs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=see_link\">",
"     \"Pulmonary Langerhans cell histiocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/19/7482?source=see_link\">",
"     \"Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/60/34762?source=see_link\">",
"     \"Treatment of idiopathic pulmonary fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Supplemental oxygen is typically prescribed for all patients with hypoxemia and PH, although it has been documented to improve survival only in patients with COPD-associated PH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. It is inferred that supplemental oxygen may benefit other groups of patients with PH and hypoxemia, including ILD-associated PH. We prescribe supplemental oxygen for our patients who have ILD-associated PH and resting or exercise-induced hypoxemia. An oxygen saturation greater than 90 percent is our usual goal.",
"   </p>",
"   <p>",
"    Patients with fluid retention may benefit from diuretics. Diuretics diminish hepatic congestion and peripheral edema, but should be used with caution to avoid decreased cardiac output (due to decreased left ventricular preload), arrhythmias induced by hypokalemia, and metabolic alkalosis (which can depress ventilation). Patients with symptomatic right heart failure may benefit from cardiac glycosides.",
"   </p>",
"   <p>",
"    Patients with ILD-associated PH are at increased risk for intrapulmonary thrombosis and thromboembolism due to sluggish pulmonary blood flow, dilated right heart chambers, venous stasis, and a sedentary lifestyle. Even a small thrombus can produce hemodynamic deterioration. In our clinical practice, we consider anticoagulant therapy for patients with ILD-associated PH on a case-by-case basis, after carefully weighing potential benefits versus risks. The anticoagulant of choice is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , with a therapeutic goal of an International Normalized Ratio (INR) of approximately two to three. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of acute pulmonary embolism\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Advanced therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced therapy refers to the administration of agents that promote vasodilation and are antiproliferative [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/58\">",
"     58",
"    </a>",
"    ]. It is not approved by the United States Food and Drug Administration (FDA) for patients with ILD-associated PH and several guideline panels recommend against its routine use in this population because larger clinical trials are needed to establish its safety and efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/52,59\">",
"     52,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it is not approved by the FDA for patients with ILD-associated PH, advanced therapy is occasionally considered for patients who remain WHO functional class III or IV (",
"    <a class=\"graphic graphic_table graphicRef62080 \" href=\"UTD.htm?24/47/25339\">",
"     table 2",
"    </a>",
"    ) despite correction of hypoxemia and optimization of the underlying ILD. This is particularly true when the severity of the PH is out of proportion to the severity of the parenchymal lung disease. Advanced therapy for such patients should be initiated only at specialized centers and needs to be administered cautiously due to its potential to worsen ventilation-perfusion mismatch and increase hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Details about patient selection, acute vasoreactivity testing, and the approach to advanced therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Advanced therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pharmacologic agents used for advanced therapy include prostanoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/52/25414?source=see_link\">",
"     treprostinil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    ), phosphodiesterase-5 (PDE5) inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    ), and endothelin receptor antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    , sitaxsentan,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/60/29637?source=see_link\">",
"     ambrisentan",
"    </a>",
"    ). Some of the agents appear to have a beneficial effect on the parenchymal fibrotic process, as well as the PH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/60\">",
"     60",
"    </a>",
"    ]. Calcium channel blockers (CCBs, primarily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ) are also used, but benefit only a small minority patients. Their limited benefit likely reflects the fact that CCBs are pure vasodilators without antiproliferative effects. Vasoconstriction is the predominant abnormality in very few patients.",
"   </p>",
"   <p>",
"    The potential for advance therapy to worsen ventilation-perfusion mismatch and increase hypoxemia may be formulation-specific. Inhaled nitric oxide, inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    , and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    have been shown in small studies to decrease pulmonary vascular resistance without increasing hypoxemia, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    appears to decrease pulmonary vascular resistance but increases hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/61-65\">",
"     61-65",
"    </a>",
"    ]. This was illustrated by a small, open-label trial of 16 patients with ILD-associated PH who were randomly assigned to receive oral sildenafil or intravenous epoprostenol [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/63\">",
"     63",
"    </a>",
"    ]. Both treatments decreased pulmonary vascular resistance at one hour. Oral sildenafil was also associated with a decrease in shunt fraction and improved arterial oxygenation, while epoprostenol therapy resulted in increased pulmonary shunting and decreased arterial oxygenation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lung transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung transplantation should be considered in patients who have severe or progressive ILD-associated PH, particularly if the patient does not improve following the initiation of advanced therapy. Single lung transplantation without cardiopulmonary bypass is appropriate for most patients with moderate ILD-associated PH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. In contrast, it is unknown whether single lung transplantation, double lung transplantation, or heart-lung transplantation is best for patients with severe ILD-associated PH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/68\">",
"     68",
"    </a>",
"    ]. Living lobar lung transplantation is also an option for a small number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/66,70\">",
"     66,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of PH on lung transplantation outcome is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/11,67,69,71,72\">",
"     11,67,69,71,72",
"    </a>",
"    ]. Several studies suggest that PH does not adversely impact the survival of patients with ILD who undergo lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/11,67,69\">",
"     11,67,69",
"    </a>",
"    ]. But, registry data suggests that PH is a risk factor for 90-day mortality after single lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ILD-associated PH have a higher mortality than patients with ILD alone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/7,22,30,36,73-75\">",
"     7,22,30,36,73-75",
"    </a>",
"    ]. Moreover, mortality increases as the severity of the PH increases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/7,30\">",
"     7,30",
"    </a>",
"    ]. This was illustrated by a retrospective study of patients with IPF [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/30\">",
"     30",
"    </a>",
"    ]. An estimated sPAP &le;35 mmHg, 36 to 50 mmHg, and &gt;50 mmHg were associated with a median survival of 4.8, 4.1, and 0.7 years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16889/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ILD-associated PH is considered present when PH exists in a patient who has ILD, and no alternative cause of the PH can be identified. PH is defined as a mean pulmonary artery pressure (mPAP) greater than 25 mmHg at rest, as measured by right heart catheterization. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of ILD-associated PH is uncertain and there are limited data regarding the prevalence of PH in specific types of ILD. Among patients with ILD, PH is most likely to complicate pulmonary Langerhans cell histiocytosis, connective tissue diseases, sarcoidosis, idiopathic pulmonary fibrosis, and pneumoconioses. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early PH is difficult to detect in patients with ILD because its symptoms are the same as those of the underlying ILD: progressive dyspnea on exertion and exercise impairment with an insidious onset. In addition, findings may be absent or minimal during physical examination and imaging. The symptoms and signs of advanced ILD-associated PH are similar to those due to other types of PH. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suspicion of ILD-associated PH is generally prompted by subtle abnormalities detected during routine assessment of ILD. This assessment usually includes history, physical examination, electrocardiography, imaging, pulmonary function testing, and lung biopsy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Initial detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Further evaluation is indicated any time ILD-associated PH is suspected. The purpose of additional assessment is to identify evidence that PH exists and estimate its severity. In addition, alternative or additional causes of PH should be excluded. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Further evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Confirmation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy directed at the underlying ILD should be initiated in all patients with ILD-associated PH, if thought to be potentially beneficial. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Primary therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend supplemental oxygen for all patients with ILD-associated PH and resting or exercise hypoxemia (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Primary therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anticoagulant therapy for patients with ILD-associated PH should be determined on a case-by-case basis, after carefully weighing the potential benefits versus risks. The anticoagulant of choice is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , with a therapeutic goal of an International Normalized Ratio (INR) of approximately two to three. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Primary therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with ILD-associated PH who have fluid retention, we suggest that diuretics be administered (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with ILD-associated PH complicated by symptomatic right heart failure, we suggest that a cardiac glycoside (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      ) be prescribed (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Primary therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with ILD-associated PH who are World Health Organization (WHO) functional class III or IV after optimization of primary therapy should be referred to a specialized center for further evaluation and management (eg, vasoreactivity testing and advanced therapy). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Advanced therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with severe or progressive ILD-associated PH be evaluated for lung transplantation, particularly if the patient does not improve following the initiation of advanced therapy. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Lung transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with ILD-associated PH have a higher mortality than patients with ILD alone. Mortality increases as the severity of the PH increases. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/1\">",
"      Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008; 31:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/2\">",
"      Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/3\">",
"      Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43:40S.",
"     </a>",
"    </li>",
"    <li>",
"     Executive summary from the World Symposium on Primary Pulmonary Hypertension. Co-sponsored by The World Health Organization, Rich S (Ed), Evian, France 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/5\">",
"      Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/6\">",
"      Corte TJ, Wells AU, Nicholson AG, et al. Pulmonary hypertension in sarcoidosis: a review. Respirology 2011; 16:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/7\">",
"      Leuchte HH, Baumgartner RA, Nounou ME, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006; 173:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/8\">",
"      Maloney JP. Advances in the treatment of secondary pulmonary hypertension. Curr Opin Pulm Med 2003; 9:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/9\">",
"      Shapiro S. Management of pulmonary hypertension resulting from interstitial lung disease. Curr Opin Pulm Med 2003; 9:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/10\">",
"      Chaowalit N, Pellikka PA, Decker PA, et al. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo Clin Proc 2004; 79:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/11\">",
"      Harari S, Simonneau G, De Juli E, et al. Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. J Heart Lung Transplant 1997; 16:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/12\">",
"      McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126:14S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/13\">",
"      Hoeper MM. Pulmonary hypertension in collagen vascular disease. Eur Respir J 2002; 19:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/14\">",
"      Rayner CF, Grubnic S. Pulmonary manifestations of systemic autoimmune disease. Best Pract Res Clin Rheumatol 2004; 18:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/15\">",
"      Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996; 110:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/16\">",
"      Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/17\">",
"      MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/18\">",
"      Fagan KA, Badesch DB. Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis 2002; 45:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/19\">",
"      Hesselstrand R, Ekman R, Eskilsson J, et al. Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001. Rheumatology (Oxford) 2005; 44:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/20\">",
"      Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003; 30:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/21\">",
"      Wigley FM, Lima JA, Mayes M, et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005; 52:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/22\">",
"      Shorr AF, Davies DB, Nathan SD. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002; 122:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/23\">",
"      Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/24\">",
"      Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005; 25:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/25\">",
"      Dobarro D, Schreiber BE, Handler C, et al. Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data. Am J Cardiol 2013; 111:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/26\">",
"      Rapti A, Kouranos V, Gialafos E, et al. Elevated pulmonary arterial systolic pressure in patients with sarcoidosis: prevalence and risk factors. Lung 2013; 191:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/27\">",
"      Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007; 131:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/28\">",
"      Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/29\">",
"      Zisman DA, Ross DJ, Belperio JA, et al. Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2007; 101:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/30\">",
"      Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128:2393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/31\">",
"      Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004; 170:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/32\">",
"      Rosenman KD, Zhu Z. Pneumoconiosis and associated medical conditions. Am J Ind Med 1995; 27:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/33\">",
"      Tomasini M, Chiappino G. Hemodynamics of pulmonary circulation in asbestosis: study of 16 cases. Am J Ind Med 1981; 2:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/34\">",
"      Scano G, Garcia-Herreros P, Stendardi D, et al. Cardiopulmonary adaptation to exercise in coal miners. Arch Environ Health 1980; 35:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/35\">",
"      Hopkins N, McLoughlin P. The structural basis of pulmonary hypertension in chronic lung disease: remodelling, rarefaction or angiogenesis? J Anat 2002; 201:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/36\">",
"      Strange C, Highland KB. Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med 2005; 11:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/37\">",
"      Mura M, Anraku M, Yun Z, et al. Gene expression profiling in the lungs of patients with pulmonary hypertension associated with pulmonary fibrosis. Chest 2012; 141:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/38\">",
"      MacLean MR. Endothelin-1 and serotonin: mediators of primary and secondary pulmonary hypertension? J Lab Clin Med 1999; 134:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/39\">",
"      Cella G, Bellotto F, Tona F, et al. Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest 2001; 120:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/40\">",
"      Tuder RM, Cool CD, Yeager M, et al. The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 2001; 22:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/41\">",
"      Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/42\">",
"      Kirchengast M, Luz M. Endothelin receptor antagonists: clinical realities and future directions. J Cardiovasc Pharmacol 2005; 45:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/43\">",
"      Braun-Moscovici Y, Nahir AM, Balbir-Gurman A. Endothelin and pulmonary arterial hypertension. Semin Arthritis Rheum 2004; 34:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/44\">",
"      Trakada G, Nikolaou E, Pouli A, et al. Endothelin-1 levels in interstitial lung disease patients during sleep. Sleep Breath 2003; 7:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/45\">",
"      Yamakami T, Taguchi O, Gabazza EC, et al. Arterial endothelin-1 level in pulmonary emphysema and interstitial lung disease. Relation with pulmonary hypertension during exercise. Eur Respir J 1997; 10:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/46\">",
"      Harari S, Brenot F, Barberis M, Simmoneau G. Advanced pulmonary histiocytosis X is associated with severe pulmonary hypertension. Chest 1997; 111:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/47\">",
"      Fartoukh M, Humbert M, Capron F, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000; 161:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/48\">",
"      Gagermeier J, Dauber J, Yousem S, et al. Abnormal vascular phenotypes in patients with idiopathic pulmonary fibrosis and secondary pulmonary hypertension. Chest 2005; 128:601S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/49\">",
"      Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990; 21:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/50\">",
"      Tuder RM, Lee SD, Cool CC. Histopathology of pulmonary hypertension. Chest 1998; 114:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/51\">",
"      Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med 2005; 143:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/52\">",
"      Hoeper MM, Barber&agrave; JA, Channick RN, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009; 54:S85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/53\">",
"      Wahidi MM, Rocha AT, Hollingsworth JW, et al. Contraindications and safety of transbronchial lung biopsy via flexible bronchoscopy. A survey of pulmonologists and review of the literature. Respiration 2005; 72:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/54\">",
"      Bossone E, Bodini BD, Mazza A, Allegra L. Pulmonary arterial hypertension: the key role of echocardiography. Chest 2005; 127:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/55\">",
"      Rubin LJ, American College of Chest Physicians. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126:4S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/56\">",
"      Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/57\">",
"      Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/58\">",
"      Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126:35S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/59\">",
"      Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC), European Respiratory Society (ERS), International Society of Heart and Lung Transplantation (ISHLT), et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/60\">",
"      Vassallo R, Thomas CF. Advances in the treatment of rheumatic interstitial lung disease. Curr Opin Rheumatol 2004; 16:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/61\">",
"      Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/62\">",
"      Strange C, Bolster M, Mazur J, et al. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest 2000; 118:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/63\">",
"      Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/64\">",
"      Fisher KA, Serlin DM, Wilson KC, et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/65\">",
"      Barnett CF, Bonura EJ, Nathan SD, et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest 2009; 135:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/66\">",
"      Alalawi R, Whelan T, Bajwa RS, Hodges TN. Lung transplantation and interstitial lung disease. Curr Opin Pulm Med 2005; 11:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/67\">",
"      Huerd SS, Hodges TN, Grover FL, et al. Secondary pulmonary hypertension does not adversely affect outcome after single lung transplantation. J Thorac Cardiovasc Surg 2000; 119:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/68\">",
"      Conte JV, Borja MJ, Patel CB, et al. Lung transplantation for primary and secondary pulmonary hypertension. Ann Thorac Surg 2001; 72:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/69\">",
"      Fitton TP, Kosowski TR, Barreiro CJ, et al. Impact of secondary pulmonary hypertension on lung transplant outcome. J Heart Lung Transplant 2005; 24:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/70\">",
"      Lu BS, Bhorade SM. Lung transplantation for interstitial lung disease. Clin Chest Med 2004; 25:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/71\">",
"      Bando K, Keenan RJ, Paradis IL, et al. Impact of pulmonary hypertension on outcome after single-lung transplantation. Ann Thorac Surg 1994; 58:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/72\">",
"      Whelan TP, Dunitz JM, Kelly RF, et al. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 2005; 24:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/73\">",
"      Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/74\">",
"      King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16889/abstract/75\">",
"      McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126:78S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8258 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-125.39.66.147-2DA2A50332-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_31_16889=[""].join("\n");
var outline_f16_31_16889=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Initial detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Further evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Confirmation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Primary therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Advanced therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/8258\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8258|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/38/43628\" title=\"table 1\">",
"      WHO pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/47/25339\" title=\"table 2\">",
"      Classification PH function",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22856?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7320?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=related_link\">",
"      Polysomnography in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=related_link\">",
"      Portable monitoring in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/19/7482?source=related_link\">",
"      Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/48/35592?source=related_link\">",
"      Pulmonary Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6935?source=related_link\">",
"      Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/60/34762?source=related_link\">",
"      Treatment of idiopathic pulmonary fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_31_16890="Introduction to recombinant hematopoietic growth factors";
var content_f16_31_16890=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Introduction to recombinant hematopoietic growth factors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/31/16890/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/31/16890/contributors\">",
"     Colin A Sieff, MB, BCh, FRCPath",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/31/16890/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/31/16890/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/31/16890/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/31/16890/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/31/16890/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The family of glycoproteins known as the hematopoietic growth factors (HGFs) plays a major role in the proliferation, differentiation, and survival of primitive hematopoietic stem and progenitor cells, as well as in functional activation of some mature cells. These effects are mediated by high affinity binding of the HGFs to specific receptors expressed on the surface of the target cells.",
"   </p>",
"   <p>",
"    Correction or amelioration of bone marrow failure by the administration of HGFs has been and continues to be the major practical goal of research in hematopoiesis. This goal could not be achieved, however, without the early tissue culture work, which led to characterization of the hematopoietic growth factor family, and without recombinant DNA technology, which provided the genes that allowed production of purified hormones in sufficient quantities to permit interpretable in vitro and in vivo studies.",
"   </p>",
"   <p>",
"    A brief review of the history of the major HGFs, the major indications for their use, and the side effects that may be seen will be presented here [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The function of specific HGFs &mdash; such as erythropoietin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and thrombopoietin &mdash; in the regulation of erythropoiesis, myelopoiesis, and megakaryocytopoiesis, respectively, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link\">",
"     \"Regulation of erythropoiesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6858?source=see_link\">",
"     \"Regulation of myelopoiesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4458?source=see_link\">",
"     \"Megakaryocyte biology and the production of platelets\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beginning with pioneering studies in the early 1960s, it has been recognized that normal and leukemic blood progenitor cells can be propagated in semisolid culture in the presence of soluble growth factors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These factors were originally termed colony-stimulating factors (CSFs) because of their ability to support the formation of colonies of blood cells by bone marrow cells plated in semisolid medium [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the 1970s and 1980s, it became clear that there were multiple types of CSFs based upon the different types of colonies that grew in the presence of the different factors. This observation led to the hypothesis that the growth and differentiation of blood cells were controlled, at least in part, by exposure of progenitor cells to CSFs having different lineage specificities [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following the molecular cloning of the genes for many of these factors and their receptors during the 1980s and 1990s, it became possible to study in detail the structure, function, and biology of the recombinant CSFs as well as the molecular biology of their respective genes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. This analysis, along with similar work on the regulation of cells in the immune system, led to the realization that there is a large family of interacting regulatory molecules now generally known as cytokines or lymphohematopoietic cytokines that control the hematopoietic and immune systems and integrate their responses with those of other systems [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This interacting network of cytokines includes the interferons [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/11\">",
"     11",
"    </a>",
"    ], interleukins [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/12\">",
"     12",
"    </a>",
"    ], tumor necrosis factors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/13\">",
"     13",
"    </a>",
"    ], and hematopoietic growth factors (including the colony-stimulating factors) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/5\">",
"     5",
"    </a>",
"    ]. The successful cloning of the HGFs and their receptors has provided an incredible array of tools for analysis of the molecular and cellular biology of hematopoiesis, and for the production of recombinant proteins for evaluation of the biology of the various factors in vivo and in vitro (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"UTD.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Interleukin-3",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discovery, cloning, and expression of the gene for murine interleukin (IL)-3 (also called murine multi-CSF) presented the first opportunity to evaluate HGFs in an unambiguous fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Sublethally irradiated mice were infused for seven days with recombinant IL-3 or control protein [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/16\">",
"     16",
"    </a>",
"    ]. The spleens of the IL-3 treated mice were much larger than those of the controls, were more cellular, and contained more progenitors of the erythroid and myeloid lineages. In contrast, bone marrow cellularity was unaffected, although progenitor content was reduced. Similar results were obtained in mice injected intraperitoneally with purified bacterially synthesized IL-3 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/17\">",
"     17",
"    </a>",
"    ]. Other changes induced by IL-3 included 10-fold increases in blood eosinophils and two- to threefold increases in neutrophil and monocyte counts. Intraperitoneal injections resulted in six- to 15-fold increases in peritoneal macrophages with an increase in phagocytic activity.",
"   </p>",
"   <p>",
"    These experiments clearly demonstrated that murine IL-3 influenced the replication and growth potential of primitive hematopoietic progenitors. They strongly suggested that the effects such hormones have on blood counts are related to their influences on progenitor function rather than peripheral blood cell kinetics. They also suggested that the function of mature cells can be altered in vivo, an effect that would be expected to decrease rather than increase the numbers of circulating phagocytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Granulocyte-macrophage colony-stimulating factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first indication that GM-CSF also can broadly stimulate hematopoiesis in vivo resulted from studies in which GM-CSF, produced in monkey kidney cells, was infused into cynomolgus macaques [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/18\">",
"     18",
"    </a>",
"    ]. Recombinant human GM-CSF (rhGM-CSF), when injected intravenously, has an overall initial half-time of 15 to 20 minutes, clearly demonstrating that infusion of the hormone at a concentration sufficient to maintain a functional blood level could be achieved. Infusions of rhGM-CSF into normal monkeys produced large increments in all classes of leukocytes, including eosinophils, lymphocytes, and reticulocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/18\">",
"     18",
"    </a>",
"    ]. The blood counts rapidly fell toward baseline when the infusion was terminated.",
"   </p>",
"   <p>",
"    Mice that lack GM-CSF have normal basal hematopoiesis, but develop progressive accumulation of surfactant lipids and proteins in the alveolar space, the defining characteristic of idiopathic human pulmonary alveolar proteinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=see_link\">",
"     \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Granulocyte colony-stimulating factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;In comparison to IL-3 and GM-CSF, G-CSF as well as erythropoietin and thrombopoietin are more lineage-specific. A primary effect of G-CSF is to promote the conversion of granulocyte colony-forming units (CFU-G) into polymorphonuclear leukocytes (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"UTD.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6858?source=see_link\">",
"     \"Regulation of myelopoiesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mice that lack G-CSF have chronic neutropenia (20 percent to 30 percent of normal levels) and reduced bone marrow myeloid precursors and progenitors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/21\">",
"     21",
"    </a>",
"    ]. They also have a markedly impaired capacity to increase neutrophil and monocyte counts after infection with Listeria monocytogenes. Mice heterozygous for the null allele of G-CSF have intermediate values, suggesting a gene dose effect.",
"   </p>",
"   <p>",
"    The efficacy of human G-CSF was initially evaluated in simian preclinical trials. Cynomolgus monkeys treated with two daily subcutaneous injections of purified G-CSF for 14 to 28 days showed a dose-related increase in polymorphonuclear neutrophils, with the plateau being reached after one week [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/22\">",
"     22",
"    </a>",
"    ]. At the intermediate dose of 10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day, total white blood cell counts of 40,000 to",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    were achieved, and neutrophil function was enhanced.",
"   </p>",
"   <p>",
"    These initial studies also evaluated two",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -treated animals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/22\">",
"     22",
"    </a>",
"    ]. G-CSF was given either from six days before until 21 days after cyclophosphamide or for 14 days starting three days after the cessation of cyclophosphamide. The neutrophil count increased dramatically by day six to seven after cyclophosphamide, reaching levels of",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    by the tenth day. On the other hand, the control animal remained pancytopenic for three to four weeks after treatment. This type of observation provided the rationale for the administration of G-CSF or GM-CSF to patients with chemotherapy-induced neutropenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Erythropoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythropoietin (EPO) is essential for the terminal maturation of erythroid cells. Its major effect appears to be at the level of the CFU-E during adult erythropoiesis; recombinant preparations are as effective as the natural hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. EPO and its receptor may also contribute to wound healing responses, angiogenesis, and the response to brain and heart injury [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recombinant human EPO has had a major impact on the quality of life in patients with marked anemia due to chronic renal failure as well as the anemia associated with cancer and its treatment. Its half-life in the circulation can be prolonged by the addition of N-linked carbohydrates (eg, darbepoetin) (",
"    <a class=\"graphic graphic_figure graphicRef51292 \" href=\"UTD.htm?29/23/30078\">",
"     figure 1",
"    </a>",
"    ), by formation of adducts with polyethylene glycol, or by preparation of EPO multimers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H19#H19\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Erythropoietin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Thrombopoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of the protooncogene c-mpl [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/28\">",
"     28",
"    </a>",
"    ], based upon its homology to the oncogene transduced by the murine myeloproliferative leukemia virus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/29\">",
"     29",
"    </a>",
"    ], revealed an orphan HGF receptor that was important for megakaryocytopoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/30\">",
"     30",
"    </a>",
"    ]. It also eventually led to the cloning of thrombopoietin (TPO), the ligand for this receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recombinant human TPO or its polyethylene glycol (PEG)-derivatized, truncated, 163 residue amino-terminus (PEG-megakaryocyte growth and development factor, or PEG-MGDF) stimulates megakaryocyte proliferation and endoreduplication in vitro and is a potent inducer of megakaryocytopoiesis and platelet production in vivo in mice and nonhuman primates [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. The role of recombinant human TPO in the treatment of thrombocytopenia has been limited [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/36\">",
"     36",
"    </a>",
"    ]. PEG-MGDF caused the development of antibodies to TPO that resulted in severe thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/37\">",
"     37",
"    </a>",
"    ], and both PEG-MGDF and TPO have been withdrawn from clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Stem cell factor and Flt 3 ligand",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stem cell factor (SCF), also known as c-Kit ligand or Steel factor [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/38\">",
"     38",
"    </a>",
"    ], and Flt3 ligand [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], both interact with a variety of hematopoietic progenitor cells, perhaps most importantly with very early stem cell populations. While SCF has potent synergistic actions on early progenitor cells, its receptor c-Kit is also expressed on mast cells, and severe allergic reactions, including respiratory symptoms, have retarded clinical development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT WITH HEMATOPOIETIC GROWTH FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several recombinant HGFs have been evaluated in a variety of clinical settings. Largely because of availability, initial studies focused on GM-CSF and G-CSF in both transient and long-standing bone marrow failure syndromes, and on erythropoietin in the anemia of chronic renal failure. Following their successes, other HGFs such as macrophage-CSF, SCF, IL-1, IL-11, and thrombopoietin have been evaluated, but none has found major clinical use.",
"   </p>",
"   <p>",
"    The following is a list of the major clinical settings in which recombinant HGFs are administered. The efficacy of therapy in these conditions is discussed separately on the appropriate topic reviews:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transient bone marrow failure following chemotherapy",
"     </li>",
"     <li>",
"      Bone marrow transplantation",
"     </li>",
"     <li>",
"      Myelodysplastic syndrome",
"     </li>",
"     <li>",
"      Chronic bone marrow failure and aplastic anemia",
"     </li>",
"     <li>",
"      Human immunodeficiency virus infection",
"     </li>",
"     <li>",
"      Inherited bone marrow failure syndromes",
"     </li>",
"     <li>",
"      Chronic anemias (eg, renal failure, prematurity, anemia of chronic disease, anemia associated with HIV infection)",
"     </li>",
"     <li>",
"      Stem cell and progenitor cell mobilization (in vitro and ex vivo)",
"     </li>",
"     <li>",
"      Gene transfer",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Dosage and schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, the recommended dose of G-CSF is 5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day for all clinical situations other than peripheral blood progenitor cell mobilization, in which case a dose of 10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day has been recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/41\">",
"     41",
"    </a>",
"    ]. The recommended dose of GM-CSF is 250",
"    <span class=\"nowrap\">",
"     mcg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day. Rounding the dose to the nearest vial size is an appropriate strategy to maximize cost benefit. The preferred route is by subcutaneous injection.",
"   </p>",
"   <p>",
"    G-CSF is usually started no earlier than 24 hours after administration of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/42\">",
"     42",
"    </a>",
"    ]. Continuation until the absolute neutrophil count following the nadir exceeds",
"    <span class=\"nowrap\">",
"     10,000/microL,",
"    </span>",
"    as specified in the G-CSF package insert, is known to be safe and effective. However, a shorter duration that is sufficient to achieve clinically adequate neutrophil recovery is a reasonable alternative, considering issues of patient convenience and cost. G-CSF should not be given in the period 24 hours before treatment with the next cycle of chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TOXICITY OF COLONY-STIMULATING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant human GM-CSF and G-CSF have been tested in multiple clinical trials and have in general been well tolerated. However, the following reactions and concerns have been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. There are more limited data on other growth factors such as M-CSF and SCF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Transient leukopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following intravenous bolus injection, both GM-CSF and G-CSF induce a transient leukopenia in the first 30 minutes after administration. GM-CSF rapidly induces surface expression of the leukocyte adhesion protein CD11b (MO1) in vitro; expression of this protein is accompanied by an increase in neutrophil aggregation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/45\">",
"     45",
"    </a>",
"    ]. CD11a (LFA-1) and CD11c (gp 150, 95), two other members of this family of cell surface adhesion glycoproteins that have distinct alpha-chains but share a common beta-chain (CD18) with CD11b, are unaffected by GM-CSF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These findings have been confirmed by in vivo studies of sarcoma patients who received 32 or 64",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day of GM-CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/46\">",
"     46",
"    </a>",
"    ]. A marked increase of CD11b was noted that was evident by 30 minutes and persisted for 12 to 24 hours after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radionuclide-labeled leukocytes are sequestered in the lungs after GM-CSF treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/47\">",
"     47",
"    </a>",
"    ], probably due to the aggregability and adhesiveness induced by increased CD11b expression. Breathlessness and hypoxia have been observed in some patients, particularly after short duration intravenous therapy.",
"   </p>",
"   <p>",
"    In comparison to these findings, CD11b is not modulated by G-CSF. Thus, the mechanism responsible for the transient leukopenia following treatment with G-CSF is at present unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other systemic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;GM-CSF can induce flu-like symptoms, including fever, flushing, malaise, myalgia, arthralgia, anorexia, and headache, and mild elevations of serum aminotransferases and rash are also reported. These effects are usually mild, are alleviated by antipyretics, and disappear with continued administration.",
"   </p>",
"   <p>",
"    Pathogenic neutrophil infiltration (acute febrile neutrophilic dermatosis or Sweet syndrome) and cutaneous necrotizing vasculitis (leukocytoclastic vasculitis) can occur in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. Upregulation of neutrophil function with the secondary release of cytokines may induce these complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40905?source=see_link\">",
"     \"Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More serious GM-CSF toxicity has been observed at higher dose levels (&gt;32",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day intravenously or &gt;15",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day subcutaneously). These include a capillary leak syndrome that is manifested by weight gain due to fluid retention, pericardial or pleural effusions, ascites,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    edema [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Phlebitis was noted in initial studies when GM-CSF was infused into small veins; large-vessel thrombosis has occurred with infusion of high doses into central veins [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/53\">",
"     53",
"    </a>",
"    ]. No dose limiting toxicity has been observed with G-CSF.",
"   </p>",
"   <p>",
"    As mentioned below, there is also a theoretical concern that G-CSF might induce or accelerate the development of acute myeloid leukemia or myelodysplasia with monosomy seven in aplastic anemia and infantile agranulocytosis (Kostmann disease). However, randomized trials have not shown any impact on the acceleration or development of AML in patients with either AML or MDS.",
"   </p>",
"   <p>",
"    Fever is the most frequent side effect associated with administration of human urinary M-CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Malaise and headache and slight depression of blood pressure have also been observed.",
"   </p>",
"   <p>",
"    Subcutaneously administered SCF frequently causes injection-site reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/57\">",
"     57",
"    </a>",
"    ]. It has also been associated with severe systemic allergic reactions that are thought to be mast cell-related, since SCF is known to activate mast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4363708\">",
"    <span class=\"h2\">",
"     CSF-related bone pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both GM-CSF and G-CSF have been commonly associated with mild to moderate bone pain, coincident with or shortly after administration; the etiology of the bone pain is uncertain. Occasional increases in leukocyte alkaline phosphatase",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serum lactate dehydrogenase also have been noted. The incidence is not well documented, particularly for GM-CSF (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/43/5814?source=see_link\">",
"     sargramostim",
"    </a>",
"    ). A retrospective analysis of randomized trial data suggests that rates are similar with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/28/12741?source=see_link\">",
"     pegfilgrastim",
"    </a>",
"    (bone pain of any grade during the first four chemotherapy cycles approximately 60 versus 66 percent, grade 3 or 4 in 6 versus 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data are limited, NSAIDs appear to be only modestly effective at reducing the frequency and severity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/28/12741?source=see_link\">",
"     pegfilgrastim",
"    </a>",
"    -induced bone pain. This was shown in a placebo-controlled trial in which 510 patients with a non-myeloid cancer and no contraindication to use of an NSAID were randomly assigned to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    (500 mg twice daily starting on the day of the pegfilgrastim injection and continuing for 5 to 8 days) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/60\">",
"     60",
"    </a>",
"    ]. Naproxen significantly reduced the overall incidence of bone pain (61 versus 71 percent) and its duration (1.92 versus 2.40 days). The incidence of severe pain (&gt;5 on a scale of 1 to 10) was also significantly, but only modestly, reduced (19 versus 27 percent). Risk factors to predict incidence, severity, or ability to prevent pegfilgrastim-induced bone pain could not be identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antibodies to recombinant growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;rhGM-CSF that is produced in mammalian cells (Chinese hamster ovary [CHO] cells) is variably glycosylated on both O-linked and N-linked sites. In comparison, production in Escherichia coli results in nonglycosylated GM-CSF, while the yeast product is glycosylated only at N-linked sites. All three products appear to be equally effective, but antibodies have been reported in 4 of 13 patients given the yeast-derived product in phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/61\">",
"     61",
"    </a>",
"    ]. The IgG antibodies developed within seven days after the start of the infusion in all four patients, three of whom had received a bolus test dose. Antibodies were non-neutralizing as judged by bone marrow colony-forming assay, and were directed at sites on the protein backbone of the GM-CSF molecule that are normally protected by O-linked glycosylation, but which are exposed in the yeast and E. coli-derived products.",
"   </p>",
"   <p>",
"    Antibodies to rhTPO have been reported in one patient with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/62\">",
"     62",
"    </a>",
"    ] and in volunteers given PEG-MGDF. Further clinical development of the latter TPO formulation has been stopped, since transient decreases in platelet count were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/35,63\">",
"     35,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=see_link\">",
"     \"Clinical applications of thrombopoietic growth factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Possible stimulation of malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because HGF receptors are expressed by hematopoietic and several nonhematopoietic cell types, there has been a concern that certain malignant cell lineages might respond to such therapy, potentially worsening the underlying condition, or by triggering the development of malignancy in a susceptible individual [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/64-66\">",
"     64-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An example of this concern has arisen in severe congenital neutropenia (SCN) or infantile agranulocytosis, the autosomal recessive form of which is Kostmann disease (mutation in the HAX1 gene). SCN may be associated with the acquisition of somatic clonal mutations in the G-CSF receptor. Affected children, if they survive infancy and early childhood, are at risk for myelodysplastic syndrome and acute myeloid leukemia; registry data suggest that the incidence of these complications in the G-CSF therapy era is 9.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. It has been speculated that G-CSF therapy might increase the risk of acute myeloid leukemia, perhaps more likely in those patients with G-CSF receptor mutations that can transduce a proliferative but not a differentiation signal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/68\">",
"     68",
"    </a>",
"    ]. At present, however, there is no evidence to support this hypothesis, as acute myeloid leukemia also occurs in patients who are untreated. It is more likely that the greatly improved survival associated with G-CSF treatment has allowed an underlying leukemia predisposition to manifest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link&amp;anchor=H12#H12\">",
"     \"Congenital neutropenia\", section on 'G-CSF receptor mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Survivors of acquired aplastic anemia are also at increased risk for late myelodysplastic syndrome and acute myeloid leukemia. Development of these disorders has been associated with the acquisition of monosomy 7 and concerns have been raised about a possible contributory role from long-term G-CSF therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. In one patient, for example, the leukemic blasts were sensitive to G-CSF but not erythropoietin or IL-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that long-term administration of G-CSF interacts with immunosuppressive therapy in patients with aplastic anemia. In one study of 72 adults with aplastic anemia, MDS developed in 1 of 47 patients treated without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or antithymocyte globulin compared with 4 of 25 treated with one or the other of these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/71\">",
"     71",
"    </a>",
"    ]. All four had received long-term G-CSF at a higher cumulative dose than those who did not develop myelodysplastic syndrome; administration for more than one year was the single most important risk factor for myelodysplastic syndrome. Similar results were noted in another study in which MDS or acute leukemia developed in 11 of 50 children with acquired aplastic anemia who were treated with cyclosporine and G-CSF compared with none of 41 treated with either agent alone and none of 48 who underwent bone marrow transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29930?source=see_link\">",
"     \"Aplastic anemia: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In order to deliver \"dose-dense\" chemotherapy regimens safely, G-CSF may need to be given during the short intervals between treatment courses. However, such an intensive schedule may increase the likelihood for the survival and proliferation of a hematopoietic stem cell that may have sustained a critical mutation from the previous chemotherapy course and would otherwise have undergone apoptosis or DNA repair.",
"   </p>",
"   <p>",
"    Several observational studies reported that the use of CSFs is associated with an increased risk of therapy-related myeloid neoplasms (acute myeloid leukemia [AML] or myelodysplastic syndrome [MDS]). This issue was addressed in a systematic review of 25 randomized trials of chemotherapy with (n = 6058 patients) or without (n = 6746 patients) G-CSF for a variety of neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/72\">",
"     72",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     AML/MDS",
"    </span>",
"    was reported in significantly more patients treated with G-CSF (43 versus 22, relative risk 1.92, 95% CI 1.19-3.07). However, all-cause mortality was significantly lower in patients receiving chemotherapy with G-CSF support (absolute risk of death lowered by 3.4 percent, 95% CI 2.01-4.80), and greater reductions in mortality were observed in patients who received greater chemotherapy dose intensity.",
"   </p>",
"   <p>",
"    Thus, the use of myeloid growth factors during chemotherapy increases the risk of a therapy-related myeloid neoplasm, although the absolute magnitude of the risk is small. The risk is probably outweighed by the benefits of using CSFs in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Possible enhancement of HIV replication",
"    </span>",
"    &nbsp;&mdash;&nbsp;A concern with rhGM-CSF therapy, but not G-CSF, in patients with AIDS is the potential for stimulation of HIV replication. This phenomenon was initially demonstrated during in vitro experiments with mononuclear phagocytes exposed to rhGM-CSF or IL-3 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/73\">",
"     73",
"    </a>",
"    ]. Later in vitro studies revealed upregulation of CCR5 coreceptor expression and enhanced HIV infectivity in fresh human monocytes exposed to rhGM-CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/74\">",
"     74",
"    </a>",
"    ]. However, in vivo data on the relationship between rhGM-CSF therapy and HIV replication have been conflicting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/0/44039?source=see_link\">",
"     \"Hematologic manifestations of HIV infection: Neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Use in sickle cell syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three case reports have indicated that the use of G-CSF in patients with sickle cell syndromes (eg, homozygous sickle cell disease, SC disease, and",
"    <span class=\"nowrap\">",
"     S/&szlig;+",
"    </span>",
"    thalassemia) has been associated with sickle cell crisis and multiorgan failure; at least one patient has died as a result of this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H30#H30\">",
"     \"Overview of the management of sickle cell disease\", section on 'Granulocyte colony-stimulating factor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TOXICITY OF ERYTHROPOIETIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    has come from the treatment of patients with anemia due to end-stage renal disease. The most common side effects of EPO therapy, aside from hypertension and its related problems, are headache, which occurs in 15 percent of cases and an influenza-like syndrome affecting 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. The influenza-like syndrome is of unknown etiology, but is responsive to antiinflammatory drugs and does not seem to occur with subcutaneous EPO administration [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypertension, which is occasionally severe enough to be associated with encephalopathy and seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/81\">",
"     81",
"    </a>",
"    ], is the most important complication of EPO therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/79,82,83\">",
"     79,82,83",
"    </a>",
"    ]. Among patients with end-stage renal disease, 20 to 50 percent of patients who receive EPO intravenously develop an elevation in diastolic pressure of 10 mmHg or more [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/79,83\">",
"     79,83",
"    </a>",
"    ]. In comparison, the blood pressure is less likely to rise after subcutaneous therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/84\">",
"     84",
"    </a>",
"    ], possibly because this route of administration does not elevate plasma endothelin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8436?source=see_link\">",
"     \"Hypertension following erythropoietin in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of hypertension can be ameliorated by raising the hematocrit",
"    <strong>",
"     slowly",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/86\">",
"     86",
"    </a>",
"    ] and by aiming for a hematocrit of 30 to 35 percent, a level that is sufficient to relieve symptoms without producing a significant elevation in blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/82\">",
"     82",
"    </a>",
"    ]. Patients who still become hypertensive can be treated with fluid removal (via dialysis or, if the patient has only chronic renal failure, diuretics) and the administration of antihypertensive agents. Beta-adrenergic blockers and vasodilators should be considered as agents of first choice, although calcium channel blockers and angiotensin converting enzyme inhibitors also may be effective. The dose of EPO should be reduced or discontinued for several weeks in severe cases or when other therapeutic measures are ineffective.",
"   </p>",
"   <p>",
"    A number of cases of production of neutralizing antibodies to exogenous recombinant EPO, causing acquired pure red cell aplasia and refractory anemia in hemodialysis patients, have been described. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8265?source=see_link\">",
"     \"Pure red cell aplasia due to anti-erythropoietin antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Side effects of EPO when given to patients with malignancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of all the HGFs, two lineage-specific factors, namely G-CSF and EPO, have proven to be most useful clinically as stimulators of granulocytic and erythroid progenitors and precursors. They have been successfully employed in both transient and chronic bone marrow failure states, and, in a randomized trial employing EPO and supplemental iron, reducing the need for postoperative blood transfusion in patients undergoing total hip joint arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link\">",
"     \"Use of red blood cells for transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combinations of these late-acting factors with those that act synergistically on stem cells will certainly find roles in mobilization strategies for the harvesting of stem and progenitor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link&amp;anchor=H9#H9\">",
"     \"Sources of hematopoietic stem cells\", section on 'Hematopoietic stem cell mobilization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A better understanding of the molecular mechanisms that control stem cell trafficking would potentially allow specific manipulation of these events. The importance of VLA-4, expressed on progenitor cells, and its receptor VCAM-1, expressed by stromal cells, in the localization of stem cells to the marrow may be important in this regard [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. Antibodies to these molecules show that they play a role in the homing of stem cells to the marrow and in the mobilization of",
"    <span class=\"nowrap\">",
"     stem/progenitor",
"    </span>",
"    cells from bone marrow to blood, an active mechanism that appears to require signaling through the SCF receptor c-Kit [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another approach is the possible manipulation of self-renewal. As an example, murine bone marrow cells engineered to overexpress HOXB4 by retrovirus-mediated gene transfer show a dramatic upregulation in stem cell activity both in vitro and in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/93\">",
"     93",
"    </a>",
"    ]. Serial transplantation studies have revealed a greatly enhanced ability of HOXB4-transduced bone marrow cells to regenerate the most primitive hematopoietic stem cell compartment, resulting in 50-fold higher numbers of transplantable totipotent hematopoietic stem cells in primary and secondary recipients, compared with serially passaged control cells. It is possible that overexpression of other transcription factors that drive hematopoietic development might allow stem cell division to be more successfully manipulated.",
"   </p>",
"   <p>",
"    A second example of this approach is a high affinity IL-3 receptor agonist that has shown promise in preclinical large animal studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/94-96\">",
"     94-96",
"    </a>",
"    ]. This protein produces greater multilineage hematopoietic stimulation and more rapid hematopoietic reconstitution after bone marrow aplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/94\">",
"     94",
"    </a>",
"    ]. Combination therapy with G-CSF appears to be more effective than the IL-3 receptor agonist alone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/95,96\">",
"     95,96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     EPO mimetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;An additional area that holds great promise for future manipulation of the hematopoietic system is the development of small molecules, peptides, or agonistic antibodies that bind to specific receptors, with the objective of finding high affinity second generation drugs that may either be developed into oral agents [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/27,97\">",
"     27,97",
"    </a>",
"    ] or generate molecules with longer-lasting activity [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/98\">",
"     98",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link&amp;anchor=H16#H16\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\", section on 'Peginesatide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progress has been made in the identification of 13 and 14 amino acid EPO mimetic peptides [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/99-101\">",
"       99-101",
"      </a>",
"      ], whose activity can be markedly increased by the construction of covalent dimers of the peptide [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/102-104\">",
"       102-104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the basis of two completed randomized trials, one of these agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"       peginesatide",
"      </a>",
"      (hematide, AF-37702, Omontys) has been approved by the United States FDA for the treatment of anemia in adult patients with chronic kidney disease (CKD) who are receiving dialysis. This product, administered as a once-a-month injection, was found to be as safe and effective as erythropoietin in maintaining hemoglobin levels within the studies&rsquo; pre-specified range of 10 to 12",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      It is not indicated for patients with CKD who are not receiving dialysis, or in patients with cancer-related anemia, and should not be used as a substitute for red blood cell transfusion in patients requiring immediate correction of anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Continuous erythropoietin receptor activator (CERA) is a chemically synthesized \"continuous\" EPO receptor activator that differs from EPO. This agent is currently in clinical trials in patients with renal failure as well as in anemic patients undergoing chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/106\">",
"     106",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link&amp;anchor=H16#H16\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\", section on 'Peginesatide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another area of interest is the development of orally-active agents that increase endogenous EPO production through interference with the oxygen-sensing pathway of EPO production [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/107\">",
"     107",
"    </a>",
"    ]. Inhibition of prolyl hydroxylase stabilizes hypoxia inducible factor 1 alpha (HIF-1&alpha;), a factor important for EPO transcription. The orally active prolyl hydroxylase inhibitor FG-2216 was evaluated in 12 hemodialysis patients (6 anephric) and 6 normal volunteers, and increases in plasma EPO were found in all of them [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link&amp;anchor=H18#H18\">",
"     \"Regulation of erythropoiesis\", section on 'Hypoxia and EPO expression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=see_link&amp;anchor=H18#H18\">",
"     \"Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera\", section on 'Polycythemias with incompletely defined molecular lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Nonhematologic effects of EPO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discovery that EPO may play a significant role in non-hematopoietic tissues (eg, brain, heart) has led to interest in EPO as a novel cytoprotective agent in both neuronal and vascular systems [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H438625\">",
"    <span class=\"h2\">",
"     TPO mimetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two small molecules that can activate the TPO receptor (c-Mpl) are under intense study and have been approved by the FDA for immune thrombocytopenia (ITP).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"       Romiplostim",
"      </a>",
"      comprises four peptides linked to an IgG Fc fragment that binds to the TPO receptor in the same way as TPO; it is administered by weekly subcutaneous injection.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"       Eltrombopag",
"      </a>",
"      is an orally administered non-peptide drug that activates the TPO receptor by binding to its transmembrane domain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies of these agents have been initiated in chemotherapy-related thrombocytopenia, hepatitis C-associated thrombocytopenia, and myelodysplastic syndromes. Adverse events are mild (headache, fatigue); long term events are being monitored (increased bone marrow reticulin, thrombosis, increase in blasts in patients with myelodysplasia) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/31/16890/abstract/110\">",
"     110",
"    </a>",
"    ]",
"    <strong>",
"     .",
"    </strong>",
"    This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=see_link\">",
"     \"Clinical applications of thrombopoietic growth factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H5#H5\">",
"     \"Chronic refractory immune thrombocytopenia (ITP) in adults\", section on 'Thrombopoiesis-stimulating agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link&amp;anchor=H2104265#H2104265\">",
"     \"Management of the complications of the myelodysplastic syndromes\", section on 'Thrombopoietin mimetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6607042\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brief review of major recombinant hematopoietic growth factors (HGFs), the major indications for their use, and the side effects that may be seen is presented here. The functions of specific HGFs (eg, erythropoietin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and thrombopoietin (TPO)) are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link\">",
"     \"Regulation of erythropoiesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6858?source=see_link\">",
"     \"Regulation of myelopoiesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4458?source=see_link\">",
"     \"Megakaryocyte biology and the production of platelets\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6607152\">",
"    <span class=\"h2\">",
"     Indications for use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a list of the major clinical settings in which recombinant HGFs are administered. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Indications for treatment with hematopoietic growth factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transient bone marrow failure following chemotherapy",
"     </li>",
"     <li>",
"      Bone marrow transplantation",
"     </li>",
"     <li>",
"      Myelodysplastic syndrome",
"     </li>",
"     <li>",
"      Acquired aplastic anemia (controversial)",
"     </li>",
"     <li>",
"      Inherited bone marrow failure syndromes",
"     </li>",
"     <li>",
"      Chronic anemias (eg, renal failure, prematurity, anemia of chronic disease, anemia associated with HIV infection)",
"     </li>",
"     <li>",
"      Stem cell and progenitor cell mobilization (in vitro and ex vivo)",
"     </li>",
"     <li>",
"      Human immunodeficiency virus infection",
"     </li>",
"     <li>",
"      Gene transfer",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6607174\">",
"    <span class=\"h2\">",
"     Toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The toxic effects of the recombinant HGFs include the following. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Toxicity of colony-stimulating factors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18\">",
"     'Toxicity of erythropoietin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transient leukopenia",
"     </li>",
"     <li>",
"      Systemic reactions (eg, bone pain (G-CSF and GM-CSF); hypertension, thrombosis (EPO))",
"     </li>",
"     <li>",
"      Production of deleterious antibodies (EPO, TPO)",
"     </li>",
"     <li>",
"      Possible stimulation of malignancy (G-CSF, GM-CSF, EPO)",
"     </li>",
"     <li>",
"      Possible enhancement of HIV replication (GM-CSF)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/1\">",
"      Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006; 354:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/2\">",
"      Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer 2010; 10:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/3\">",
"      Bradley TR, Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 1966; 44:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/4\">",
"      Pluznik DH, Sachs L. The cloning of normal \"mast\" cells in tissue culture. J Cell Physiol 1965; 66:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/5\">",
"      Metcalf D. Hemopoietic regulators and leukemia development: a personal retrospective. Adv Cancer Res 1994; 63:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/6\">",
"      Clark SC, Kamen R. The human hematopoietic colony-stimulating factors. Science 1987; 236:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/7\">",
"      Metcalf D. The colony stimulating factors. Discovery, development, and clinical applications. Cancer 1990; 65:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/8\">",
"      Moore MA. Haemopoietic growth factor interactions: in vitro and in vivo preclinical evaluation. Cancer Surv 1990; 9:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/9\">",
"      Wong GG, Clark SC. Multiple actions of interleukin 6 within a cytokine network. Immunol Today 1988; 9:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/10\">",
"      Bazan JF. Neuropoietic cytokines in the hematopoietic fold. Neuron 1991; 7:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/11\">",
"      Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987; 56:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/12\">",
"      Strober W, James SP. The interleukins. Pediatr Res 1988; 24:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/13\">",
"      Shalaby MR, Pennica D, Palladino MA Jr. An overview of the history and biologic properties of tumor necrosis factors. Springer Semin Immunopathol 1986; 9:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/14\">",
"      Fung MC, Hapel AJ, Ymer S, et al. Molecular cloning of cDNA for murine interleukin-3. Nature 1984; 307:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/15\">",
"      Yokota T, Lee F, Rennick D, et al. Isolation and characterization of a mouse cDNA clone that expresses mast-cell growth-factor activity in monkey cells. Proc Natl Acad Sci U S A 1984; 81:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/16\">",
"      Kindler V, Thorens B, de Kossodo S, et al. Stimulation of hematopoiesis in vivo by recombinant bacterial murine interleukin 3. Proc Natl Acad Sci U S A 1986; 83:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/17\">",
"      Metcalf D, Begley CG, Johnson GR, et al. Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. Blood 1986; 68:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/18\">",
"      Donahue RE, Wang EA, Stone DK, et al. Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF. Nature 1986; 321:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/19\">",
"      Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994; 264:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/20\">",
"      Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A 1994; 91:5592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/21\">",
"      Lieschke GJ, Grail D, Hodgson G, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/22\">",
"      Welte K, Bonilla MA, Gillio AP, et al. Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 1987; 165:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/23\">",
"      Sieff CA, Emerson SG, Mufson A, et al. Dependence of highly enriched human bone marrow progenitors on hemopoietic growth factors and their response to recombinant erythropoietin. J Clin Invest 1986; 77:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/24\">",
"      Eaves CJ, Eaves AC. Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera. Blood 1978; 52:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/25\">",
"      Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/26\">",
"      Merchionne F, Dammacco F. Biological functions and therapeutic use of erythropoiesis-stimulating agents: perplexities and perspectives. Br J Haematol 2009; 146:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/27\">",
"      Bunn HF. New agents that stimulate erythropoiesis. Blood 2007; 109:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/28\">",
"      Wendling F, Maraskovsky E, Debili N, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994; 369:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/29\">",
"      Souyri M, Vigon I, Penciolelli JF, et al. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 1990; 63:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/30\">",
"      Methia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993; 82:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/31\">",
"      de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/32\">",
"      Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994; 77:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/33\">",
"      Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/34\">",
"      Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996; 88:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/35\">",
"      Harker LA. Physiology and clinical applications of platelet growth factors. Curr Opin Hematol 1999; 6:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/36\">",
"      Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100:3457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/37\">",
"      Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/38\">",
"      Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol 1994; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/39\">",
"      Hannum C, Culpepper J, Campbell D, et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994; 368:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/40\">",
"      Lyman SD, James L, Johnson L, et al. Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood 1994; 83:2795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/41\">",
"      Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/42\">",
"      Burris HA, Belani CP, Kaufman PA, et al. Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies. J Oncol Pract 2010; 6:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/43\">",
"      Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 2008; 111:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/44\">",
"      Lyman GH, Dale DC. Long-term outcomes of myeloid growth factor treatment. J Natl Compr Canc Netw 2011; 9:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/45\">",
"      Arnaout MA, Wang EA, Clark SC, Sieff CA. Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Clin Invest 1986; 78:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/46\">",
"      Socinski MA, Cannistra SA, Elias A, et al. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; 1:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/47\">",
"      Devereux S, Linch DC, Campos Costa D, et al. Transient leucopenia induced by granulocyte-macrophage colony-stimulating factor. Lancet 1987; 2:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/48\">",
"      Johnson ML, Grimwood RE. Leukocyte colony-stimulating factors. A review of associated neutrophilic dermatoses and vasculitides. Arch Dermatol 1994; 130:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/49\">",
"      Glaspy JA, Baldwin GC, Robertson PA, et al. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 1988; 109:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/50\">",
"      Pietsch T, B&uuml;hrer C, Mempel K, et al. Blood mononuclear cells from patients with severe congenital neutropenia are capable of producing granulocyte colony-stimulating factor. Blood 1991; 77:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/51\">",
"      Welte K, Zeidler C, Reiter A, et al. Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 1990; 75:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/52\">",
"      Bidyasar S, Montoya M, Suleman K, Markowitz AB. Sweet syndrome associated with granulocyte colony-stimulating factor. J Clin Oncol 2008; 26:4355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/53\">",
"      Antman KS, Griffin JD, Elias A, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988; 319:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/54\">",
"      Brandt SJ, Peters WP, Atwater SK, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/55\">",
"      Motoyoshi K, Takaku F, Maekawa T, et al. Protective effect of partially purified human urinary colony-stimulating factor on granulocytopenia after antitumor chemotherapy. Exp Hematol 1986; 14:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/56\">",
"      Masaoka T, Motoyoshi K, Takaku F, et al. Administration of human urinary colony stimulating factor after bone marrow transplantation. Bone Marrow Transplant 1988; 3:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/57\">",
"      Shpall EJ. The utilization of cytokines in stem cell mobilization strategies. Bone Marrow Transplant 1999; 23 Suppl 2:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/58\">",
"      Costa JJ, Demetri GD, Harrist TJ, et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 1996; 183:2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/59\">",
"      Gregory SA, Schwartzberg LS, Mo M, et, al. Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: a retrospective analysis. Commun Oncol 2010; 7:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/60\">",
"      Kirshner JJ, Heckler CE, Janelsins MC, et al. Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base. J Clin Oncol 2012; 30:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/61\">",
"      Gribben JG, Devereux S, Thomas NS, et al. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 1990; 335:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/62\">",
"      Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997; 126:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/63\">",
"      Goodnough LT, Dipersio J, Mccullough J, et al. Transfusion 1997; 37 Suppl 9S:67S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/64\">",
"      Touw IP, Bontenbal M. Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy? J Natl Cancer Inst 2007; 99:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/65\">",
"      Pamphilon D, Nacheva E, Navarrete C, et al. The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors. Transfusion 2008; 48:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/66\">",
"      Beekman R, Touw IP. G-CSF and its receptor in myeloid malignancy. Blood 2010; 115:5131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/67\">",
"      Welte K, Boxer LA. Severe chronic neutropenia: pathophysiology and therapy. Semin Hematol 1997; 34:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/68\">",
"      Smith OP, Reeves BR, Kempski HM, Evans JP. Kostmann's disease, recombinant HuG-CSF, monosomy 7 and MDS/AML. Br J Haematol 1995; 91:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/69\">",
"      Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997; 90:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/70\">",
"      Hashino S, Imamura M, Tanaka J, et al. Transformation of severe aplastic anemia into acute myeloblastic leukemia with monosomy 7. Ann Hematol 1996; 72:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/71\">",
"      Kaito K, Kobayashi M, Katayama T, et al. Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Br J Haematol 1998; 103:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/72\">",
"      Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010; 28:2914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/73\">",
"      Koyanagi Y, O'Brien WA, Zhao JQ, et al. Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science 1988; 241:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/74\">",
"      Wang J, Roderiquez G, Oravecz T, Norcross MA. Cytokine regulation of human immunodeficiency virus type 1 entry and replication in human monocytes/macrophages through modulation of CCR5 expression. J Virol 1998; 72:7642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/75\">",
"      Abboud M, Laver J, Blau CA. Granulocytosis causing sickle-cell crisis. Lancet 1998; 351:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/76\">",
"      Adler BK, Salzman DE, Carabasi MH, et al. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 2001; 97:3313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/77\">",
"      Grigg AP. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. Blood 2001; 97:3998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/78\">",
"      Bennett WM. A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. J Am Soc Nephrol 1991; 1:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/79\">",
"      Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/80\">",
"      Buur T, Lundberg M. Secondary effects of erythropoietin treatment on metabolism and dialysis efficiency in stable hemodialysis patients. Clin Nephrol 1990; 34:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/81\">",
"      Edmunds ME, Walls J, Tucker B, et al. Seizures in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 1989; 4:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/82\">",
"      Raine AE, Roger SD. Effects of erythropoietin on blood pressure. Am J Kidney Dis 1991; 18:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/83\">",
"      Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 1991; 2:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/84\">",
"      Watson AJ, Gimenez LF, Cotton S, et al. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med 1990; 89:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/85\">",
"      Kang DH, Yoon KI, Han DS. Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients. Nephrol Dial Transplant 1998; 13:2877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/86\">",
"      Kaupke CJ, Kim S, Vaziri ND. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol 1994; 4:1874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/87\">",
"      Feagan BG, Wong CJ, Kirkley A, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med 2000; 133:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/88\">",
"      Dale DC. Neutrophil biology and the next generation of myeloid growth factors. J Natl Compr Canc Netw 2009; 7:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/89\">",
"      Papayannopoulou T, Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci U S A 1993; 90:9374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/90\">",
"      Papayannopoulou T, Craddock C, Nakamoto B, et al. The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci U S A 1995; 92:9647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/91\">",
"      Craddock CF, Nakamoto B, Andrews RG, et al. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood 1997; 90:4779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/92\">",
"      Papayannopoulou T, Priestley GV, Nakamoto B. Anti-VLA4/VCAM-1-induced mobilization requires cooperative signaling through the kit/mkit ligand pathway. Blood 1998; 91:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/93\">",
"      Sauvageau G, Thorsteinsdottir U, Eaves CJ, et al. Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. Genes Dev 1995; 9:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/94\">",
"      Farese AM, Herodin F, McKearn JP, et al. Acceleration of hematopoietic reconstitution with a synthetic cytokine (SC-55494) after radiation-induced bone marrow aplasia. Blood 1996; 87:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/95\">",
"      MacVittie TJ, Farese AM, Herodin F, et al. Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC-55494 and recombinant human granulocyte colony-stimulating factor. Blood 1996; 87:4129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/96\">",
"      Fleming WH, Lankford-Turner P, Turner CW, et al. Administration of daniplestim and granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in nonhuman primates. Biol Blood Marrow Transplant 1999; 5:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/97\">",
"      Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006; 368:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/98\">",
"      Liu Z, Stoll VS, Devries PJ, et al. A potent erythropoietin-mimicking human antibody interacts through a novel binding site. Blood 2007; 110:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/99\">",
"      Livnah O, Stura EA, Johnson DL, et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 1996; 273:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/100\">",
"      Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996; 273:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/101\">",
"      Johnson DL, Farrell FX, Barbone FP, et al. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. Biochemistry 1998; 37:3699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/102\">",
"      Livnah O, Stura EA, Middleton SA, et al. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 1999; 283:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/103\">",
"      Johnson DL, Farrell FX, Barbone FP, et al. Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. Chem Biol 1997; 4:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/104\">",
"      Stead RB, Lambert J, Wessels D, et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 2006; 108:1830.",
"     </a>",
"    </li>",
"    <li>",
"     FDA news release: peginesatide. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm297464.htm (Accessed on March 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/106\">",
"      Osterborg A, Steegmann JL, Hellmann A, et al. Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy. Br J Haematol 2007; 136:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/107\">",
"      Hsieh MM, Linde NS, Wynter A, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 2007; 110:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/108\">",
"      Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010; 21:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/109\">",
"      Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005; 293:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/31/16890/abstract/110\">",
"      Kuter DJ. New thrombopoietic growth factors. Clin Lymphoma Myeloma 2009; 9 Suppl 3:S347.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8383 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-125.69.132.100-B0D0D57A02-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_31_16890=[""].join("\n");
var outline_f16_31_16890=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6607042\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Interleukin-3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Granulocyte-macrophage colony-stimulating factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Granulocyte colony-stimulating factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Erythropoietin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Thrombopoietin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Stem cell factor and Flt 3 ligand",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS FOR TREATMENT WITH HEMATOPOIETIC GROWTH FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Dosage and schedule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TOXICITY OF COLONY-STIMULATING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Transient leukopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other systemic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4363708\">",
"      CSF-related bone pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antibodies to recombinant growth factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Possible stimulation of malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Possible enhancement of HIV replication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Use in sickle cell syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TOXICITY OF ERYTHROPOIETIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      EPO mimetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Nonhematologic effects of EPO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H438625\">",
"      TPO mimetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6607042\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6607152\">",
"      Indications for use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6607174\">",
"      Toxicities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/8383\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8383|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?34/9/34968\" title=\"algorithm 1\">",
"      Hematopoiesis regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8383|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/23/30078\" title=\"figure 1\">",
"      Pharmacokinetics of epoetin alfa and darbepoetin alfa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29930?source=related_link\">",
"      Aplastic anemia: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Chronic refractory immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=related_link\">",
"      Clinical applications of thrombopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=related_link\">",
"      Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=related_link\">",
"      Congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/0/44039?source=related_link\">",
"      Hematologic manifestations of HIV infection: Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8436?source=related_link\">",
"      Hypertension following erythropoietin in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=related_link\">",
"      Management of the complications of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4458?source=related_link\">",
"      Megakaryocyte biology and the production of platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29978?source=related_link\">",
"      Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=related_link\">",
"      Overview of hematopoiesis and stem cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8265?source=related_link\">",
"      Pure red cell aplasia due to anti-erythropoietin antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6858?source=related_link\">",
"      Regulation of myelopoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=related_link\">",
"      Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40905?source=related_link\">",
"      Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_31_16891="Storage of blood components";
var content_f16_31_16891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Storage conditions for blood components",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Component",
"      </td>",
"      <td class=\"subtitle1\">",
"       Temperature",
"      </td>",
"      <td class=\"subtitle1\">",
"       Other",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Red blood cells, liquid",
"      </td>",
"      <td>",
"       1 to 6&deg;C",
"      </td>",
"      <td>",
"       Not mixed or agitated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fresh frozen plasma",
"      </td>",
"      <td>",
"       -18&deg;C",
"      </td>",
"      <td>",
"       Bubble on side*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cryoprecipitated AHF",
"      </td>",
"      <td>",
"       -18&deg;C",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Platelet concentrate",
"      </td>",
"      <td>",
"       20 to 24&deg;C",
"      </td>",
"      <td>",
"       Gentle agitation, swirling",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Platelets, apheresis",
"      </td>",
"      <td>",
"       20 to 24&deg;C",
"      </td>",
"      <td>",
"       Gentle agitation, swirling",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AHF: antihemophilic factor.",
"     <br>",
"      * Frozen plasma is stored so that the small air bubble in the bag is at 90&deg; from vertical. If the plasma has inadvertently thawed during storage, the bubble will be at the 12 o'clock position.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_31_16891=[""].join("\n");
var outline_f16_31_16891=null;
var title_f16_31_16892="NB resuscitation equipment";
var content_f16_31_16892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Neonatal resuscitation supplies and equipment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Suction equipment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bulb syringe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mechanical suction, tubing, and catheters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meconium aspirator",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8F feeding tube and 20 cc syringe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intubation equipment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laryngoscope with straight blades (Number 0 and 1 for preterm and term infants, respectively)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Face masks (preterm and term infant sizes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxygen source with flowmeter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dextrose solution 10 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epinephrine (0.1 mg/mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isotonic solution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Naloxone hydrochloride (0.4 mg/mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Needles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syringes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Umbilical vessel catheterizations supplies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sterile gloves, scalpel, antiseptic prep solution, umbilical catheter, tape, three-way stopcock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiant warmer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Warm towels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac monitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulse oximeter and probe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oropharyngeal airways",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Additional equipment for delivery of preterm infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Compressed air source",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxygen blender",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plastic wrap",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transport incubator",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kattwinkel J. Textbook of neonatal resuscitation, 5th ed, American Academy of Pediatrics, 2006. Copyright &copy; 2006 American Academy of Pediatrics.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_31_16892=[""].join("\n");
var outline_f16_31_16892=null;
var title_f16_31_16893="Differential DX night sweats";
var content_f16_31_16893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of night sweats or flushing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Malignancy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Lymphoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Non-Hodgkin's lymphoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Hodgkin's disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Solid tumors",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Germ cell tumors",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Medullary carcinoma of the thyroid",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Prostate cancer",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Renal cell carcinoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Miscellaneous cancers",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Infections",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Mycobacterial",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Tuberculosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Atypical mycobacteria",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Bacterial",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Abscess",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Brucellosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Endocarditis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          Osteomyelitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Fungal infections",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Viral",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1\">",
"          <p>",
"           HIV infection",
"          </p>",
"          <p>",
"           Chronic hepatitis C",
"          </p>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Medications (see Table 2)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Substance withdrawal",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Alcohol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cocaine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Opioids",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Endocrine disorders",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Carcinoid syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diabetes insipidus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hyperthyroidism",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypoglycemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pheochromocytoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Postorchiectomy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Menopause",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Neurologic disorders",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Autonomic dysreflexia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Autonomic neuropathy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Post-traumatic syringomyelia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Stroke",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Miscellaneous",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Chronic fatigue syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Common blushing",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Food additives",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Gastroesophageal reflux",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Mastocytosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Panic disorder",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Rosacea",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sleep apnea",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Temporal arteritis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Idiopathic hyperhidrosis",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_31_16893=[""].join("\n");
var outline_f16_31_16893=null;
var title_f16_31_16894="CT scan SMA syndrome";
var content_f16_31_16894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan of the abdomen in a patient with SMA Syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 218px; height: 148px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is a distended, contrast-filled stomach (closed arrowhead) and a dilated, contrast-filled proximal duodenum (open arrowhead). The duodenum can be seen narrowing as it approaches the aorta where it is compressed between the aorta and the SMA.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from Ross J Bellavia, MD and Sheila Berlin, MD from Rainbow Babies and Children's Hospital in Cleveland, OH (uhrad.com). Reprinted with permission from Sheila Berlin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_31_16894=[""].join("\n");
var outline_f16_31_16894=null;
var title_f16_31_16895="Hip aspiration";
var content_f16_31_16895=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hip aspiration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Aspiration of the hip joint is performed to confirm acute synovitis or septic arthritis. The patient is placed in the lateral decubitus position with the hips and knees flexed to 90&ordm;. A 3.5 inch (9 cm), 22-gauge spinal needle is inserted perpendicular to the skin,&nbsp;2.5 cm (1 in)&nbsp;above the superior trochanter. 1 mL of local anesthetic is injected around the periosteum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_31_16895=[""].join("\n");
var outline_f16_31_16895=null;
